


PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

14



Applicant's or agent's file reference PD-5947-01-MJA		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) FOR FURTHER ACTION	
International application No. PCT/US99/23519	International filing date (day/month/year) 07/10/1999	Priority date (day/month/year) 07/10/1998	
International Patent Classification (IPC) or national classification and IPC C07K14/00		RECEIVED SEP 12 2001 TECH CENTER 1600/2900	
Applicant WARNER-LAMBERT COMPANY et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 16 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 11/04/2000	Date of completion of this report 26.01.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Alt, G Telephone No. +49 89 2399 8545



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/23519

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

Description, pages:

1-45 as originally filed

Claims, No.:

1-34 as originally filed

Drawings, No.:

1-4 as originally filed

Sequence listing part of the description, pages:

1-40, filed with the letter of 02.08.00

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

RECEIVED

SEP 12 2001

TECH CENTER 1600/2900

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/23519

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 4, 19, 20, 25, 31-33.

because:

- ☒ the said international application, or the said claims Nos. 19, 20, 31-33 as far as industrial applicability is concerned relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☒ the claims, or said claims Nos. 4, 25 are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

IV. Lack of unity of invention

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/23519

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☒ paid additional fees.
- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.
- ☒ not complied with for the following reasons:
see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☒ all parts.
- ☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	3, 5-7, 9-21, 27-34
	No:	Claims	1, 2, 8, 22-24, 26
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-34
Industrial applicability (IA)	Yes:	Claims	1-3, 5-18, 21-24, 26-30, 34
	No:	Claims	

2. Citations and explanations
see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/23519

2. Non-written disclosures (Rule 70.9)

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item I

Basis of the opinion

1. This opinion is inter alia based on a sequence listing comprising SEQ ID Nos. 1-49 on pages 1-44 and received on 14.12.1999. In view of Rule 13ter.1 f) PCT these pages do therefore not form part of the application because they were not contained in the international application as filed.

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

2. Claim 4 is directed to a DNA sequence that has at least 70% identity to a polynucleotide encoding the polypeptide expressed by SEQ ID No. "X". In order to determine all the DNA fragments covered by this claim the following steps must be performed:
 1. Determination of all possible DNA sequences encoding the protein of SEQ ID No. "X" due to the degeneracy of the genetic code.
 2. Determination of all DNA fragments having a sequence which has at least 70% identity to the DNA sequences determined in step 1. The DNA fragments determined in this step are all encompassed by claim 4.
 3. Comparison of the sequences of step 2 with prior art sequences in order to be able to evaluate novelty and inventive step.

Currently, there is no method available (computer-based or otherwise) that can compare the almost infinite number of hypothetical sequences of this claim with all the known sequences in the prior art.

Consequently, due to the complexity of the claim, an assessment of novelty and inventive step is not possible.

3. Essentially the same reasoning applies to claim 25. The only exception is that here as a first step the amino acid sequence of the polypeptide encoded by the listed SEQ ID Nos. must be determined.
4. Claims 19, 20, 31-33 (the diagnostic method of claim 3 may be performed in the

body) relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Re Item IV

Lack of Unity

5. The common inventive concept linking the present claims can formally be defined as "proteins and nucleic acid fragments related to the alpha 2 delta subunit of calcium channel protein". This concept is however not novel because, according to page 4, lines 23-25 of the application two human alpha 2 delta proteins are already known. Hence, the above defined concept does not provide a link for the present claims.

Consequently, the subject-matter of the claims is directed to separate inventions:

i) The subject-matter of claims 1-26 and 31-34 is inter alia directed to the calcium channel alpha 2 delta C protein, related nucleic acid fragments and applications (claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 3; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 5; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta C"; claims 22-26 as far as they relate to SEQ ID Nos. 11, 14, 40, 41, 43, 44, 47-49; claims 34 as far as it is related to accession nos. from AU022914.1 to AI051759.1 and SEQ ID Nos. 3, 5, 9-14, 36-41, 43, 44, 47.)

ii) The subject-matter of claims 1-26, 31-34 (inter alia) and of claims 27-30 is directed to the calcium channel alpha 2 delta D protein, related nucleic acid sequences and applications (claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 4; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 6; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta D"; claims 22-26 as far as they relate to SEQ ID Nos. 15, 16, 21-24; claim 34 as far as it is related to accession nos. from T70594.1 to AA001473.1 and SEQ ID Nos. 4, 6, 15, 16, 18-24, 42, 45, 46, 48, 49).

iii) The subject-matter of claims 22-26 and 34 is inter alia directed to polynucleotide sequences related to calcium channel alpha 2 delta B protein and

to a method of using calcium channel alpha 2 delta B protein related nucleic acid sequences for identifying their binding potential to gabapentin (subject-matter related to calcium channel alpha 2 delta B protein: claims 22-26 as far as they relate to SEQ ID Nos. 31-35; claim 34 as far as it relates to accession no. AF040709.1 and accession nos. from T80372.1 to Z84492.1 as well as SEQ ID Nos. 1, 2, 7, 8, 25-35.)

iv) The remaining subject-matter of claim 34 is directed to a method of using calcium channel alpha 2 delta A related polynucleotide sequences to identify their gabapentin binding potential (claim 34 as far as it is related to accession nos. not mentioned before.)

The specific features of the subject-matter mentioned in point i) (calcium channel alpha 2 delta C protein and encoding sequence), ii) (calcium channel alpha 2 delta D protein and encoding sequence) and iii) (sequences related to calcium channel alpha 2 delta B protein and encoding sequence) are structurally unrelated. Moreover, the method of point iv) uses calcium channel alpha 2 delta A related polynucleotide sequences which are structurally unrelated to each of the above mentioned protein and nucleic acid sequences. Consequently, the above features cannot be regarded as the same or corresponding special technical features as required by Rule 13.2 PCT. Therefore, the present application is directed to 4 different inventions represented by the above mentioned claims.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

6. The validity of the priority documents of the present application has not been checked. In the case that none of the three priority dates is validly claimed, the document KLUGBAUER, N. ET AL.: 'Molecular diversity of the calcium channel alpha 2 delta subunit' NEUROSCIENCE, vol. 19, no. 2, 15 January 1999 (1999-01-15), pages 684-691 could become relevant for the evaluation of novelty and inventive step.

7. For the assessment of the present claims 19, 20, 31-33 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

As far as the present claims can be understood in view of the many clarity-objections (see section VIII of this opinion) novelty, inventive step and industrial applicability are judged as follows:

Alpha 2 delta C protein:

Novelty:

8. The subject-matter of claims 1, 2, 22 and 23 is not novel in view of **D1** = DATABASE EMBL [Online] AC AA190607, 21 January 1997 (1997-01-21) HILLIER, L. ET AL.: 'zq44e03.r1 Stratagene hNT neuron, Homosapiens cDNA clone IMAGE: 632572 5' similar to TR:G179762 G179762 Calcium Channel Alpha-2B subunit; mRNA sequence', **D2** = DATABASE EMBL [Online] AC Z44942, 6 November 1994 (1994-11-06) AUFRAY, C. ET AL.: 'Homo sapiens partial cDNA sequence; clone c-2dd03'. Moreover, the subject-matter of claims 1 and 2 is anticipated by the disclosure of **D3** = DATABASE EMBL [Online] AC R20288, 23 April 1995 (1995-04-23) HILLIER, L. ET AL.: 'yg20f03.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:32708 5', mRNA sequence' or **D4** = DATABASE EMBL [Online] AC AA459684, 13 June 1997 (1997-06-13) HILLIER, L. ET AL.: 'zx49d08.s1 Soares testis NHT Homo sapiens cDNA clone 759567 3' EST'.
- D1:** 97.6% identity in 413bp overlap with SEQ ID No. 3 residues 1584-1987; 96.8% identity in 340 bp overlap with SEQ ID No. 43 residues 1584-1917, 97.6% identity in 413bp overlap with SEQ ID No. 44 residues 1584-1988.
- D2:** 99.7% identity in 340 bp overlap with SEQ ID No. 3 residues 2509-2848, 100% identity in 17bp overlap with SEQ ID No. 11 residues 1-17.
- D3:** 97.6% identity in 340bp overlap with SEQ ID No. 3 residues 1948-2352.

D4: 100% identity in 304bp overlap with SEQ ID No. 3 residues 3447-3750 of the complementary strand.

The subject-matter of claim 8 is not novel in view of SEQ ID NO. 31 of **D5** = WO 95 04822 A (SALK INST BIOTECH IND) 16 February 1995 (1995-02-16): 34,4% identity in 540 aa overlap with SEQ ID No. 5 residues 1-540.

Moreover, claim 1, 8 and 22 are not novel in view of the **alpha 2 delta A protein** because the claims do not contain any limitations as to the extent of possible modifications (see page 14 and 18 of the description for the definition of the term "substantially similar" and page 37 for similarity).

Inventive step

Evaluation of inventive step is performed under the assumption that all claims are novel.

9. The closest prior art with respect to the subject of this invention is the known calcium channel subunit alpha 2 delta A, cited on page 36 of the application. The difference between this protein and subunit alpha 2 delta C consists in the chemical structure, i.e. the full-length alpha 2 delta C is 28% identical and 48% similar at the amino acid level to alpha 2 delta A. The molecules are related functionally because alpha 2 delta C can replace alpha 2 delta A in voltage activated calcium channel molecules. However, the increase in current is only 2-fold compared to 20fold (see page 39 of the application).
The problem to be solved is therefore seen in the provision of a protein that can replace alpha 2 delta A in the calcium channel protein complex.
The solution to this problem as claimed in claims 1 and 8, respectively are the proteins characterized by SEQ ID NO. 5 and derivatives thereof as well as the corresponding genes. Due to their broadness the subject-matter of these claims cannot be considered as inventive, because they encompass molecules with a very similar chemical structure compared to alpha 2 delta A. It is evident that the probability that proteins with a high homology perform the same functions is high. Moreover, a person skilled in the art has an incentive to look for variants of delta calcium channel subunits because he is aware of the diversity of other calcium

channel subunits (see for example **D11** = WALKER, D. AND DE WAARD, M.: 'Subunit interaction sites in voltage-dependent Ca²⁺ channels: role in channel function' TRENDS IN NEUROSCIENCES, vol. 21, no. 4, 1998 page 152, right-hand column, "Promiscuity of subunit interactions ...". For Example: "...brain expresses five out of the six alpha 1 genes ..." and also of methods how further subunits may be isolated (see for example **D9**, page 9, lines 1-3).

10. The specific protein characterized by SEQ ID No. 5 and proteins having at least 70% similarity with the protein of SEQ ID No. 5 (claims 9 and 10) are however regarded as inventive because it is not considered as obvious that a protein with a similarity of 48% or less to another protein can perform the same function. Thus, claims 9 and 10 are regarded as involving an inventive step. The same applies to the subject-matter of claims 2, 3 and 5.

As far as the dependent claims relate to novel and inventive subject-matter their subject-matter could likewise be regarded as inventive.

Alpha 2 delta D protein

Novelty

11. The subject-matter of claims 1, 2, 22 and 23 is not novel in view of **D6** = DATABASE EMBL [Online] ACAC005343, 4 August 1998 (1998-08-04) MUZNY, D. ET AL.: 'Homo sapiens chromosome 12p13.3 BAC RPCI 11-21K20 (Roswell Park Cancer Institute Human BAC Library) complete sequence', **D7** = DATABASE EMBL [Online] AC AA719773, 7 January 1998 (1998-01-07) HILLIER, L. ET AL.: 'zh38g01.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone 414384 3' or **D8** = DATABASE EMBL [Online] AC AA001473, 20 July 1996 (1996-07-20) HILLIER, L. ET AL.: 'ze45d04.r1 Soares retina N2b4Hr Homo sapiens cDNA clone 361927 5'.
- D6**: 98,5% identity in 1847 bp overlap with SEQ ID No. 4 (residues 3215-5056), 15 (residues 3143-4984), 16 (residues 3854-5695).
- D7**: 98,4% identity in 436 bp overlap with SEQ ID No. 4 residues 4643-5073 of the complementary strand.
- D8**: 97,8% identity in 489bp overlap with SEQ ID Nos. 4 (residues 2558-3038), 15 (residues 2486-2966), 16 (residues 2558-2873).

The subject-matter of claim 8 is not novel in view of SEQ ID No. 4 of **D9**= WO 98 11131 A (CHEN AI RU SUN ;FRANCO RODRIGO (US); AMERICAN HOME PROD (US); SHUE) 19 March 1998 (1998-03-19) (29,0% identity in 1129aa overlap with residues 33-1101 of SEQ ID No. 6.

Moreover, the subject-matter of claims 1, 8 and 22 is not novel in view of the **alpha 2 delta A protein** because the claims do not contain any limitations as to the extent of possible modifications (see page 14 and 18 of the description for the definition of the term "substantially similar" and page 42 for similarity).

Inventive step

12. Subunit alpha 2 delta D has a chemical structure which is 28% identical and 47% similar at the amino acid level to subunit alpha 2 delta A. The function of this protein has not been determined. In this case any protein can be regarded as the closest prior art document with the effect that the problem to be solved must be formulated as the mere provision of a further protein regardless of its property.

The proteins according to claims 8-10 are regarded as an arbitrary choice from the list of possible solutions to this problem. The selection of compounds in order to be inventive must however not be arbitrary, but must be justified by an unknown technical effect caused by the structural features which distinguish the claimed compounds from the numerous other compounds. Since this is not the case for the compounds of claims 8-10 the subject-matter of these claims does not involve an inventive step. The same reasoning applies to claims dependent on these claims or related thereto.

Alpha 2 delta B protein

Novelty

13. The subject-matter of claims 22-24 and 26 is not novel in view of **D10** = DATABASE EMBL [Online] AC Z75742, 9 July 1996 (1996-07-09) WILKINSON; J.: 'Human DNA sequence from cosmid LUCA10 on chromosome 3p21.3 contains ESTs': :82,8% identity in 87bp overlap with SEQ ID No. 33 residues 1-87 and in view of **alpha 2 d Ita B** available in the public database Genbank (see page 5,

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/23519

lines 2-3 and accession numbers on page 30, line 17). None of these citations refers however to the use of these sequences or related sequences to test for gabapentin binding. Therefore, the subject-matter of claim 34 is novel.

Inventive step

14. Since any polynucleotide can be used in a method to identify gabapentin binding, the sequences relating to alpha 2 delta B protein are only an arbitrary choice from the list a possibilities. Consequently, the subject-matter of claim 34 does not involve an inventive step.

Method of using polynucleotide sequences to identify their gabapentin binding potential

Novelty

15. The subject-matter of this claim as far as it relates to accession numbers which do not belong to any of the three aforementioned inventions is novel, because none of the documents related to these numbers discloses the use of the sequences in the claimed method.

Inventive step

16. The reasoning set out in paragraph 15 above applies here as well.

Re Item VI

Certain documents cited

Certain published documents (Rule 70.10)

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 0012711	09.03.00	02.09.99	02.09.98

Re Item VIII

Certain observations on the international application (Articles 5 and 6 PCT)

17. The term "substantially similar" used in claims 1 and 22 is not clear. The claim should be amended on the basis of the description, page 14, line 15 et seq. Moreover, a DNA sequence" is not a product, but rather the definition for a product. Thus, the category of claims 1-5 and 22-26 is not clear. The latter objection could be overcome by using the following expression: "An isolated and purified DNA fragment having the sequence..."
- Claim 1 could be amended in the following way: "An isolated and purified DNA fragment having the sequence shown in SEQ ID No. 3 and variants thereof obtained by deletions, substitutions or additions and encoding a protein product reacting with an antibody directed against the protein encoded by SEQ ID No. 3."
- Claim 22 could read: "An isolated and purified DNA fragment having a DNA sequence as shown in any of SEQ ID Nos. and variants thereof obtained by deletions, substitutions or additions and encoding a protein product reacting with an antibody directed against the protein encoded by SEQ ID No. 3."
- The functional limitation of the variants is necessary in order to ensure novelty and that all variants belong to the inventive concept of the application. For the same reason this definition should also be encompassed in claims 2 and 23.
18. In claims 2 and 24 the term "consists essentially" is vague and renders the matter for which protection is sought unclear. Is the sequence the same or not and if not, how many modifications are allowed? In order to overcome this objection, the term "essentially" should be deleted.
19. Claims 1-3, 5, 22-24 and 26 are drafted as independent product claims. This gives rise to a lack of clarity of the claims as a whole, since the plurality of independent claims makes it difficult, if not impossible, to determine the matter for which protection is sought, and places an undue burden on others seeking to establish the extent of the protection.
- If the claims are amended as suggested above, claims 2 and 3 could be made dependent on claim 1. Claim 5 could remain an independent claim. The same applies to claims 23 and 24 which could be dependent on claim 22 with claim 26 remaining independent.
20. The objection raised with respect to claim 1 in view of the term "substantially

similar" applies as well to claim 8. In view of page 18 of the description the claim could for example take the following form: "A substantially purified recombinant polypeptide having the amino acid sequence shown in SEQ ID No. 5 and variants thereof obtained by deletions, substitutions or additions said variants reacting with an antibody directed to a protein having the amino acid sequence shown in SEQ ID No. 5."

21. For the same reasons as mentioned in point 18 the functional limitation should also be introduced into claim 9.
22. The objection raised in point 19 also applies to claim 10.
23. The term "substantially similar" in claim 11 is superfluous and thus renders the claim unclear. In claim 11 reference is made to amino acid sequences of claim 8. This claim however already includes "substantially similar" sequences. In order to overcome this objection the term should be deleted.
24. Claim 13 is inconsistent for two reasons:
 - i) The claim mentions two methods for detecting alpha2delta-C mutations: PCR and hybridization. In connection with hybridization the probes used for hybridization should be indicated, i.e. DNA fragments of claims 1, 2 or 3.
 - ii) At the end of the claim it is stated the it should be determined whether the PCR product contains a mutation. However, the hybridisation method does not seem to lead to a PCR product.
25. Claim 16 lacks the essential features of the invention since it does not define that the primers are derived from the fragments of claims 1, 2 or 3.
26. The wording of Claim 17 is inconsistent because it relates to an assay, i.e. to a method with out reciting any method step. In order to overcome this objection claims 17 and 18 should be combined.
27. The wording of Claim 31 is inconsistent because it does not recite any method step. Moreover, due to its formulation the category of the claim is not entirely clear (method or use claim?) The claim could be reformulated in the following way: "a

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/23519

method to treat diseases which may resultcomprising the step of using polynucleotide sequences selected from the group". The same objection essentially applies to claims 33 and 34.

28. Claim 31 defines the disease to be treated by functional terms "which may result ". This definition is only clear if a person skilled in the art knows which disease falls under this definition. This means that there must be instructions in form of experimental tests or any other testable criteria allowing to determine the skilled person which diseases result from alterations of the genes or from alterations of cellular pathways involving the genes or proteins. The application mentions a list of diseases in which alpha 2 delta C or D may be involved however a direct link has not been established for any of them. Moreover, there are no tests given how this link can be established. Consequently, a person skilled in the art is not in the position to determine which diseases can be treated. Consequently, the claim is not clear.
29. Claim 32 is only at first glance more specific. Since the alterations in the alpha 2 delta C or D genes or alterations in the pathway in which the proteins are implicated has not been shown to cause any disease, the list of claim 32 is purely speculative and only based on the assumption that the alpha 2 delta C or D subunits will as the alpha 2 delta a subunit bind to gabapentin and therefore be involved in the same disease conditions. The description or the common technical knowledge of a skilled person do not provide any tangible evidence into which diseases the alpha 2 delta C or D subunit is involved. Therefore, the method of claims 31 and 32 can only be carried out by exercising inventive skill. Consequently, the description with regard to these claims does not comply with the requirements of Article 5 PCT. The same argumentation applies to claim 33.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 5947-01-MJA	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 99/ 23519	International filing date (day/month/year) 07/10/1999	(Earliest) Priority Date (day/month/year) 07/10/1998
Applicant WARNER-LAMBERT COMPANY et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 9 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☒ Unity of invention is lacking (see Box II).

4. With regard to the title,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

CALCIUM CHANNEL ALPHA-2/DELTA GENE

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/23519

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 19, 20, 31-33
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-26, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta C protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 3; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 5; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta C"; claims 22-26 as far as they relate to SEQ ID Nos. 11, 14, 40, 41, 43, 44, 47-49; claims 34 as far as it is related to accession nos. from AU022914.1 to AI051759.1 and SEQ ID Nos. 3, 5, 9-14, 36-41, 43, 44, 47

2. Claims: 1-26 (all partially), 27-30, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta D protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 4; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 6; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta D"; claims 22-26 as far as they relate to SEQ ID Nos. 15, 16, 21-24; claim 34 as far as it is related to accession nos. from T70594.1 to AA001473.1 and SEQ ID Nos. 4, 6, 15, 16, 18-24, 42, 45, 46, 48, 49.

3. Claims: 22-26, 34

subject-matter related to calcium channel alpha 2 delta B protein: claims 22-26 as far as they relate to SEQ ID Nos. 31-35; claim 34 as far as it relates to accession no. AF040709.1 and accession nos. from T80372.1 to Z84492.1 as well as SEQ ID Nos. 1, 2, 7, 8, 25-35.

4. Claim : 34 (partially)

method of using polynucleotides sequences to identify the binding potential of polynucleotide sequences to gabapentin: claim 34 as far as it is related to accession nos. not mentioned before

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 33 directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Although claims 19, 20, 31, 32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 19, 20, 31-33

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IS 99/23519

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C07K14/47 C07K16/18 C07K16/28
C12Q1/68 A61K38/17 G01N33/68 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, STRAND, MEDLINE, BIOSIS, SCISEARCH, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC AA190607, 21 January 1997 (1997-01-21) HILLIER, L. ET AL.: "zq44e03.r1 Stratagene hNT neuron, Homosapiens cDNA clone IMAGE: 632572 5' similar to TR:G179762 G179762 Calcium Channel Alpha-2B subunit; mRNA sequence" XP002136760 see the whole document: 97,6% identity in 413bp overlap with SEQ ID No. 3; 96,8% identity in 340bp overlap with SEQ ID No. 43; 97,6% identity in 413bp overlap with SEQ ID No. 44</p> <p style="text-align: center;">--- -/-</p>	1,2,22, 23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

21 July 2000

Date of mailing of the international search report

24.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alt, G

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC Z44942, 6 November 1994 (1994-11-06) AUFRAY, C. ET AL.: "Homo sapiens partial cDNA sequence; clone c-2dd03" XP002136761 see the whole document: 99,7% identity in 340 bp overlap with SEQ ID No. 3; 100% identity in 17bp overlap with SEQ ID No. 11</p> <p>---</p>	1,2,22, 23
X	<p>DATABASE EMBL 'Online! AC R20288, 23 April 1995 (1995-04-23) HILLIER, L. ET AL.: "yg20f03.r1 Soares infant brain INIB Homo sapiens cDNA clone IMAGE:32708 5', mRNA sequence" XP002136762 see the whole document: 97,6% identity in 340 bp overlap with SEQ ID No. 3</p> <p>---</p>	1,2
X	<p>DATABASE EMBL 'Online! AC AA459684, 13 June 1997 (1997-06-13) HILLIER, L. ET AL.: "zx49d08.s1 Soares testis NHT Homo sapiens cDNA clone 759567 3' EST" XP002136763 see whole document: 100% identity in 304bp overlap with SEQ ID No. 3</p> <p>---</p>	1,2
X	<p>WO 95 04822 A (SALK INST BIOTECH IND) 16 February 1995 (1995-02-16) see SEQ ID No. 31: 34,4% identity in 540 aa overlap with SEQ ID No. 5; 29,1% identity in 1122aa overlap with SEQ ID No. 6;</p> <p>---</p>	8
X	<p>DATABASE EMBL 'Online! ACAC005343, 4 August 1998 (1998-08-04) MUZNY, D. ET AL.: "Homo sapiens chromosome 12p13.3 BAC RPCI 11-21K20 (Roswell Park Cnacer Institute Human BAC Library) complete sequence" XP002143146 see the whole document: 98,5% identity in 1847 bp overlap with SEQ ID No. 4, 15, 16;</p> <p>---</p>	1,2,22, 23
X	<p>DATABASE EMBL 'Online! AC AA719773, 7 January 1998 (1998-01-07) HILLIER, L. ET AL.: "zh38g01.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone 414384 3'" XP002143147 see the whole document: 98,4% identity in 436 bp overlap with SEQ ID NO. 4</p> <p>---</p>	1,2,22, 23

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC AA001473, 20 July 1996 (1996-07-20) HILLIER, L. ET AL.: "ze45d04.r1 Soares retina N2b4Hr Homo sapiens cDNA clone 361927 5'" XP002143148 see the whole document: 97,8% identity in 489bp overlap with SEQ ID NO. 4, 15, 16</p>	1,2,22, 23
X	<p>WO 98 11131 A (CHEN AI RU SUN ;FRANCO RODRIGO (US); AMERICAN HOME PROD (US); SHUE) 19 March 1998 (1998-03-19) see SEQ ID NO.4: 29,0% identity in 1129aa overlap with SEQ ID No. 6</p>	8
X	<p>DATABASE EMBL 'Online! AC Z75742, 9 July 1996 (1996-07-09) WILKINSON; J.: "Human DNA sequence from cosmid LUCA10 on chromosome 3p21.3 contains ESTs" XP002143149 see the whole document: 82,8% identity in 87bp overlap with SEQ ID No. 33</p>	23
A	<p>DATABASE EMBL 'Online! AC AB011130, 10 April 1998 (1998-04-10) OHARA, O. ET AL.: "Homo sapiens mRNA for KIAA0558 protein, partial cds." XP002143150 see the whole document; 100% identity in 1145aa overlap with SEQ ID No. 2</p>	22-26,34
Y	<p>GEE N S ET AL: "THE NOVEL ANTICONVULSANT DRUG, GABAPENTIN (NEURONTIN), BINDS TO THEALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5768-5776, XP002022221 ISSN: 0021-9258 cited in the application see the whole document</p>	34

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>BROWN J P ET AL: "CLONING AND DELETION MUTAGENESIS OF THE ALPHA 2 DELTA CALCIUM CHANNEL SUBUNIT FROM PORCINE CEREBRAL CORTEX" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 39, 1998, pages 25458-25465, XP000887190 ISSN: 0021-9258 see the paragraph bridging pages 25461-25462</p>	34
P, X	<p>KLUGBAUER, N. ET AL.: "Molecular diversity of the calcium channel alpha 2 delta subunit" NEUROSCIENCE, vol. 19, no. 2, 15 January 1999 (1999-01-15), pages 684-691, XP000886459 see Figure 1; 89,4% identity in 1902bp overlap with SEQ ID 3; 94,0% identity in 251bp overlap with SEQ ID No. 14; 94,8% identity in 561 bp overlap with SEQ ID NO. 40; 96,0% identity in 273bp overl overlap with SEQ ID No. 41; 88,0% identity in 1494bp of SEQ ID NO. 43; 88,1% identity in 1494bp overlap with SEQ ID NO. 44; 57,1% identity in 2962bp overlap with SEQ ID No. 4; 65,6% identity in 1454bp overlap with SEQ ID NO. 15; 65,6% identity in 1454bp overlap with SEQ ID No. 16;</p>	1,2,4, 6-10,22, 23
E	<p>WO 00 12711 A (INCYTE PHARMA INC ;AZIMZAI YALDA (US); CORLEY NEIL C (US); REDDY R) 9 March 2000 (2000-03-09) see SEQ ID No. 28: 98.1% identity in SEQ ID No. 28: 1276bp overlap with SEQ ID 3; 89,5% identity in 516bp overlap with SEQ ID No. 40; 98,0% identity in 1276bp overlap with SEQ ID No. 43; 98,1% identity in 1276bp overlap with SEQ ID No. 44; 67,0% identity in 1268bp overlap SEQ ID NO. 4 and SEQ ID No. 28; 67,0% identity in 1268bp overlap with SEQ ID No. 15; 67,0% identity in 1268bp overlap with SEQ ID No. 16;</p>	1,2,8, 22,23

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WILLIAMS, M.E. ET AL.: "Structure and functional expression of alpha 1, alpha2, and beta subunits of a novel human neuronal calcium channel subtype" NEURON, vol. 8, January 1992 (1992-01), pages 71-84, XP000886416 see Figure 3; last paragraph, second column, page 84</p> <p>----</p>	1
A	<p>WALKER, D. AND DE WAARD, M.: "Subunit interaction sites in voltage-dependent Ca²⁺ channels: role in channel function" TRENDS IN NEUROSCIENCES, vol. 21, no. 4, 1998, XP000887176 cited in the application see the whole document</p> <p>-----</p>	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/23519

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504822 A	16-02-1995	US 5874236 A	23-02-1999
		AU 3390499 A	19-08-1999
		AU 707793 B	22-07-1999
		AU 7632294 A	28-02-1995
		EP 0716695 A	19-06-1996
		GB 2284814 A, B	21-06-1995
		JP 9509041 T	16-09-1997
WO 9811131 A	19-03-1998	US 6040436 A	21-03-2000
		AU 4343097 A	02-04-1998
WO 0012711 A	09-03-2000	AU 6137699 A	21-03-2000

PCTD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/00		A2	(11) International Publication Number: WO 00/20450
			(43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/23519 (22) International Filing Date: 7 October 1999 (07.10.99) (30) Priority Data: 60/103,322 7 October 1998 (07.10.98) US 60/106,473 30 October 1998 (30.10.98) US 60/114,088 29 December 1998 (29.12.98) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): JOHNS, Margaret, Ann [US/US]; 2800 Deake Avenue, Ann Arbor, MI 48108 (US). MOLDOVER, Brian [US/US]; 4893 S. Ridgeside Circle, Ann Arbor, MI 48105 (US). OFFORD, James, David [US/US]; 3388 Alan Mark Drive, Ann Arbor, MI 48105 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.			(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: ALPHA-2/DELTA GENE			
(57) Abstract The present invention relates to three novel genes and polypeptides derived therefrom encoding " $\alpha 2\delta$ -C" and/or " $\alpha 2\delta$ -D" proteins which exist as a subunit in many calcium channels. The invention also describes methods for using the novel gene and polypeptides in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, binding assays in connection with chemical databases, gene therapy.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

69/787657

RECEIVED

SEP 28 2001

TECH CENTER 1600/2900

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 April 2000 (13.04.2000)

PCT

(10) International Publication Number
WO 00/20450 A3(51) International Patent Classification⁷: **C12N 15/12**,
C07K 14/05, 14/47, 16/18, 16/28, C12Q 1/68, A61K
38/17, G01N 33/68, A61K 48/00(74) Agents: RYAN, M., Andrea; Warner-Lambert Company,
201 Tabor Road, Morris Plains, NJ 07950 et al. (US).

(21) International Application Number: PCT/US99/23519

(81) Designated States (*national*): AE, AL, AU, BA, BB, BG,
BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID,
IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN,
MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA,
US, UZ, VN, YU, ZA.

(22) International Filing Date: 7 October 1999 (07.10.1999)

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:
60/103,322 7 October 1998 (07.10.1998) US
60/106,473 30 October 1998 (30.10.1998) US
60/114,088 29 December 1998 (29.12.1998) USPublished:
— With international search report.(71) Applicant (*for all designated States except US*):
WARNER-LAMBERT COMPANY [US/US]; 201
Tabor Road, Morris Plains, NJ 07950 (US).(88) Date of publication of the international search report:
23 November 2000

(72) Inventors; and

(48) Date of publication of this corrected version:
5 April 2001(75) Inventors/Applicants (*for US only*): **JOHNS, Margaret**,
Ann [US/US]; 2800 Deake Avenue, Ann Arbor, MI 48108
(US). **MOLDOVER, Brian** [US/US]; 4893 S. Ridgeside
Circle, Ann Arbor, MI 48105 (US). **OFFORD, James**,
David [US/US]; 3388 Alan Mark Drive, Ann Arbor, MI
48105 (US).(15) Information about Correction:
see PCT Gazette No. 14/2001 of 5 April 2001, Section II*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CALCIUM CHANNEL ALPHA-2/DELTA GENE

(57) Abstract: The present invention relates to three novel genes and polypeptides derived therefrom encoding " $\alpha 2\delta$ -C" and/or " $\alpha 2\delta$ -D" proteins which exist as a subunit in many calcium channels. The invention also describes methods for using the novel gene and polypeptides in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, binding assays in connection with chemical databases, gene therapy.

WO 00/20450 A3

-1-

ALPHA-2/DELTA GENE

FIELD OF THE INVENTION

The present invention relates to novel genes and polypeptides derived and identified therefrom encoding polypeptides related to the alpha-2-delta ("α2δ") protein that is a subunit of the voltage-sensitive calcium channel. In particular, three human novel genes and polypeptides derived and identified therefrom encoding three human polypeptides related to the α2δ protein are disclosed. The invention also describes vectors and host cells comprising the novel genes. The invention also describes methods for using the novel genes, polypeptides, and antibodies specifically targeting the polypeptides in the detection of genetic alterations of the gene, subcellular localization of the polypeptide, gene therapy applications, diagnostics for syndromes associated with altered α2δ expression, such as neurological diseases and disorders, diabetes, cancer, and other diseases associated with α2δ expression, and binding assays in connection with chemical databases, specifically, development of proprietary screening strategies for molecules which modify α2δ protein activity.

BACKGROUND OF THE INVENTION

The voltage activated calcium channels ("VSCCs") of vertebrates have been shown to be involved in a variety of different physiological processes including muscle contraction, insulin release from the pancreas, and neurotransmitter release in the nervous system (Greenberg D. Annals of Neurology, 1997;42:275-82; Catterall W.A., Trends in Neurosciences, 1993;16:500-506; Catterall W., Epstein P.N., Diabetologia, 35(Suppl 2:S23-33) 1992; Birnbaumer L., et al., Neuron, 1994;13; Rorsman P., et al., Diabete. Metab., 1994;20:138-145).

VSCCs are most highly expressed in excitable tissues including brain, skeletal muscle, and heart. They are multiprotein complexes composed of a

-2-

central $\alpha 1$ pore-forming subunit variably associated with beta, gamma, and/or an $\alpha 2\delta$ subunit. Nine different functional classes of VSCCs have been described, based on biophysical and pharmacological studies. These functional classes are mainly determined by the $\alpha 1$ subunit composition. The beta, gamma, and $\alpha 2\delta$ subunits modulate channel function, affecting the kinetics of activation and inactivation, voltage-dependence, peak amplitude, and ligand binding. Walker N., De Waard M., Trends in Neurosciences, 1998;21(4):148-154.

A number of compounds useful in treating various diseases in animals, including humans, are thought to exert their beneficial effects by modulating functions of voltage-dependent calcium channels. Many of these compounds bind to calcium channels and alter cellular calcium flux in response to a depolarizing signal. However, a lack of understanding of the structure of channel subunits and the genes that code for them has hampered scientists both in discerning the pharmacology of compounds that interact with calcium channels and in the ability to rationally design compounds that will interact with calcium channels to have desired therapeutic effects. The lack of understanding is due in part to the fact that it has not been possible to obtain the large amounts of highly purified channel subunits that are required to understand, at the molecular level, the nature of the subunits and their interactions with one another, with the cell membranes across which the channels allow calcium ions to pass, with calcium and other ions, and with low molecular weight compounds that affect channel function.

Further, the lack of information on genes that code for calcium channel subunits has prevented the understanding of the molecular properties of the mature calcium channel subunits and their precursor proteins (i.e., the mature subunits with signal peptides appended to the amino-terminus) and the regulation of expression of calcium channel subunits. An understanding of these properties, and of how expression of calcium channel subunits genes is regulated, may provide the basis for designing therapeutic agents which have beneficial effects through affecting calcium channel function or concentration. Furthermore, the availability of sequences of genes coding for calcium channel subunits would make possible the diagnosis of defects, which might underlie a number of diseases, in genes coding for such subunits.

-3-

Expression experiments in *Xenopus* oocytes have demonstrated that in order to produce fully functional calcium channels, the $\alpha 1$ and $\alpha 2\delta$ subunits must both be expressed. Absence of the $\alpha 2\delta$ subunit results in a nonfunctional channel, even though the $\alpha 1$ subunit, through which ions flow, is fully expressed. Indeed, not only the ion flux through these channels, but the pharmacological properties of the $\alpha 1$ are different in the absence of the $\alpha 2\delta$ subunit. The $\alpha 2\delta$ subunit, therefore, is a critical component of VSCCs and one that must be studied if one is to better characterize VSCC function.

A detailed understanding of VSCC operation is beginning to reveal some mechanisms for interceding in the progression of diseases associated with abnormal VSCC functions. US Patent No. 5,618,720, which issued April 8, 1997, references $\alpha 1$ and $\alpha 2\delta$ subunits and the polynucleotide sequences that encode the subunits. The publication, however, does not disclose any additional $\alpha 2\delta$ subunits and in light of the importance of the $\alpha 2\delta$ subunit, it can be understood that the identification and characterization of new $\alpha 2\delta$ subunits and the genes encoding these subunits would advance molecular genetic and pharmacological studies to understand the relations between the structure and the function of VSCCs.

Also, a further understanding of the biochemical mechanisms behind these subunits and their effect on mammals may lead to new opportunities for treating and diagnosing diseases related to abnormal (high or low) VSCC operation. Stated another way, a better understanding of the molecular mechanisms of VSCC operation will allow improved design of therapeutic drugs that treat diseases related to abnormal VSCC expression, and specifically abnormal $\alpha 2\delta$ expression.

The cDNAs, oligonucleotides, peptides, antibodies for the $\alpha 2\delta$ proteins, which are the subject of this invention, provide a plurality of tools for studying VSCC operations in various cells and tissues and for diagnosing and selecting inhibitors or drugs with the potential to intervene in various disorders or diseases in which altered $\alpha 2\delta$ expression is implicated. Such disease states affected include epilepsy and other seizure-related syndromes, migraine, ataxia and other vestibular defects (for review, Terwindt, GM et. Al., Eur J Hum Genet 1998 Jul-Aug; 6(4):297-307), chronic pain (Backonja M, JAMA 1998 Dec 2;280(21):1831-6), mood, sleep interference (Rowbotham M, JAMA 1998 Dec

-4-

2;280(21):1837-42), anxiety (Singh et al., Psychopharmacology 1996 Sep. 127(1): 1-9), ALS (Mazzini L et. Al., J Neurol Sci 1998 Oct, 160 Suppl 1:S57-63), multiple sclerosis (Metz L, Semin Neurol 1998;18(3):389-95), mania (Erfurth A, et al., J Psychiatr Res 1998 Sep-Oct;32(5):261-4), tremor (Evidente VG, et al., Mov Disord 1998 Sep;13(5):829-31), parkinsonism (Olson WL, et al., Am J Med 1997 Jan;102(1):60-6) substance abuse/addiction syndromes (Watson, WP et al., Neuropharmacology 1997 Oct;36(10):1369-75), depression, and cancer, since at least one $\alpha 2\delta$ gene is located in a region of the genome which is thought to harbor an important tumor suppressor gene (Kok K., et al., Adv Cancer Res 1997;71:27-92).

The $\alpha 2\delta$ gene is also thought to play a part in proliferative diseases other than cancer, such as inflammation. Treatment with compounds which bind to $\alpha 2\delta$ lead to changes in the signal transduction mechanism of certain proteins. This includes altered levels of MEK (eg, MEK1 and MEK2) which activates the MAP kinase. Inhibitors of MEK appear to mimic the analgesic activities associated with the binding of gabapentin to $\alpha 2\delta$. Activation of MAP kinase by mitogens appears to be essential for proliferation, and constitutive activation of this kinase is sufficient to induce cellular transformation.

SUMMARY OF THE INVENTION

While the $\alpha 1$ subunit is known to be coded for by 9 genes, the beta subunit by 4 genes, and the gamma subunit by 2 genes, previously only two human $\alpha 2\delta$ genes were known: " $\alpha 2\delta$ -A (cDNA Accession No. M76559.1 and protein Accession No. P54289.1) and $\alpha 2\delta$ -B (cDNA SEQ ID NO 1 and protein SEQ ID NO 2). The $\alpha 2\delta$ -A gene codes for at least five different splice variants which show tissue-specific expression (Angelotti T., Hoffman F., FEBS, 1996;397:331-337). Translation of the $\alpha 2\delta$ -A gene produces a polypeptide which is post-translationally cleaved into the $\alpha 2$ and the δ subunits. $\alpha 2$ and δ are then joined by disulfide bonds (De Jongh K., JBC, 1990;265(25):14738-14741; Jay S., JBC, 1991;266(5):3287-3293). $\alpha 2$ is thought to be completely extracellular and is heavily glycosylated, while δ probably forms a single transmembrane domain with five intracellular amino acids at its c-terminus (Brickley K., FEBS,

-5-

1995;364:129-133). This transmembrane domain anchors the protein to the membrane. A2 δ -B is related to α 2 δ -A and is available in the public database, GENBANK.

The inventors, however, have discovered the existence of two new human α 2 δ genes, hereinafter referred to as " α 2 δ -C", and " α 2 δ -D" genes (gene names CACNA2C and CACNA2D). The present invention, therefore, relates to the isolation of polynucleotide sequences which identify and encode novel α 2 δ -related proteins (preferably α 2 δ -C and α 2 δ -D proteins) that are expressed in various cells and tissues, both the polynucleotide sequences for the full length genes and any splice variants and their encoded proteins. The polynucleotide sequences are identified in SEQ ID NOS 3-4 and the amino acid sequences of the α 2 δ proteins encoded by the three novel genes are set forth in SEQ ID NOS 5-6.

The invention also concerns a purified or isolated nucleic acid comprising at least 20 consecutive nucleotides of the nucleotide sequences SEQ ID NOS 3-4, or a nucleotide sequence complementary thereto.

A2 δ -C protein of SEQ ID NO 5 is 28% identical and 48% similar at the protein level to α 2 δ -A protein. A2 δ -C protein is 28% identical and 47% similar to α 2 δ -B. A2 δ -C gene of SEQ ID NO 3 contains a mapped marker (known as an STS) within its nucleotide sequence which has been mapped to human chromosome 3p21.1. This region of the human genome is thought to harbor an important tumor suppressor gene, thus α 2 δ -C gene is a candidate tumor suppressor gene (Kersemaekers AM, et al., Br J Cancer 1998;77(2); 192-200).

A2 δ -D protein of SEQ ID NO 6 is 28% identical and 47% similar at the protein level to α 2 δ -A protein. A2 δ -D protein is 28% identical and 46% similar to α 2 δ -B protein. A2 δ -D gene of SEQ ID 4 maps to a previously published cosmid contig on human chromosome 12p13.3.

The unique full length polynucleotides of the present invention were initially discovered by mining the genbank database for sequences with homology to α 2 δ , by utilizing known nucleotide sequences and various methods known in the art, including tools provided by Compugen Systems Ltd. See Sequence Analysis Primer by Michael Gribskov, John Devereux, Oxford University Press, 1994. After identification of expressed sequenced tags (ESTs) and full-length

-6-

sequences related to $\alpha 2\delta$ -A, cloning methods were used to obtain, in hand, full-length sequences for $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, see Examples 1, 2 and 3. In short, an arrayed human, kidney cDNA library obtained from Origene, was screened by PCR, using oligonucleotide primers derived from the database sequences. Clones identified from the library screen were sequenced by standard methods for verification. A summary of the sequencing information is provided in Example 3.

Analysis of the cloned sequences for $\alpha 2\delta$ -B, $\alpha 2\delta$ -C, and $\alpha 2\delta$ -D led to the identification of a conserved domain and of a number of splice variants. The conserved domain is known as a vonWillebrand factor A3 domain (Huizinga, EG, et. al., Structure 1997, Sept 15;5(9):1147-56). This domain has been described in a large number of proteins and is thought to mediate cell adhesion. Interesting splice-variants of $\alpha 2\delta$ -C and $\alpha 2\delta$ -D were also identified. These variants result in a c-terminal truncation of the respective protein sequences. Truncation of the c-terminus may lead to the production of a soluble, secreted $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein with new functions beyond that previously described for $\alpha 2\delta$.

The $\alpha 2\delta$ proteins are of interest because they play an important role in many disease states. In one example, $\alpha 2\delta$ -A has been shown to be a high-affinity binding target of the anti-convulsant drug gabapentin (NEURONTIN) (Gee N., JBC 1996;271:5768-5776). This property of the $\alpha 2\delta$ -A protein has the potential to have profound physiological effects. Thus, by regulating the levels or activities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, or by modulating their function, desirable physiological effects may be obtained. Such effects may be used to treat a variety of diseases involving abnormal expression of $\alpha 2\delta$ or the abnormal expression of VSCCs (i.e., disease states include, but are not limited to epilepsy, chronic pain, anxiety, diabetes, ALS, mania, cancer, tremor, parkinsonism, migraine, ataxia, mood, sleep interference, depression, multiple sclerosis, inflammation).

The rationale for the therapeutic use of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins to design or discover treatment for these diseases is based upon the fact that gabapentin has been successfully used for treating epilepsy, chronic pain, and ALS, and has implications for use in the treatment of mania, tremor, parkinsonism, migraine, ataxia, mood, inflammation, sleep interference, and/or multiple sclerosis). Gabapentin is known to bind to $\alpha 2\delta$ -A with high affinity and

-7-

this binding is thought to represent the mechanism of action of gabapentin. Therefore, gabapentin and/or other compounds which bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may have similar, or related, therapeutic effects to the effects seen with gabapentin. Also, compounds which are known to have therapeutic effects on calcium channels are regulated in their affinity by the presence of $\alpha 2\delta$. Thus, pharmacological or genetic approaches to alleviating this deficiency will have a major impact on the diseases described above.

One aspect of the invention is to provide purified $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The purified proteins may be obtained from either recombinant cells or naturally occurring cells. The purified $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention may be mammalian in origin. Primate, including human-derived $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, are examples of the various proteins specifically provided for. The invention also provides allelic variants and biologically active derivatives of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

Another aspect of the invention is to provide polynucleotides encoding the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention and to provide polynucleotides complementary to polynucleotide coding strand. The polynucleotides of the invention may be used to provide for the recombinant expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The polynucleotides of the invention may also be used for genetic therapy purposes so as to 1) treat diseases which may result from alterations of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes or from alterations of cellular pathways involving $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, 2) test for presence of a disease, or susceptibility to a disease, due to alterations or deletions in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, 3) analyze or alter the subcellular localization of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D polypeptide, 4) clone or isolate discrete classes of RNA similar to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes, 5) express discrete classes of RNA in order to alter the levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes.

The invention also relates to oligonucleotide molecules useful as probes or primers, wherein said oligonucleotide molecules hybridize specifically with any nucleotide sequence comprising or related to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes, particularly the sequences of SEQ ID NOS 3-4. These oligonucleotides are useful

-8-

either as primers for use in various processes such as DNA amplification and microsequencing or as probes for DNA recognition in hybridization analyses.

A nucleic acid probe or primer according to the invention comprises at least 8 consecutive nucleotides of a polynucleotide of SEQ ID NOS 3-4, preferably from 8 to 200 consecutive nucleotides, more particularly from 10, 15, 20 or 30 to 100 consecutive nucleotides, more preferably from 10 to 90 nucleotides, and most preferably from 20 to 80 consecutive nucleotides of a polynucleotide of SEQ ID NOS 3 or 4. Preferred probes or primers of the invention comprise the oligonucleotides selected from the group consisting of the oligonucleotides set forth in the examples below.

The invention also concerns a method for the amplification of a region of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes. The method comprises the step of: contacting a test sample suspected of containing the desired $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D sequence or portion thereof with amplification reaction reagents, comprising a pair of amplification primers such as those described above, the primers being located on either side of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D nucleotide region to be amplified. The method may further comprise the step of detecting the amplification product. For example, the amplification product may be detected using a detection probe that can hybridize with an internal region of the amplified sequences. Alternatively, the amplification product may be detected with any of the primers used for the amplification reaction themselves, optionally in a labeled form.

The invention also concerns diagnostic kits for detecting the presence of at least one copy of a $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D DNA in a test sample, said kits containing a primer, a pair of primers or a probe according to the invention.

In a first embodiment, the kit comprises primers such as those described above, preferably forward and reverse primers which are used to amplify the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene or a fragment thereof.

In a second embodiment, the kit comprises a hybridization DNA probe, that is or eventually becomes immobilized on a solid support, which is capable of hybridizing with the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene or a fragment thereof. The

-9-

techniques for immobilizing a nucleotide primer or probe on a solid support are well-known to the skilled person.

The kits of the present invention can also comprise optional elements including appropriate amplification reagents such as DNA polymerases when the kit comprises primers, reagents useful in hybridization reactions and reagents useful to reveal the presence of a hybridization reaction between a labeled hybridization probe and the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene.

Another aspect of the invention is to provide antibodies capable of binding to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention. The antibodies may be polyclonal or monoclonal. The invention also provides methods of using the subject antibodies to detect and measure expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins either *in vitro* or *in vivo*, or for detecting proteins that interact with $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, or molecules that regulate any of the activities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

Another aspect of the invention is to provide assays for the detection of proteins that interact with $\alpha 2\delta$ -C or $\alpha 2\delta$ -D using genetic approaches. A preferred embodiment involves the use of yeast two-hybrid approaches for this screening. (Bartel and Fields, The Yeast Two-Hybrid System, Oxford University Press, 1997)

Another aspect of the invention is to provide assays for the detection or screening of therapeutic compounds that interfere with, or mimic in any way, the interaction between $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins and ligands that bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

In a first embodiment, such a method for the screening of a candidate substance comprises the following steps :

- a) providing a polypeptide comprising the amino acid sequence of SEQ ID NO 5 and/or 6, or a peptide fragment or a variant thereof;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance; and
- d) detecting the complexes formed between said polypeptide and said candidate substance.

-10-

In one embodiment of the screening method defined above, the complexes formed between the polypeptide and the candidate substance are further incubated in the presence of a polyclonal or a monoclonal antibody that specifically binds to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein of the invention or to the peptide fragment or variant thereof.

The candidate substance or molecule to be assayed for interacting with the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D polypeptide may be of diverse nature, including, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides.

In another embodiment of the present screening method, increasing concentrations of a substance competing for binding to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein with the considered candidate substance is added, simultaneously or prior to the addition of the candidate substance or molecule, when performing step c) of said method. By this technique, the detection and optionally the quantification of the complexes formed between the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or the peptide fragment or variant thereof and the candidate substance or molecule to be screened allows the one skilled in the art to determine the affinity value of said substance or molecule for said $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or the peptide fragment or variant thereof.

The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein having the amino acid sequence of SEQ ID NO 5 and/or 6 or a peptide fragment or a variant thereof, and optionally means useful to detect the complex formed between the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or its peptide fragment or variant and the candidate substance. In a preferred embodiment the detection means consist in monoclonal or polyclonal antibodies directed against the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or a peptide fragment or a variant thereof.

The assays of the invention therefore comprise the step of measuring the effect of a compound of interest on binding between $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and the ligands that bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. Binding may be measured in a variety of ways, including the use of labeled $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or labeled ligands. These ligands may include, but are not limited to,

-11-

neutral alpha-amino acids, which have been shown to bind to $\alpha 2\delta$ -A, or therapeutic compounds such as gabapentin or related analogues.

Another aspect of the invention is to provide assays for the discovery of proteins that interact directly or indirectly with $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The assays of the invention comprise a method for detecting such interactions in cells, or in biochemical assays. These interactions may be detected in a variety of ways, including the use of the cDNA encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, or $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins themselves, or fragments or modifications thereof. The assays may also comprise a method for detecting the interaction between $\alpha 2\delta$ subunits and other subunits of the calcium channel, such as $\alpha 1$ subunits. These assays may involve measuring the interaction between the proteins directly, or assaying the activity of a fully assembled calcium channel.

Before the present sequences, polypeptides, methods for making and using the invention are described, it is to be understood that the invention is not to be limited only to the particular sequences, polypeptides and methods described. The sequences, polypeptides and methodologies may vary, and the terminology used herein is for the purpose of describing particular embodiments. The foregoing is not intended and should not be construed as limiting the invention in any way since the scope of protection will ultimately depend upon the claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All U.S. patents and all publications mentioned herein are incorporated in their entirety by reference thereto.

BRIEF DESCRIPTION OF THE INVENTION

Figure 1: Fine-mapping of $\alpha 2\delta$ -B to mouse chromosome 9

Figure 2: Human $\alpha 2\delta$ -B tissue distribution

Figure 3: [3 H] gabapentin binding activity by human $\alpha 2\delta$ -B in transiently transfected COS7

Figure 4: Human $\alpha 2\delta$ -C tissue distribution

-12-

DETAILED DESCRIPTION OF THE INVENTION

Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: *Molecular Cloning: A Laboratory Manual* (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in *Methods in Enzymology* (M.P. Deutscher, ed., (1990) Academic Press, Inc.); *PCR Protocols: A Guide to Methods and Applications* (Innis, et al. 1990. Academic Press, San Diego, CA), *Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed.* (R.I. Freshney. 1987. Liss, Inc. New York, NY), and *Gene Transfer and Expression Protocols*, pp. 109-128, ed. E.J. Murray, The Humana Press Inc., Clifton, N.J.) *Sequence Analysis Primer* (Gribskov, et al., 1994, Oxford University Press).

In one aspect, the present invention provides novel isolated and purified polynucleotides, hereinafter referred to as alpha-2-delta-C and alpha-2-delta-D ("α2δ-C", "α2δ-D") genes, encoding α2δ-C and α2δ-D proteins, wherein the polynucleotide sequences are substantially similar to those shown in SEQ ID NOS 3-4 and the polypeptide sequences are substantially similar to those shown in SEQ ID NOS 5-6. The terms "α2δ-C" and "α2δ-D" are used broadly herein. Unless noted otherwise, the terms "α2δ-C" and "α2δ-D" include any natural mammalian-derived form of α2δ-C and α2δ-D and the like. It is preferred that the terms α2δ-C and α2δ-D include all mammals, including but not limited to primates and humans.

The polynucleotides provided for may encode complete α2δ-C and/or α2δ-D proteins or portions thereof. The polynucleotides of the invention may be produced by a variety of methods including *in vitro* chemical synthesis using well known solid phase synthesis technique, by cloning or combinations thereof. The polynucleotide of the invention may be derived from cDNA or genomic libraries. Persons of ordinary skill in the art are familiar with the degeneracy of the genetic code and may readily design polynucleotides that encode α2δ-C and/or α2δ-D proteins that have either partial or polynucleotide sequence homology to naturally

-13-

occurring polynucleotide sequences encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The polynucleotides of the invention may be single stranded or double stranded. Polynucleotide complementary to polynucleotides encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins are also provided.

5 Polynucleotides encoding an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein can be obtained from cDNA libraries prepared from tissue believed to possess $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or mRNA and to express it at a detectable level. For example, a cDNA library can be constructed by obtaining polyadenylated mRNA from a cell line known to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, and using the mRNA as a
10 template to synthesize double stranded cDNA.

Libraries, either cDNA or genomic, are screened with probes designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries, suitable probes include monoclonal and polyclonal antibodies that recognize and specifically bind to an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein. For cDNA
15 libraries, suitable probes include carefully selected oligonucleotide probes (usually of about 20-80 bases in length) that encode known or suspected portions of an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the same or different species, and/or complementary or homologous cDNAs or fragments thereof that encode the same or a similar gene, and/or homologous genomic DNAs or fragments thereof.
20 Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures as described in Chapters 10-12 of Sambrook et al., Molecular Cloning: A Laboratory Manual, New York, Cold Spring Harbor Laboratory Press, 1989).

A preferred method of practicing this invention is to use carefully selected
25 oligonucleotide sequences to screen cDNA libraries from various tissues. The oligonucleotide sequences selected as probes should be sufficient in length and sufficiently unambiguous that false positives are minimized. The actual nucleotide sequence(s) is/are usually designed based on regions of an $\alpha 2\delta$ protein that have the least codon redundancy. The oligonucleotides may be degenerate at
30 one or more positions. The use of degenerate oligonucleotides is of particular importance where a library is screened from a species in which preferential codon usage is not known.

-14-

The oligonucleotide must be labeled such that it can be detected upon hybridization to DNA in the library being screened. The preferred method of labeling is to use ATP (e.g., T32P) and polynucleotide kinase to radiolabel the 5' end of the oligonucleotide. However, other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labeling.

cDNAs encoding $\alpha 2\delta$ proteins can also be identified and isolated by other known techniques of recombinant DNA technology, such as by direct expression cloning or by using the polymerase chain reaction (PCR) as described in U.S. Patent No. 4,683,195, in section 14 of Sambrook, et al. , Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, New York, 1989, or in Chapter 15 of Current Protocols in Molecular Biology, Ausubel et al. eds., Green Publishing Associates and Wiley-Interscience 1991. This method requires the use of oligonucleotide probes that will hybridize to DNA encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

As defined herein, "substantially similar" includes identical sequences, as well as deletions, substitutions or additions to a DNA, RNA or protein sequence that maintain any biologically active portion thereof of the protein product and possess any of the conserved motifs. This includes, but is not limited to, any splice variants of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D which are found to exist. Preferably, the DNA sequences according to the invention consist essentially of the DNA sequence of SEQ ID NOS 3-4. These novel purified and isolated DNA sequences can be used to direct expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and for mutational analysis of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein function.

Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein, and techniques well known in the art.

In a preferred embodiment, the present invention comprises a nucleotide sequence that hybridizes to the nucleotide sequence shown in SEQ ID NOS 3-4 under high stringency hybridization conditions. As used herein, the term "high stringency hybridization conditions" refers to hybridization on a filter support at 65°C in a low salt hybridization buffer to the probe of interest at 2×10^8 cpm/ μ g for between about 8 hours to 24 hours, followed by washing in 1% SDS, 20 mM

-15-

phosphate buffer and 1 mM EDTA at 65°C, for between about 30 minutes to 4 hours. In a preferred embodiment, the low salt hybridization buffer comprises between, 0.5-10% SDS, and 0.05M and 0.5 M sodium phosphate. In a most preferred embodiment, the low salt hybridization buffer comprises, 7% SDS, and 0.125M sodium phosphate.

As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about $T_m - 5^\circ\text{C}$ (5°C below the melting temperature (T_m) of the probe) to about 20°C to 25°C below T_m . As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

The polynucleotides of the invention have a variety of uses, some of which have been indicated or will be addressed in greater detail, *infra*. The particular uses for a given polynucleotide depend, in part, on the specific polynucleotide embodiment of interest. The polynucleotides of the invention may be used as hybridization probes to recover $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins from genetic libraries. The polynucleotides of the invention may also be used as primers for the amplification of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein encoding polynucleotides or a portion thereof through the polymerase chain reaction (PCR) and other similar amplification procedures. The polynucleotides of the invention may also be used as probes and amplification primers to detect mutations in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein encoding genes that have been correlated with diseases, particularly diseases related to an altered function for $\alpha 2\delta$ -A protein. Including, but not limited to, those diseases stated above.

-16-

The invention also provides a variety of polynucleotide expression vectors, comprising $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, or a sequence substantially similar to it subcloned into an extra-chromosomal vector. This aspect of the invention allows for *in vitro* expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene, thus permitting an analysis of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene regulation and $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein structure and function. As used herein, the term "extra-chromosomal vector" includes, but is not limited to, plasmids, bacteriophages, cosmids, retroviruses and artificial chromosomes. In a preferred embodiment, the extra-chromosomal vector comprises an expression vector that allows for $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein production when the recombinant DNA molecule is inserted into a host cell. Such vectors are well known in the art and include, but are not limited to, those with the T3 or T7 polymerase promoters, the SV40 promoter, the CMV promoter, or any promoter that either can direct gene expression, or that one wishes to test for the ability to direct gene expression.

In a preferred embodiment, the subject expression vectors comprise a polynucleotide sequence encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein in functional combination with one or more promoter sequences so as to provide for the expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (or an anti-sense copy of the sequence suitable for inhibition of expression of an endogenous gene). The vectors may comprise additional polynucleotide sequences for gene expression, regulation, or the convenient manipulation of the vector, such additional sequences include terminators, reporters, enhancers, selective markers, packaging sites, and the like. Detailed description of polynucleotide expression vectors and their use can be found in, among other places Gene Expression Technology: Methods in Enzymology Volume 185 Goeddel ed, Academic Press Inc., San Diego, CA (1991), Protein Expression in Animal Cells Roth et al., Academic Press, San Diego, CA (1994).

The polynucleotide expression vectors of the invention have a variety of uses. Such uses include the genetic engineering of host cells to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. In a further aspect, the present invention provides recombinant host cells that are stably transfected with a recombinant DNA molecule comprising $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D subcloned into an extra-chromosomal

-17-

vector. The host cells of the present invention may be of any type, including, but not limited to, bacterial, yeast, mammalian cells, and *Xenopus* oocytes.

Transfection of host cells with recombinant DNA molecules is well known in the art (Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, 1989) and, as used herein, includes, but is not limited to calcium phosphate transfection, dextran sulfate transfection, electroporation, lipofection and viral infection. This aspect of the invention allows for *in vitro* and *in vivo* expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D and its gene product, thus enabling high-level expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. In a further aspect of the invention the RNA molecules containing $\alpha 2\delta$ -C or $\alpha 2\delta$ -D can be injected into *Xenopus* oocytes along with other calcium channel subunit clones and calcium flux across the oocyte membrane can be measured using standard electrophysiological techniques.

In another aspect of the invention transgenic animals can be constructed by injection of the nucleotide sequence for $\alpha 2\delta$ -C or $\alpha 2\delta$ -D cloned in suitable expression vectors into germ cells.

Other uses of the polynucleotide expression vectors, discussed in greater detail, *infra*, include, their use for genetic therapy for diseases and conditions in which it may be desirable use to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins at levels greater than naturally occurring expression levels. Alternatively, it may be desirable to use the subject vectors for anti-sense expression to reduce the naturally occurring levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

$\alpha 2\delta$ -C and $\alpha 2\delta$ -D share amino acid homology to $\alpha 2\delta$ -A, thus it is very likely that they share some structural and functional characteristics with $\alpha 2\delta$ -A. $\alpha 2\delta$ -A is known to interact with other subunits of voltage-sensitive calcium channels, such as $\alpha 1$ and β . When calcium channels are expressed in oocytes, a functional channel is only produced when an $\alpha 2\delta$ subunit is present. Therefore, $\alpha 2\delta$ is required for calcium channel function. In addition, $\alpha 2\delta$ -A has been shown to bind to gabapentin, a drug used to treat epilepsy, chronic pain, ALS, and potentially other neurological diseases. The mechanism of action of gabapentin is thought to be through its interaction with $\alpha 2\delta$. Given the homology between the $\alpha 2\delta$ proteins, it is likely that $\alpha 2\delta$ -C and $\alpha 2\delta$ -D also share these functions.

-18-

The polynucleotide sequences of SEQ ID NOS 3-4 were mapped to human chromosomes using the nucleotide sequences for the cDNA from library sources (See Examples 2-3) to generate probes. The sequences were mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include in situ hybridization to chromosomal spreads, and PCR-based mapping by amplifying DNA from standard radiation hybrid cell lines. (Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, NYC. A2 δ -C of SEQ ID NO 3 maps to human chromosome 3p21.1. A2 δ -D of SEQ ID NO 4 maps to a previously published cosmid contig on human chromosome 12p13.3.

In another aspect, the present invention provides a substantially purified recombinant protein comprising a polypeptide substantially similar to the α 2 δ -C and/or α 2 δ -D polypeptides shown in SEQ ID NOS 5-6. Furthermore, this aspect of the invention enables the use of α 2 δ protein in several *in vitro* assays described below. As used herein, the term "substantially similar" includes deletions, substitutions and additions to the sequences of SEQ ID NOS 5-6 introduced by any *in vitro* means, or any genetic alterations naturally seen *in vivo*. As used herein, the term "substantially purified" means that the protein should be free from detectable contaminating protein, but the α 2 δ -C and/or α 2 δ -D protein may be co-purified with an interacting protein, or as an oligomer. In a most preferred embodiment, the protein sequence according to the invention comprises an amino acid sequence of SEQ ID NOS 5-6. Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein and techniques well known in the art. This aspect of the invention provides a novel purified protein that can be used for *in vitro* assays, and as a component of a pharmaceutical composition.

A2 δ -C and/or α 2 δ -D proteins may be used to discover molecules that interfere with its activities. For example, molecules that prevent the binding of α 2 δ -C and/or α 2 δ -D to ligands such as neutral alpha-amino acids (for example (L)-leucine), or to other molecules such as other subunits of the voltage-sensitive calcium channels.. Additionally, α 2 δ -C and/or α 2 δ -D proteins may be used to

-19-

find other proteins with which it directly interacts, and potentially representing additional important regulators of VSCC transport.

The $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the present invention have a putative biological activity of modulating the cellular flux of calcium, potentially including both intracellular and extracellular calcium stores. The $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein of the invention may be isolated from a variety of mammalian animal species. Preferred mammalian species for isolation are primates and humans. The invention also contemplates allelic variants of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may be prepared from a variety of mammalian tissues. Preferably, $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins are obtained from recombinant host cells genetically engineered to express significant quantities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may be isolated from non-recombinant or recombinant cells in a variety of ways well known to a person of ordinary skill in the art.

The terms " $\alpha 2\delta$ -C protein" and " $\alpha 2\delta$ -D protein" as used herein refers not only to proteins having the amino acid residue sequence of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, but also refers to functional derivatives and variants of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. A "functional derivative" of a native polypeptide is a compound having a qualitative biological activity in common with the native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Thus, a functional derivative of a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein is a compound that has a qualitative biological activity in common with a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, e.g., binding to other calcium channel subunits and modulating the flux of calcium in cells, or binding to neutral alpha-amino acids and other cognate ligands. "Functional derivatives" include, but are not limited to, fragments of native polypeptides from any animal species (including human), and derivatives of native (human and non-human) polypeptides and their fragments, provided that they have a biological activity in common with a respective native polypeptide. "Fragments" comprise regions within the sequence of a mature native polypeptide. The term "derivative" is used to define amino acid sequence and glycosylation variants, and covalent modifications of a native polypeptide, whereas the term "variant" refers to amino acid sequence and glycosylation

-20-

variants within this definition. Preferably, the functional derivatives are polypeptides which have at least about 70% amino acid sequence similarity, more preferably about 80% amino acid sequence similarity, even more preferably at least 90% amino acid sequence similarity, most preferably at least about 99% amino acid sequence similarity with the sequence of a corresponding native polypeptide. Most preferably, the functional derivatives of a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein retain or mimic the region or regions within the native polypeptide sequence that directly participate in ligand binding. The phrase "functional derivative" specifically includes peptides and small organic molecules having a qualitative biological activity in common with a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

"Identity" or "homology" with respect to a native polypeptide and its functional derivative is defined herein as the percentage of amino acid residues in the candidate sequence that are similar to residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Neither N- or C-terminal extensions nor insertions, nor alternatively-spliced variants, shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known in the art.

Amino acid sequence variants of native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins and $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein fragments are prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein encoding DNA, or by *in vitro* synthesis of the desired polypeptide. There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. With the exception of naturally-occurring alleles, which do not require the manipulation of the DNA sequence encoding the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, the amino acid sequence variants of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein are preferably constructed by mutating the DNA, either to arrive at an allele or an amino acid sequence variant that does not occur in nature.

-21-

Alternatively or in addition, amino acid alterations can be made at sites that differ in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins from various species, or in highly conserved regions, depending on the goal to be achieved.

Sites at such locations will typically be modified in series, e.g. by
5 (1) substituting first with conservative choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue or residues, or (3) inserting residues of the same or different class adjacent to the located site, or combinations of options 1-3.

One helpful technique is called "alanine scanning" Cunningham and
10 Welis, Science 244, 1081-1085 (1989). Here, a residue or group of target residues is identified and substituted by alanine or polyalanine. Those domains demonstrating functional sensitivity to the alanine substitutions are then refined by introducing further or other substituents at or for the sites of alanine substitution.

After identifying the desired mutation(s), the gene encoding an $\alpha 2\delta$ -C
15 and/or $\alpha 2\delta$ -D protein variant can, for example, be obtained by chemical synthesis.

More preferably, DNA encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein amino acid sequence variant is prepared by site-directed mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Site-directed (site-specific) mutagenesis allows the production of
20 $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 20 to 25
25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered. In general, the techniques of site-specific mutagenesis are well known in the art, as exemplified by publications such as, Edelman et al., DNA 2:183 (1983). As will be appreciated, the site-specific mutagenesis technique typically employs a phage vector that exists in both a
30 single-stranded and double-stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. This and other phage vectors are commercially available and their use is well known to those skilled in the art.

-22-

A versatile and efficient procedure for the construction of oligodeoxyribonucleotide directed site-specific mutations in DNA fragments using M13-derived vectors was published by Zoller, M.J. and Smith, M., *Nucleic Acids Res.* 10, 6487-6500 [1982]). Also, plasmid vectors that contain a single-stranded phage origin of replication, Veira et al., *Meth. Enzymol.* 153:3 (1987)] may be employed to obtain single-stranded DNA. Alternatively, nucleotide substitutions are introduced by synthesizing the appropriate DNA fragment in vitro, and amplifying it by PCR procedures known in the art.

In general, site-specific mutagenesis may be performed by obtaining either a double-stranded or a single-stranded vector that includes within its sequence a DNA sequence that encodes the relevant protein. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example, by the method of Crea et al., *Proc. Natl. Acad. Sci. USA* 75, 5765 (1978). This primer is then annealed with the single-stranded protein sequence-containing vector, and subjected to DNA-polymerizing enzymes such as, *E. coli* polymerase I Klenow fragment, to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate host cells such as HB101 cells, and clones are selected that include recombinant vectors bearing the mutated sequence arrangement. Thereafter, the mutated region may be removed and placed in an appropriate expression vector for protein production.

The PCR technique may also be used in creating amino acid sequence variants of an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the

-23-

opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 500-5000 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primes can be easily
5 sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.

Further details of the foregoing and similar mutagenesis techniques are
10 found in general textbooks, such as, for example, Sambrook et al., Molecular Cloning: H Laboratory Manual 2nd edition, Cold Spring Harbor Press, Cold Spring Harbor (1989), and Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley and Sons (1995).

Naturally-occurring amino acids are divided into groups based on common
15 side chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophobic: cys, ser, thr;
- (3) acidic: asp, glu;
- 20 (4) basic: asn, gin, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Conservative substitutions involve exchanging a member within one group
25 for another member within the same group, whereas non-conservative substitutions will entail exchanging a member of one of these classes for another. Variants obtained by non-conservative substitutions are expected to result in significant changes in the biological properties/function of the obtained variant, and may result in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein variants which block $\alpha 2\delta$ -C and/or
30 $\alpha 2\delta$ -D protein biological activities, i.e., modulation of calcium flux, or binding to neutral, alpha-amino acids. Amino acid positions that are conserved among

-24-

various species are generally substituted in a relatively conservative manner if the goal is to retain biological function.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous.

5 Deletions may be introduced into regions not directly involved in ligand binding.

Amino acid insertions include amino- and/or carboxyl terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions (i.e. insertions within the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D

10 protein amino acid sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5 residues, more preferably 1 to 3 residues. Examples of terminal insertions include the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins with an N-terminal methionyl residue, a naturally-occurring N-terminal signal sequence, an artifact of direct expression in bacterial recombinant cell culture, and fusion of a

15 heterologous N-terminal signal sequence to the N-terminus of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein to facilitate the secretion of the mature $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein from recombinant host cells. Such signal sequences will generally be obtained from, and thus homologous to, the intended host cell species. Suitable sequences include STII or Ipp for E. coli, alpha factor for yeast, and viral signals

20 such as herpes gD for mammalian cells. Other insertional variants of the native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein molecules include the fusion of the N- or C-terminus of an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein to immunogenic polypeptides, e.g. bacterial polypeptides such as betalactamase or an enzyme encoded by the E. coli trp locus, or yeast protein, and C-terminal fusions with proteins having a long

25 half-life such as immunoglobulin regions (preferably immunoglobulin constant regions), albumin, or ferritin, as described in PCT published application WO 89/02922.

Since it is often difficult to predict in advance the characteristics of a variant $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, it will be appreciated that screening will be

30 needed to select the optimum variant. For this purpose biochemical screening assays, such as those described herein below, will be readily available.

In a further aspect, the present invention provides antibodies and methods

-25-

for detecting antibodies that selectively bind polypeptides with an amino acid sequence substantially similar to the amino acid sequence of SEQ ID NOS 5-6. As discussed in greater detail, *infra*, the antibody of the present invention can be a polyclonal or a monoclonal antibody, prepared by using all or part of the sequence of SEQ ID NOS 5-6, or modified portions thereof, to elicit an immune response in a host animal according to standard techniques (Harlow and Lane (1988), eds. Antibody: A Laboratory Manual, Cold Spring Harbor Press). In a preferred embodiment, the entire polypeptide sequence of SEQ ID NOS 5-6 is used to elicit the production of polyclonal antibodies in a host animal.

The method of detecting $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D antibodies comprises contacting cells with an antibody that recognizes $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and incubating the cells in a manner that allows for detection of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein-antibody complex. Standard conditions for antibody detection of antigen can be used to accomplish this aspect of the invention (Harlow and Lane, 1988). This aspect of the invention permits the detection of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein both *in vitro* and *in vivo*.

The subject invention provides methods for the treatment of a variety of diseases characterized by undesirably abnormal cellular levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D. Diseases may be treated through either *in vivo* or *in vitro* genetic therapy. Protocols for genetic therapy through the use of viral vectors can be found, among other places, in Viral Vector Gene Therapy and Neuroscience Applications, Kaplit and Lowry, Academic Press, San Diego (1995). Gene therapy applications typically involve identifying target host cells or tissues in need of the therapy, designing vector constructs capable of expressing a desired gene product in the identified cells, and delivering the constructs to the cells in a manner that results in efficient transduction of the target cells. The cells or tissues targeted by gene therapy are typically those that are affected by the disease that the vector construct is designed to treat. For example, in the case of cancer, the targeted tissues are malignant tumors.

The genetic therapy methods of the present invention comprise the step of introducing a vector for the expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (or inhibitory anti-sense RNA) into a patient cell. The patient cell may be either in


-26-

the patient, i.e., *in vivo* genetic therapy, or external to the patient and subsequently reintroduced into the patient, i.e., *in vitro* genetic therapy. Diseases that may be treated by the subject genetic therapy methods include, but are not limited to epilepsy, chronic pain, ALS, mania, cancer, anxiety, diabetes, tremor,
 5 parkinsonism, migraine, ataxia, mood, sleep interference, multiple sclerosis and inflammation).

In a preferred aspect of the invention, a method is provided for protecting mammalian cells from abnormal levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D in cells, comprising introducing into mammalian cells an expression vector comprising a
 10 DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4, that is operatively linked to a DNA sequence that promotes the expression of the DNA sequence and incubating the cells under conditions wherein the DNA sequence of SEQ ID NOS 3 or 4 will be expressed at high levels in the mammalian cells. Suitable expression vectors are as described above. In a
 15 preferred embodiment, the coding region of the human $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene is inserted into an expression vector under the transcriptional control of the

ive $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D

PUBLICATION



20 Nombre de pages.....

BD/AB.....1.....

25 BD/AB.....

DE.....3.....

CL.....

DR.....

3 SR.....

SR.....

Contrôlé par.....

Scanné par.....

Nbre de copies.....

Article 20.....

tion, a method is provided and/or $\alpha 2\delta$ -D in VSCCs, cells an expression vector antially similar to the DNA eratively linked to a DNA e DNA sequence. The cells e DNA sequence of SEQ ID malian cells.

uence consists essentially of ment, the expression vector $\alpha 2\delta$ -D cDNA is operatively as (CMV) promoter to allow D antisense cDNA in a host

-27-

cell. In a preferred embodiment, the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D adenoviral expression vector is introduced into cells by injection into a mammal.

Another aspect of the invention is to provide assays useful for determining if a compound of interest can bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. This binding may interfere with, or mimic, the binding of ligands to the VSCCs, or this binding may affect the function of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D in modulating calcium flux. The assay comprises the steps of measuring the binding of a compound of interest to an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Either the $\alpha 2\delta$ -C and/or the $\alpha 2\delta$ -D protein or the compound of interest to be assayed may be labeled with a detectable label, e.g., a radioactive or fluorescent label, so as to provide for the detection of complex formation between the compound of interest and the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. In another embodiment of the subject assays, the assays involve measuring the interference, i.e., competitive binding, of a compound of interest with the binding interaction between an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and a ligand already known to bind to $\alpha 2\delta$ -A protein. For example, the effect of increasing quantities of a compound of interest on the formation of complexes between radioactivity labeled ligand and an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein may be measured by quantifying the formation of labeled ligand- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein complex formation. In another embodiment of the subject assays, the assays involve measuring the alteration, i.e., non-competitive inhibition, of a compound of interest with the activity of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (compounds which bind to a different region of $\alpha 2\delta$ and inhibit $\alpha 2\delta$ activity, but don't prevent binding of ligands such as gabapentin).

Polyclonal antibodies to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins generally are raised in animals by multiple subcutaneous (se) or intraperitoneal (ip) injections of an $\alpha 2\delta$ protein and an adjuvant. It may be useful to conjugate the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g. keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues),

-28-

N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}_1\text{-N}=\text{C}=\text{NR}$, where R and R_1 are different alkyl groups.

Animals are immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1 μg of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein antibody titer.

Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, but also may be conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.

Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies. For example, the anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein monoclonal antibodies of the invention may be made using the hybridoma method first described by Kohler & Milstein, Nature 256:495 (1975), or may be made by recombinant DNA methods [Cabilly, et al, U.S. Pat. No. 4,816,567].

Antibodies can also be generated using phage display. In this approach libraries of peptides of random sequence are generated in antibody genes cloned into phage. These phage libraries are screened for antibodies by screening against the immobilized protein. (Hoogenboom-HR, Trends-Biotechnol. 1997 Feb; 15(2): 62-70)

In the hybridoma method, a mouse or other appropriate host animal, such as hamster is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*.

-29-

Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Coding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (academic Press, 1986)].

5 The anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein specific antibodies of the invention have a number of uses. The antibodies may be used to purify $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins from either recombinant or non-recombinant cells. The subject antibodies may be used to detect and/or quantify the presence of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins in tissue samples, e.g., from blood, skin, and the like.

10 Quantitation of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may be used diagnostically for those diseases and physiological or genetic conditions that have been correlated with particular levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein expression levels.

15 In a further aspect, the present invention provides a diagnostic assay for detecting cells containing $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D deletions, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR amplification using primers derived from the DNA sequence of SEQ ID NOS 3 or 4.

20 This aspect of the invention enables the detection of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D deletions in any type of cell, and can be used in genetic testing or as a laboratory tool. The PCR primers can be chosen in any manner that allows the amplification of an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene fragment large enough to be detected by gel electrophoresis. Detection can be by any method, including, but not limited to ethidium bromide staining of agarose or polyacrylamide gels, autoradiographic detection of radio-labeled $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene fragments, Southern blot hybridization, and DNA sequence analysis. In a preferred embodiment, detection is accomplished by polyacrylamide gel electrophoresis, followed by DNA sequence analysis to verify the identity of the deletions. PCR conditions are routinely determined based on the length and base-content of the primers selected according to techniques well known in the art (Sambrook et al., 1989).

25 30 An additional aspect of the present invention provides a diagnostic assay for detecting cells containing $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D deletions, comprising isolating total cell RNA and subjecting the RNA to reverse transcription-PCR amplification using primers derived from the DNA sequence of SEQ ID NOS 3 or 4. This

-30-

aspect of the invention enables the detection of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D deletions in any type of cell, and can be used in genetic testing or as a laboratory tool.

Reverse transcription is routinely accomplished via standards techniques (Ausubel et al., in Current Protocols in Molecular Biology, ed. John Wiley and Sons, Inc., 1994) and PCR is accomplished as described above.

The present invention may be better understood with reference to the accompanying examples that are intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.

Examples

Example 1

The sequence for human $\alpha 2\delta$ -A, c-DNA Accession No. M76559.1, was used to perform standard BLASTP searches against the Genbank non-redundant protein database and TBLASTN searches against the expressed sequence tag database (dbEST). Four full-length RNA sequences were identified (c-DNA Accession Nos. AF040709.1, AF042792.1, AF042793.1, and AB011130.1) which were highly homologous to $\alpha 2\delta$ -A. The DNA sequence of $\alpha 2\delta$ -B is provided by SEQ ID NO 1 and the amino acid sequence of $\alpha 2\delta$ -B is provided by SEQ ID NO 2. Using standard alignment tools, these four sequences were found to represent 4 different variants of the same gene. This gene was named $\alpha 2\delta$ -B. Further searches of the sequence databases, and analysis of proprietary clustered sequences generated using Compugen software, led to the identification of additional sequences related to $\alpha 2\delta$ -B. This includes human ESTs (Accession Nos. T80372.1, AA360556.1, AI563965.1, N53512.1, a mouse EST (Accession No. AA000341.1), and a sequence from C.elegans (Accession No. CAA90091.1). Since the initial identification of $\alpha 2\delta$ -B, additional related sequences have been deposited into the Genbank database. These correspond to Accession Nos. (human: AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1,

-31-

AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1; **mouse**: AA008996.1; **rat**: AI105056.1, AI502878.1).

A2 δ -B is 53 % identical and 69% similar at the amino acid level to α 2 δ -A.

5 The α 2 δ -B mRNA is 5482 bp long, and codes for a protein of 1145 amino acids. The three splice-variants of α 2 δ -B which were identified differ only in the 5' untranslated region, and do not alter the amino acid sequence. A2 δ -B aligns to genomic sequence from a previously published cosmid contig on human chromosome 3p21.3. This DNA contig covers more than 600kb of sequence. The
10 Accession Nos. for these genomic sequences are Z84493.1, Z84494.1, Z75743.1, Z75742.1, and Z84492.1. Analysis of the DNA sequences flanking α 2 δ -B led to the identification of genes flanking α 2 δ -B on human chromosome 3p21.3 which had been mapped in both human and mouse. These flanking genes include CIS, HyaL1, GNAI-2, and GNAT-1. In mouse, all of the flanking genes were localized
15 to mouse chromosome 9, 60cM. Analysis of mapping data stored in the Mouse Genome Database, by Jackson Laboratory, led to the identification of three mouse neurological phenotypes that had been genetically mapped to the same mouse chromosome 9, 60cM region. These phenotypes include epilepsy1, ducky and tippy. Epilepsy1 and ducky both have spike-wave activity consistent with
20 epilepsy. This tentatively maps α 2 δ -B to the chromosome 9, 60cM region in mouse, and identifies α 2 δ -B as a candidate gene for the mouse mutants ducky, tippy, and El1 (for overview of mapping data see Figure 1).

Northern and RT-PCR analysis of RNA expression levels of human α 2 δ -B were performed to analyze the expression pattern of α 2 δ -B. For Northern
25 analysis, multiple tissue Northern blots and brain blots were obtained from Clontech. Non-isotopic DNA probes for α 2 δ -B were generated by PCR using SEQ ID NOS 7-8 and SEQ ID NO 1 as a template. Hybridization and washing conditions were in accordance with the manufacturer's instructions (Boehringer Mannheim). A2 δ -B was found to have highest expression in lung, and was also
30 detected in brain, heart, skeletal muscle, and at lower levels in all tissues tested (Figure 2). For the Northern blot surveying different areas of human brain, α 2 δ -B had the highest level of expression in the cerebral cortex, but was detected in all

-32-

areas of the human brain (Figure 2). RT-PCR expression analysis of human $\alpha 2\delta$ -B was also performed. RT-PCR analysis, using a cDNA tissue panel obtained from Clontech and SEQ ID NOS 7-8 for PCR-based gene amplification (cycles: 1X at 94 C 1', 35X at 94 C 0.5', 55 C 1', 72 C 2'; 1X at 72 C 10'), produced an expression pattern for $\alpha 2\delta$ -B consistent with results from Northern analysis. Overall, the expression pattern of $\alpha 2\delta$ -B is consistent with a proposed role of $\alpha 2\delta$ -B in epilepsy.

In order to determine if $\alpha 2\delta$ -B has functional properties comparable to $\alpha 2\delta$ -A, the ability of $\alpha 2\delta$ -B to bind to amino acids and gabapentin was measured. For this analysis, COS-7 cells were transiently transfected with the full-length porcine $\alpha 2\delta$ -A, and human $\alpha 2\delta$ -B genes each in the vector pcDNA3 (Invitrogen)(pcDNA3.1 for $\alpha 2\delta$ -B) by the lipofectamine mediated transfection method. The cells were transfected and membranes harvested by the generic methods outlined below. The K_D for binding of [3 H] gabapentin to $\alpha 2\delta$ -B, as compared to $\alpha 2\delta$ -A, can be found in Table 1. Additional binding studies were performed using techniques similar to those outlined below. Alterations to the protocol are listed below under the subheading "Alternative Method for Measuring [3 H] Gabapentin binding". The data for these binding studies are in figure 3. Overall, the binding and Western data demonstrated that the porcine $\alpha 2\delta$ -A and human $\alpha 2\delta$ -B full-length gene-products expressed transiently in the COS-7 system bind [3 H]gabapentin with high affinity.

Table 1: Saturation binding data for $\alpha 2\delta$ -B

Porcine $\alpha 2\delta$ -A (n=2)	Human $\alpha 2\delta$ -B (n=2)
K_D , 23.1 nM	K_D , 32.6 nM
K_D , 21.2 nM	K_D , 87.2 nM
<i>Mean = 22.2 nM</i>	<i>Mean = 59.9 nM</i>

-33-

Transient Transfection method (150mm plate)

1: Seed 3.9×10^6 COS-7 cells/150mm plate in 42ml DMEM + 10% FBS +
5u/ml Penicillin / 5µg/ml Streptomycin on 150mm plate. Grow O/N.

2: Setup

Tube A – 30ug DNA in 300ul TE + 1.8ml Optimem (5u/ml Penicillin /
5µg/ml Streptomycin)

Tube B – 150ul Lipofectamine + 1.95ml Optimem (5u/ml Penicillin /
5µg/ml Streptomycin)

3: At time=0 mix tubes A and B and leave at RT for 45 minutes.

4: Wash cells with 30ml Optimem (5u/ml Penicillin / 5µg/ml
Streptomycin) twice then add 16.8ml Optimem (5u/ml Penicillin / 5µg/ml
Streptomycin) to the plates. At t=45 minutes add A/B mix to plates.

5: At t=6 hours add 21ml of Optimem (5u/ml Penicillin / 5µg/ml
Streptomycin).

6: At t=24 hours replace medium with 42ml Optimem (5u/ml Penicillin /
5µg/ml Streptomycin)

7: At t=48 hours rinse the cells twice with 20ml of PBS then harvest.

Membrane preparation (perform at 4°C)

1 Harvest cells into a 2ml eppendorf in 1.5ml 1mM EDTA/1mM
EGTA/0.1mM PMSF (added immediately prior to use from a 1000x
stock)/20% Glycerol/10mM HEPES pH7.4 @ 4°C using a cell scraper.

2 Mix cells end-over-end for 30 minutes at 4°C then centrifuge at
20,000 x g for 5 minutes.

3 Resuspend pellet in 1.5ml 1mM EDTA/1mM EGTA/20%
Glycerol/10mM HEPES pH7.4 @ 4°C then immediately re-centrifuge at
20,000 x g for 5 minutes.

-34-

4 Resuspend pellet to ~1mg/ml (protein concentration as determined by the Bradford protein assay) in 1mM EDTA/1mM EGTA/20% Glycerol/10mM HEPES pH7.4 @ 4°C

For total [H3] binding, cells were sonicated for 30-40 seconds, centrifuged for 10' at 750-1000Xg, and the supernatant was centrifuged for 30' at 50,000Xg. The resulting pellet was resuspended in 5mM

[³H]Gabapentin saturation binding assay methodology and data analysis

Assays were carried out at 21°C in a final volume of 250µl in 96-well deep-well plates. Duplicate wells were set up for both ‘total’ and ‘non-specific’ binding. Specific binding was defined as that remaining after subtraction of the ‘non-specific binding’ values from the ‘total’ binding values. Assay components were added in the following order (all reagents were diluted in 10mM HEPES (pH 7.4 at 21°C)):

Total binding 200μl 10mM HEPES pH 7.4

Non-specific binding 175μl 10mM HEPES pH 7.4 and 25μl 100μM
(S+)-3-isobutyl GABA

25μl Appropriate COS membrane sample

25μl [³H]gabapentin

The reaction was incubated at 21°C for 45 minutes then filtered through GF/B filters soaked in 50 mM Tris-Cl pH 7.4 @4°C (wash buffer), filters were washed three times with wash buffer.

The filters were then counted in a scintillation counter.

Saturation experiments were performed with 12 duplicate data points ('Total' and 'Non-Specific' binding determined in duplicate for each concentration of [³H]gabapentin tested) and a [³H]gabapentin concentration range from ~1 to 400nM. Data was analyzed using KEL-RADLIG for Windows.

Alternative Method for Measuring [³H] Gabapentin binding

The method described above was followed with the following exceptions:

1) **COS7 transfection:** 20ug of $\alpha 2\delta$ -A or $\alpha 2\delta$ -B plasmid DNA were incubated with 30ul of lipofectamine. The mixture was overlaid onto the cells in 1.5ml of serum-free medium and incubated for 5 hours. Then FBS was added to the dishes to bring the final concentration to 10%. The medium was changed the next morning. Forty-eight hours after transfection the cells were harvested for membrane preparation.

2) **Membrane preparation:** Cells were washed twice with cold PBS and then scraped off the tissue culture plates in cold 5mM of Tris/5mM EDTA (pH7.4) containing PMSF (0.1mM), leupeptin (0.02mM), and pepstatin (0.02mM). The cells were incubated on ice for 30 minutes and then sonicated for 30-40 seconds. The homogenate was centrifuged for 10 minutes at 750-1000xg, and then the supernatant was centrifuged for 30 minutes at 50,000xg. The resulting pellet was resuspended in the same buffer as described above.

3) **Binding Assays:** The radioligand binding assay was done using 0.05 mg of membrane protein incubated in the presence of 20 nM of [³H] gabapentin. The membranes were incubated in 10 mM Hepes (pH 7.4) for 40-50 minutes at room temperature, and then filtered onto pre-wetted GF/C membranes and quickly washed five times with 3ml of ice cold 50mM tris buffer pH7.4. The filters were dried and counted in a liquid scintillation counter. To determine background binding, 10 uM of isobutyl GABA was used and the resulting counts subtracted from the total counts of each sample.

Detection of $\alpha 2\delta$ -A and $\alpha 2\delta$ -B expression with anti- α_2 polyclonal antibodies

Using affinity purified anti- α_2 polyclonal antibodies (antigen derived from porcine $\alpha 2\delta$ -A; See Brown and Gee (1998) *JBC* 273 25458-25465 for pAb

-36-

generation details) the expression of the porcine $\alpha_2\delta$ -A and human $\alpha_2\delta$ -B proteins (over and above control levels - COS cells transfected with the parent pcDNA3 vector) was confirmed. N.B. Cross reaction of the pAb's with $\alpha_2\delta$ -B was not unexpected given the ~50% amino acid sequence identity. Furthermore, and with reference to Example 2, expression of $\alpha_2\delta$ -C was not detected using this antibody (sequence identity with $\alpha_2\delta$ -A ~30%).

Example 2

The sequence for human $\alpha_2\delta$ -A, Accession No. M76559.1, was used to perform standard BLASTP searches against the Genbank non-redundant protein database and TBLASTN searches against the expressed sequence tag database (dbEST). EST sequences were identified (Accession Nos. AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1) corresponding to a new gene, with similarity to $\alpha_2\delta$ -A, named $\alpha_2\delta$ -C. Additional searches of the sequence databases led to the identification of other sequences related to $\alpha_2\delta$ -C. This includes a mouse EST (Accession No. AU022914.1, AI843362.1), and an STS (Accession No. G36524.1) which maps to human chromosome 3p21.1. Since the initial identification of $\alpha_2\delta$ -B, additional related sequences have been deposited into the Genbank database. These correspond to Accession Nos. (human ESTs: AA459804.1, AI696320.1, AI051759.1, AI696214.1; human genomic sequence: AC010180.1; mouse EST: AA445859.1, mouse RNA: AJ010949.1).

In order to clone a full-length $\alpha_2\delta$ -C, a PCR-based cDNA library screen was carried out by Origene using primers (SEQ ID NOS 9-10) based on sequence derived from EST clone accession number AA190607.1 which were designed to amplify a 273 bp fragment. A positive clone was identified in a kidney library. After sequencing, this clone was identified as a novel 3' splice variant (SEQ ID NO 43). The protein sequence, which can be derived from SEQ ID NO 43, of this novel splice variant is a truncated, potentially secreted soluble form of $\alpha_2\delta$ -C. PCR was performed, using primers (SEQ ID NOS 9 and 11) and a human adult

-37-

brain library from LTI as a template, and the resulting fragment of 248 bp was cloned in pBS and sequence verified. A SacI-NcoI fragment from the kidney clone, a NcoI-KpnI fragment from the PCR center clone, and a KpnI-NotI fragment from a clone obtained from the IMAGE consortium (corresponding to Accession No. R43629.1) were ligated together, using methods standard to the art, to create a full-length clone. Each individual clone, and the full-length clone (SEQ ID NO 3), were sequence verified. A number of other EST clones from the IMAGE consortium were also obtained and sequenced. One of these clones (corresponding to Accession No. AI051759.1) contained a two novel splice-variants which result in a truncated, potentially soluble $\alpha_2\delta$ -C (SEQ ID NO 44).

Full-length $\alpha_2\delta$ -C is 28 % identical and 48% similar at the amino acid level to $\alpha_2\delta$ -A. The $\alpha_2\delta$ -C mRNA sequence (SEQ ID NO 3) is 3770 bp long, and codes for a protein of 1085 amino acids (SEQ ID NO 5). In addition, three splice variants of $\alpha_2\delta$ -C were identified. Two of the variants contain deletions of internal exons. The third variant contains a novel 3' end. Two of these splice-variants produce a truncated protein which is devoid of the membrane anchoring delta subunit. These variants may represent a secreted alpha2 protein which could have additional functions beyond regulation of voltage-sensitive calcium channels.

In order to identify sequences for $\alpha_2\delta$ -C from other species, human and mouse specific primers (SEQ ID NOS 9-10 and 12-13, respectively) were used to amplify $\alpha_2\delta$ -C RT-PCR products. RNA from human brain was purchased from Invitrogen, Carlsbad, CA (catalog #D6030-15). RNA from rat and mouse brain was isolated using standard in-house protocols. First-strand cDNA synthesis was completed using Superscript Choice System (LTI, Bethesda, MD, catalog #18090-019). Ethanol precipitated cDNA was added to PCR mix containing 1X PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ High Fidelity (LTI, Bethesda, MD). Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes. PCR products were assayed on 1% agarose (TAE) gels at 100 volts for 45 minutes. Gels were visualized under UV and photographed. Products

-38-

were purified using Millipore Ultrafree-MC PCR purification filter units (catalog # UFC3LTKOO) prior to DNA sequence analyses. Using this approach, three sets of primers (SEQ ID NO 36, 37; SEQ ID NO 12, 13, SEQ ID NO 38, 39) were used for PCR amplification of rat $\alpha 2\delta$ -C. Three partial rat sequences for $\alpha 2\delta$ -C were identified (SEQ ID NOS 40, SEQ ID NO 14, SEQ ID NO 41).

RT-PCR analysis of RNA expression levels were performed to analyze the expression pattern of $\alpha 2\delta$ -C. cDNA Expression Panels were purchased from OriGene Technologies, Inc. (Rockville, Maryland). Human (catalog # HSC-101) and Mouse (catalog # MSCB-101) cDNAs from 24 tissue sources were pre-arrayed in a 96-well PCR format. PCR mix containing 1X PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ (LTI, Bethesda, MD) was added to each well. Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes.

PCR products were assayed on 1% agarose (TAE) gels at 100 volts for 45 minutes. Gels were visualized under UV and photographed. The primers used for this amplification from the human template correspond to SEQ ID NOS 9-10, and from the mouse template correspond to SEQ ID NOS 12-13. By RT-PCR, $\alpha 2\delta$ -C was found to be expressed in a wide variety of tissues (Table 2). The highest levels of $\alpha 2\delta$ -C were detected in human brain, and also in human testis and kidney. In addition to RT-PCR, the cDNA sequence for this gene has been detected in a human, adult brain library and also libraries from: infant brain, hNT neural cell line, testis, total fetus, alveolar rhabdomyosarcoma, adenocarcinoma, and a pooled germ cell library.

Northern blot analysis was performed using $\alpha 2\delta$ -C as a probe. Human total RNA was obtained from Invitrogen (Carlsbad, CA) (brain. total RNA(Cat #D6030-01), kidney total RNA (Cat #D6070-01), testis total RNA(Cat #D6121-01), liver total RNA(Cat # D6080-015)) or Ambion Inc(Austin, TX)(placenta total RNA Cat#7950, heart total RNA Cat #7966), lung total RNA(Cat #7968)) RNA was electrophoresed in formaldehyde agarose gels then transferred to charged nylon membranes(Ambion Inc. (Austin TX) Cat #10104. The EST clone (SEQ ID NO 47) was digested with BamHI and used as template in an RNA synthesis

-39-

reaction that yielded ^{32}P labeled probe. The nylon membranes containing the RNA were prehybridized for 2 hours in ExpressHyb hybridization solution (Clontech Inc. (Palo Alto, CA)(Cat # 8015-1). After the prehybridization 4×10^6 cpm of RNA probe labeled with ^{32}P were added to the solution and the hybridization was performed in the same solution for 2 hours. After hybridization the nylon filter was washed for 1 hour with 4 changes of $2\times$ SSC, 0.5% SDS at room temperature. The nylon filter was transferred to a solution of $0.2\times$ SSC, 0.5% SDS at 68°C and washed with 4 changes of solution. The nylon filters were then exposed to phosphorimager screens Molecular Dynamics(Sunnyvale, CA) and read on a Storm phosphorimager. Molecular Dynamics(Sunnyvale, CA). Results from Northern analysis (Figure 4) indicate that $\alpha_2\delta$ -C has highest levels of expression in human brain, kidney, and testis.

Since $\alpha_2\delta$ -C has sequence homology to $\alpha_2\delta$ -A, and $\alpha_2\delta$ -A functions as a subunit of VSCCs, experiments were undertaken to determine if $\alpha_2\delta$ -C can replace $\alpha_2\delta$ -A and produce functional VSCCs. Xenopus oocytes were isolated using standard techniques and injected with cRNA for α_{1B} , β_{1C} and $\alpha_2\delta$ -C subunits of voltage-gated Ca^{2+} channels. Four days to 1 week following injection of cRNA, Ca^{2+} channel currents were measured using two-electrode voltage clamp with 5 mM Ba^{2+} as the charge carrier. Test pulses to +10 mV from a holding membrane potential of -80 mV were applied to evoke Ca^{2+} channel currents. Peak inward currents evoked during the test pulse were measured. The amplitude of inward currents is proportional to the expression level of voltage-gated Ca^{2+} channels.

Expression of α_{1B} , β_{1C} without $\alpha_2\delta$ subunits produced currents with an average amplitude of 105 ± 13 nA ($n=20$). Co-injection of $\alpha_2\delta_c$ with α_{1B} and β_{1C} subunits produced a significant increase in current amplitude to 213 ± 12 nA ($n=20$, $p < 0.01$ compared to no $\alpha_2\delta$ subunits). These data suggest that $\alpha_2\delta_c$ has an effect on Ca^{2+} channels similar to $\alpha_2\delta_A$, enhancing the level of channel expression. However, $\alpha_2\delta_c$ did not produce as large of an effect on channel expression as $\alpha_2\delta_A$, producing a 2-fold increase in current compared to a 20-fold increase observed with the co-injection of $\alpha_2\delta_A$. Overall, these initial functional

-40-

studies indicate that $\alpha_2\delta$ -C can replace $\alpha_2\delta$ -A in voltage-sensitive calcium channels after co-injection into *Xenopus* oocytes with the $\alpha 1$ and beta subunits.

Table 2: RT-PCR EXPRESSION PROFILE FOR ALPHA2-DELTA C

5	<i>Tissue</i>	<i>Human $\alpha 2\delta$-C</i>	<i>Mouse $\alpha 2\delta$-C</i>
	Brain	+++	+
	Heart	++++	-
	Kidney	++	++
10	Liver	-	-
	Colon	+	not assayed
	Lung	+	++
	Small Intestine	++	+
	Muscle	++++	++
15	Stomach	++	-
	Testis	+++	++
	Placenta	++	not assayed
	Salivary Gland	++	not assayed
	Thyroid Gland	++	not assayed
20	Adrenal Gland	++	-
	Pancreas	++	not assayed
	Ovary	++	-
	Uterus	++	-
	Prostrate	++	++
25	Skin	++	-
	PBL	-	not assayed
	Bone Marrow	-	not assayed
	Fetal Brain	++	not assayed
	Fetal Liver	++	not assayed
30			

Example 3

The sequence for human $\alpha 2\delta$ -A, Accession No. M76559.1, was used to perform BLASTP searches against the Genbank non-redundant protein database

-41-

and TBLASTN searches against the expressed sequence tag database (dbEST). EST sequences were identified (Accession No. T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1) corresponding to a new gene, with similarity to $\alpha 2\delta$ -A, named $\alpha 2\delta$ -D. Additional searches of the sequence databases led to the identification of other sequences related to $\alpha 2\delta$ -D. This includes genomic sequence derived from human chromosome 12p13.3 (Accession No. AC005342.1, AC005343.1). Since the initial identification of $\alpha 2\delta$ -D, additional related sequences have been deposited into the Genbank database. These sequences correspond to Accession Nos. (human ESTs: T96900.1, AI457823.1, AI377638.1, and AI433691.1).

To isolate a full-length $\alpha 2\delta$ -D clone, a PCR-based cDNA library screen was carried out by Origene using primers (SEQ ID NOS 18-19) based on sequence derived from EST clone Accession No. AA001473.1 which were designed to amplify a 372 bp fragment. A positive clone was identified in a placental library, and was confirmed using a nested internal primer (SEQ ID NO 20). This clone was fully sequenced. The sequence extended 350 bp 5' of the sequence obtained from the EST sequences, but did not include the 5' end.

To obtain the 5' end, two approaches were undertaken. One approach utilized 5' RACE (Rapid Amplification of cDNA Ends). For 5' RACE, placenta poly A+ RNA from Clontech was used to construct a RACE-ready cDNA library using a Marathon cDNA Amplification kit purchased from Clontech. The 5'-end sequence of $\alpha 2\delta$ -D was obtained by 5' RACE PCR using first set of primers: Marathon cDNA adapter primer 1 (SEQ ID NO 45) and gene specific primer I (SEQ ID NO 21). The PCR product was re-amplified using a set of nested primers: adapter primer 2 (SEQ ID NO 46) and gene specific primer II (SEQ ID NO 22). A resulting 1 kb PCR product was cloned into a TA vector (Invitrogen) and sequenced. Sequence analysis revealed that it contains the 5' sequence of $\alpha 2\delta$ -D.

A second method undertaken to identify the 5' end of $\alpha 2\delta$ -D was a PCR-based library screen performed by Edge, using the 5' most sequence known for $\alpha 2\delta$ -D. Nine clones were PCR amplified by the methods indicated above, for

-42-

verification using primers with SEQ ID NOS 48 and 49. These nine positive clones were then sequenced for verification by standard methods. All nine clones were identical to each other, and all were short of the 5' end by approximately 500 bp. However, these clones contained novel splice-variants of $\alpha 2\delta$ -D, with
5 insertions of novel nucleotide sequences (SEQ ID NO 16).

The full-length sequence of $\alpha 2\delta$ -D is 28 % identical and 47% similar at the amino acid level to $\alpha 2\delta$ -A. The $\alpha 2\delta$ -D mRNA is 5,073 bp long (SEQ ID NO 4), and codes for a protein of 1120 amino acids (SEQ ID NO 6) . In addition, two splice variants of $\alpha 2\delta$ -D were identified. One of the variants contains a 72 bp
10 deletion of an internal exon (SEQ ID NO 15). The amino acid sequence of this variant can be found in SEQ ID NO 17. The second variant contains two novel insertions, one of 338 bp and one of 305 bp (SEQ ID NO 16). These insertions appear to result in a truncated protein (SEQ ID NO 42), comparable to the truncated protein sequence identified for $\alpha 2\delta$ -C in Example 2.

RT-PCR analysis of RNA expression levels of human $\alpha 2\delta$ -D were
15 performed in order to analyze the tissue distribution of $\alpha 2\delta$ -D. cDNA Expression Panels were purchased from OriGene Technologies, Inc. (Rockville, Maryland). Human (catalog # HSC-101) and Mouse (catalog # MSCB-101) cDNAs from 24 tissue sources were pre-arrayed in a 96-well PCR format. PCR mix containing 1X
20 PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ (LTI, Bethesda, MD) was added to each well. Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes. PCR products were assayed on 1% agarose (TAE) gels at 100
25 volts for 45 minutes. Gels were visualized under UV and photographed. In the case of the $\alpha 2\delta$ -D human panels two separate sets of primers were used to distinguish splice variants and wild type species (SEQ ID NOS 18 & 20, SEQ ID NOS 23 & 19, respectively).

Analysis of the results from RT-PCR of $\alpha 2\delta$ -D (see Table 3) indicate that
30 $\alpha 2\delta$ -D is expressed in a wide variety of tissues, with highest levels in placenta, adrenal gland and pancreas, but also detected in all tissues other than colon. Of note, $\alpha 2\delta$ -D was detected in human brain, consistent with a potential role in

-43-

neurological disease. In addition, based on the tissue distribution of EST sequences, the cDNA sequence for $\alpha_2\delta$ -D has been detected in human libraries from: adult brain, retina, fetal liver/spleen, fetal heart, pineal gland, and testis.

5 Table 3. RT-PCR EXPRESSION PROFILE FOR ALPHA2-DELTA D

	Tissue	Human $\alpha_2\delta$ -D **	Human $\alpha_2\delta$ -D
	Brain	+++	+++
	Heart	+++	-
10	Kidney	+++*	-
	Liver	++	-
	Colon	-	-
	Lung	++	-
	Small Intestine	++*	-
15	Muscle	++	-
	Stomach	++	-
	Testis	+++	-
	Placenta	++++*	-
	Salivary Gland	++	++++
20	Thyroid Gland	+++	++++
	Adrenal Gland	++++	+++
	Pancreas	++++*	++
	Ovary	++*	++
	Uterus	++*	++
25	Prostrate	++*	+
	Skin	+	-

-44-

PBL	+++	-
Bone Marrow	+++	-
Fetal Brain	+++	-
Fetal Liver	++	-

5

*2 products: wt and splice
variant

** Primers d2+dhD-2 detects
splice region

10 **Example 4. Knockout of $\alpha 2\delta$ -B**

In order to create a mouse knockout of $\alpha 2\delta$ -B, Genome Systems (Catalog: BAC 4922 Mouse ES 129Svj PCR based Library Screen) performed a PCR-based screen of a mouse BAC library using primers SEQ ID NOS 25-26, which were predicted to amplify an 650 bp cDNA or genomic fragment. One positive
15 BAC clone (Genome Systems DNA control number: BAC-22401) from this screen was received. The same primers were used to generate a human DNA probe. This probe was used on a Southern blot to identify a ~10kb HindIII mouse genomic fragment from the BAC, which was subcloned into the HindII site of plasmid vector pRS416 (Stratagene). Two separate subclones were sequenced by
20 standard techniques, using the T3 and T7 primers and SEQ ID NOS (25-32). Two 500 bp regions of sequence from the 5' and 3' ends of the 10kb genomic fragment (SEQ ID NOS 33 and 34, respectively), plus a 1.8kb sequence contig (SEQ ID NO 35) were identified. This genomic sequence can be used to identify the intron/exon structure of a portion of mouse $\alpha 2\delta$ -B gene, and may contain
25 regulatory elements important for $\alpha 2\delta$ -B gene expression.

Example 5. Identification of amino acids encoded by $\alpha 2\delta$ gene

The amino acid sequences of $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, indicated in SEQ ID NOS 5 and 6, were determined by translating the nucleotide sequences described in
30 SEQ ID NOS 3 and 4, and aligning the amino acid sequences of $\alpha 2\delta$ -A, $\alpha 2\delta$ -B, $\alpha 2\delta$ -C, and $\alpha 2\delta$ -D. The correct open reading frame for each amino acid sequence was determined based on homology of the amino acid sequences to other $\alpha 2\delta$ -A

-45-

homologs. At the amino acid level, $\alpha 2\delta$ -C is 28% identical and 48% similar to $\alpha 2\delta$ -A and is 28% identical and 47% similar to $\alpha 2\delta$ -B, and $\alpha 2\delta$ -D is 28% identical and 47% similar to $\alpha 2\delta$ -A and is 28% identical and 46% similar to $\alpha 2\delta$ -B. Although $\alpha 2\delta$ -C and $\alpha 2\delta$ -D are related to $\alpha 2\delta$ -A, they are distinctly new and different genes.

Example 6. Proposed method of detecting the $\alpha 2\delta$ -C and $\alpha 2\delta$ -D proteins by using an $\alpha 2\delta$ -C and $\alpha 2\delta$ -D antibody

Antibodies could be developed which specifically detect epitopes unique to $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, or which detect all $\alpha 2\delta$ proteins. These antibodies could be developed by either synthesizing a peptide which is identical to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, or by bacterially-expressing a fusion protein containing either $\alpha 2\delta$ -C or $\alpha 2\delta$ -D, and then injecting these peptides into a research animal in order to stimulate an immunogenic response. Antibodies generated in such a manner could be used to detect levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein in cells. This could be done by immunocytochemistry, where whole cells are fixed and then the antibody is used on the whole cells to detect expression of $\alpha 2\delta$ -C or $\alpha 2\delta$ -D, and to detect the subcellular localization of $\alpha 2\delta$ -C or $\alpha 2\delta$ -D. Or, cells may be lysed and protein extracts generated and analyzed for $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D expression.

Example 7. Isolation of RNA for cDNA Library

In order to isolate $\alpha 2\delta$ -C or $\alpha 2\delta$ -D from cells, RNA could be isolated by lysing cells from any tissue of interest using standard methods known in the field. After isolation, RNA is reverse-transcribed into cDNA using the enzyme reverse transcriptase and a poly(T) primer or a mix of random primers. A mix of cDNA is produced, representing a large number of the genes which are expressed in the beginning cell population at a particular point in time. Once the cDNA pool has been created, it can be restricted and then ligated into a cloning vector using methods standard in the field. This results in a cDNA library.

-46-

Example 8. cDNA Cloning Procedure

A2 δ -C or α 2 δ -D could be cloned from a cDNA library, created as above, by using primers specific for α 2 δ -C or α 2 δ -D nucleotide sequences in a polymerase chain reaction, with the cDNA used as a template. Alternatively, α 2 δ -C or α 2 δ -D sequences could be used as a probe in order to screen the cDNA library by hybridization. Using either technique, single clones are ultimately isolated from the library and sequenced using standard techniques. By sequencing multiple clones from a library, one could look for the existence of alternatively-spliced variants of α 2 δ -C or α 2 δ -D, or for the existence of single nucleotide polymorphisms, or for mutations/alterations in α 2 δ -C or α 2 δ -D.

Example 9. Screening cDNA Library with Antibody

A cDNA library could also be screened by using an antibody to α 2 δ -C or α 2 δ -D. The cDNA library is cloned into a vector which allows induction of protein expression of the cloned inserts. The complete cDNA library is induced to express a protein representing the cloned insert, then single clones which contain an insert that codes for α 2 δ -C or α 2 δ -D are identified if they hybridize to an antibody generated against α 2 δ -C or α 2 δ -D. Positive clones are isolated, and then sequenced using standard methods.

It is to be understood that the invention is not to be limited to the exact details of operation, or to the exact compounds, compositions, methods, procedures or embodiments shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art, and the invention is therefore to be limited only by the full scope of the appended claims.

-47-

We claim

1. An isolated and purified DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4.
2. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID NOS 3 or 4 under high stringency hybridization conditions.
3. An isolated and purified DNA sequence that consists essentially of the DNA sequence shown in SEQ ID NOS 3 or 4.
4. An isolated and purified DNA sequence that has at least a 70% identity to a polynucleotide encoding the polypeptide expressed by SEQ ID NOS 5 or 6.
5. An isolated and purified DNA sequence that is fully complementary to the DNA sequence shown in SEQ ID NOS 3 or 4.
6. A recombinant DNA molecule comprising the isolated and purified DNA sequence of Claim 3 or 4 subcloned into an extra-chromosomal vector.
7. A recombinant host cell comprising a host cell transfected with the recombinant DNA molecule of Claim 6.
8. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID NOS 5 or 6.
9. A substantially purified recombinant polypeptide of Claim 8, wherein the polypeptide has at least about 70% amino acid sequence similarity to the amino acid sequence shown in SEQ ID NOS 5 or 6.
10. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially of the amino acid sequence shown in SEQ ID NOS 5 or 6.

-48-

11. An antibody that selectively binds polypeptides with an amino acid sequence substantially similar to the amino acid sequence of Claim 8.

12. A method of detecting $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein in cells, comprising contacting cells with the antibody of Claim 11 and incubating the cells in a manner that allows for detection of the $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein-antibody complex.

13. A diagnostic assay for detecting cells containing $\alpha 2\delta$ -C or $\alpha 2\delta$ -D mutations, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, or 3 or by analyzing the genomic DNA directly by a hybridization method and determining whether the resulting PCR product contains a mutation.

14. A diagnostic assay for detecting cells containing $\alpha 2\delta$ -C or $\alpha 2\delta$ -D mutations, comprising isolating total cell RNA, subjecting the RNA to reverse transcription-PCR amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, or 3 and determining whether the resulting PCR product contains a mutation.

15. A method for the amplification of a region of the DNA sequence of Claim 1, 2, or 3, the method comprising the step of: contacting a test sample suspected of containing the desired sequence of Claim 1, 2, or 3 or portion thereof with amplification reaction reagents.

16. A diagnostic kit for detecting the presence of at least one copy of the DNA sequence of Claim 1, 2, or 3 in a test sample, said kits containing a primer, a pair of primers or a probe, and optionally amplification reagents.

-49-

17. An assay for the detection or screening of therapeutic compounds that interfere with or mimic the interaction between the polypeptide of Claim 8, 9, or 10 and ligands that bind to the polypeptide of Claim 8, 9, or 10.

18. The assay of Claim 17, herein the assay comprises the steps of:

- a) providing a polypeptide of Claim 8, 9, or 10;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance;
and
- d) detecting the complexes formed between said polypeptide and said candidate substance.

19. A method for protecting mammalian cells from abnormal calcium flux, comprising introducing into mammalian cells an expression vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3, which is operatively linked to a DNA sequence that promotes the high level expression of the isolated and purified DNA sequence in mammalian cells.

20. A method for treating or preventing epilepsy, comprising introducing into a mammal an expression vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3, which is operatively linked to a DNA sequence that promotes the high level expression of the antisense strand of the isolated and purified DNA sequence in mammalian cells.

21. A method for purifying $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from cells, comprising:

- a) transfecting a host cell with a vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3 operatively linked to a promoter capable of directing gene expression in a host cell;

-50-

b) inducing expression of the isolated and purified DNA sequence in the cells;

c) lysing the cells;

d) isolating $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the cells ; and

5 e) purifying $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the isolate.

22. An isolated and purified DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.

10 23. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49 under high stringency hybridization conditions.

24. An isolated and purified DNA sequence that consists essentially of the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.

15 25. An isolated and purified DNA sequence that has at least a 70% identity to a polynucleotide encoding the polypeptide expressed by SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.

20 26. An isolated and purified DNA sequence that is fully complementary to the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.

27. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID NOS 17 or 42.

28. A substantially purified recombinant polypeptide of Claim 26, wherein the

-51-

polypeptide has at least about 70% amino acid sequence similarity to the amino acid sequence shown in SEQ ID NOS 17 or 42.

29. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially of the amino acid sequence shown in SEQ ID NOS 17 or 42.

30. An antibody that selectively binds polypeptides with an amino acid sequence substantially similar to the amino acid sequence of Claim 26.

31. A method of using polynucleotide sequences to treat diseases which may result from alterations of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes or from alterations of cellular pathways involving $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1, AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1, AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1, AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1, AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1, T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID NOS 1-16, 18-41, or 43-49.

32. The method of claim 31 wherein the disease is selected from the group consisting essentially of: seizure-related syndromes, migraine, ataxia, vestibular defects, chronic pain, mood, sleep interference, anxiety, ALS, multiple sclerosis,

-52-

mania, tremor, parkinsonism, substance abuse/addiction syndromes, mood, depression, and cancer.


33. A method of using polynucleotide sequences to test for presence of a disease, or susceptibility to a disease, due to alterations or deletions in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1, AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1, AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1, AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1, AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1, T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID NOS 1-16, 18-41, or 43-49.

34. A method of using polynucleotide sequences to identify the binding potential of the polynucleotide sequences to gabapentin, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1,

-53-

AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1,
AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1,
AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1,
AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1,
5 AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1,
T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1,
AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1,
H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and
AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID
10 NOS 1-16, 18-41, or 43-49.

FIG. 1 FINE MAPPING OF ALPHA2/DELTA TO MOUSE CHROMOSOME 9



2/4

FIG. 2 HUMAN $\alpha 2\delta 2$ TISSUE DISTRIBUTION






FIG. 3 [³H] GABAPENTIN BINDING ACTIVITY BY HUMAN $\alpha 2\delta 2$ IN TRANSIT LY TRANSFECTED Cos 7 CELLS



4/4

FIG. 4



SEQUENCE LISTING

<110> Johns, Margaret Ann
Moldover, Brian Jay
Offord, James David

<120> Alpha-2/Delta Gene

<130> Combined Applications 5947L1,L2,L3

<140> PCT/US99/23519

<141> 1999-10-07

<150> 60/103,322

<151> 1998-10-07

<150> 60/106,473

<151> 1998-10-30

<150> 60/114,088

<151> 1998-12-29

<160> 49

<170> PatentIn Ver. 2.1

<210> 1

<211> 5482

<212> DNA

<213> Homo sapiens

<400> 1

```

cgggcagcgc agcccgacaga ggcgctgcgg cccgtgcagc cccggaggcc cctcgcgagg 60
aaggcggcgg cggaggagag gccgagttac cgcccgccgc ccgcgcccc ccaaccccgcc 120
cgccgcccgc gccgcccga ctgccccccc tccccgcggc gccgcatctt gaatggaaac 180
atggcggtgc cggctcggac ctgcggcgcc tctcgcccc gccagcgcg gactgcgcgc 240
ccctggcccg gctgcggccc ccaccctggc cccggcacc gccgcccgc gtccggggccc 300
ccgcgccccg tgtggctgct gctgcgctt ctaccgctgc tcgcgcccc cggcgccctt 360
gcctacagct tccccagca gcacacgatg cagcactggg cccggcgctt ggagcaggag 420
gtcgacggcg tgatgcggat ttttgaggc gtccagcagc tccgtgagat ttacaaggac 480
aaccggaacc tgttcgaggt acaggagaat gagcctcaga agttggtgga gaaggaggca 540
ggggacattg agagccttct ggacaggaag gtgcaggccc tgaagagact ggctgatgct 600
gcagagaact tccagaaagc acaccgctgg caggacaaca tcaaggagga agacatcgtg 660
tactatgacg ccaaggctga cgctgagctg gacgacctg agagtgagga tgtggaaagg 720
gggtctaagg ccagcaccct aaggctggac ttcatcgagg acccaaactt caagaacaag 780
gtcaactatt catacgcggc tgtacagatc cctacggaca tctacaaagg ctccactgtc 840
atcctcaatg agctcaactg gacagaggcc ctggagaatg tgttcatgga aaaccgcaga 900
caagacccca cactgctgtg gcaggtcttc ggcagcgcca caggagtcac tcgctactac 960

```

```

ccggccaccc cgtggcgagc cccaagaag atcgacctgt acgatgtccg aaggagaccc 1020
tggtatatcc agggggcctc gtcacccaaa gacatgggtca tcatcgtgga tgtgagtggc 1080
agtgtgagcg gcctgaccct gaagctgatg aagacatctg tctgcgagat gctggacacg 1140
ctgtctgatg atgactatgt gaatgtggcc tcgttcaacg agaaggcaca gcctgtgtca 1200
tgcttcacac acctggtgca ggccaatgtg cgcaacaaga aggtgttcaa ggaagctgtg 1260
cagggcatgg tggccaaggg caccacaggc tacaaggccg gctttgagta tgccttgac 1320
cagctgcaga actccaacat cactcgggcc aactgcaaca agatgatcat gatgttcacg 1380
gatggtgggtg aggaccgctg gcaggacgtc tttgagaagt acaattggcc aaaccggacg 1440
gtgcgcgtgt ttactttctc cgtggggcag cataactatg acgtcacacc gctgcagtgg 1500
atggcctgtg ccaacaaagg ctactatttt gagatccctt ccatcggagc catccgcac 1560
aacacacagg aatatctaga tgtgttgggc aggccatgg tgctggcagg caaggaggcc 1620
aagcaggttc agtggaacaa cgtgtatgag gatgcactgg gactgggggtt ggtggttaaca 1680
gggaccctcc ctgttttcaa cctgacacag gatggccctg gggaaaagaa gaaccagctg 1740
atcctgggcg tgatgggcat tgacgtggct ctgaatgaca tcaagaggct gaccccaac 1800
tacacgcttg gagccaacgg ctatgtgttt gccattgacc tgaacggcta cgtgttgctg 1860
caccccaatc tcaagcccca gaccaccaac ttccgggagc ctgtgactct ggacttcctg 1920
gatgcggagc tagaggatga gaacaaggaa gagatccgtc ggagcatgat tgatggcaac 1980
aagggccaca agcagatcag aacgttggtc aagtccttgg atgagaggta catagatgag 2040
gtgacacgga actacacctg ggtgcctata aggagcacta actacagcct ggggctggtg 2100
ctccccacct acagcacctt ctacctccaa gccaatctca gtgaccagat cctgcaggct 2160
aagtattttg agttcctgct cccagcagc tttgagtctg aaggacacgt ttctattgct 2220
cccagagagt actgcaagga cctgaatgcc tcagacaaca acaccgagtt cctgaaaaac 2280
tttattgagc tcatggagaa agtgactcca gactccaagc agtgcaacaa ctctcttctg 2340
cacaacctga tcttgacac gggcatcacg cagcagctgg tagagcgtgt gtggagggac 2400
caggatctca acacgtacag cctactggcc gtgttcgctg ccacagacgg tggcatcacc 2460
cgagtcttcc ccaacaaggc agctgaggac tggacagaga accctgagcc cttcaatgcc 2520
agcttctacc gccgcagcct ggataaccac ggttatgtct tcaagcccc acaccaggat 2580
gccctgttaa ggccgctgga gctggagaat gacactgtgg gcatectcgt cagcacagct 2640
gtggagctca gcctaggcag gcgcacactg aggccagcag tgggtgggct caagctggac 2700
ctagaggctt gggctgagaa gttcaagggtg ctagccagca accgtacca ccaagaccag 2760
cctcagaagt gcggcccaa cagccactgt gagatggact gcgaggttaa caatgaggac 2820
ttactctgtg tctcattga tgatggagga ttcttgggtc tgtcaaacca gaaccatcag 2880
tgggaccagg tgggcagggt cttcagttag gtggatgcca acctgatgct ggcactctac 2940
aataactcct tctacacccg caaggagtcc tatgactatc aggcagcctg tgcccctcag 3000
ccccctggca acctgggtgc tgcaccccg ggtgtctttg tgcccaccgt tgcagatttc 3060
cttaacctgg cctgggtggac ctctgctgcc gcctgggtccc tgttccagca gcttctctac 3120
ggcctcatct accacagctg gttccaagca gaccccgcg aggccgaggg gagccccgag 3180
acgcgcgaga gcagctgcgt catgaaacag acccagtact acttcggctc ggtaaacgcc 3240
tctacaacg ccatcatcga ctgcggaaac tgctccaggc tgttccacgc gcagagactg 3300
accaacacca atcttctctt tgtgttggcc gagaagccgc tgtgcagcca gtgcgaggct 3360
ggccggctgc tgcagaagga gacgcactgc ccagcggacg gcccggagca gtgtgagcta 3420
gtgcagagac cgcgataccg gagaggcccg cacatctgct tcgactacaa cgcgacagaa 3480
gatacctcag actgtggccg cggggcctcc ttcccgcgt cgctgggctg cctggtctcc 3540
ctgcaactgc tgctcctcct gggcctgcg ccccgccgc agcctcaagt cctcgtccac 3600
gcctctcgcc gcctctgagc accctgcccc accccacctc cactccacc tcaccggcc 3660
tcttcgctt tcccacctc ctgccccaca ctccccgct tagagcctcg tccctccctc 3720
actgaaggac ctgagctggc caggccctga gagtctggtc tgcgccttgg gatggggagt 3780
cccaaagcgg gacgcccgag gtgtttggca cccaaatcac atctcacctc cgaactgttc 3840

```

```

aagtgtcccc agacccttct tgcctgctgg gctcccccca gtgggatggg acagggaggc 3900
cacacgcact ggtgccaaaa ccaggcctct gctgccgccc ttcctggagg ctgcctatgt 3960
tggtgggggac cctgcctcag ctgacccggc ctctctgccc cacccaagcc caaacttggt 4020
ttctgtgaga atagtggagg aaggtgagat ggccagtttg aagcctgtgc ctcccagctt 4080
aaatcctagc aggagagagg ctctggggca gccccatgg gctcctgccc ctttcaggcc 4140
tacagccaca tccccaaagcc caccagggtg caggatagtc acagtgatac cagttcagac 4200
actaccccat atacacctgg aacattgagg atggaaactg gactcacatt cgacataccc 4260
cactgggcac acgcacaaac acacacacta tggggtgggg tgggtgtagg ggcttacaaa 4320
gccttacaca gggcgagggg ttggtgggag ggttggcacc tgcacactcc atctcctgct 4380
caccacctgc ctctaactct agctgcagcc tggctggtcc tccatttct aaagctgaat 4440
gtcaaacagt gccaaatgct ggggcagggg gtgaagaacc ctctgtccca cccctagcca 4500
ccagtgtcct ccaagtggcc cctcacctct ccaggtgtc attgtaacca tttctcacta 4560
gtgtcaggcc cccagtggga ccacatgcca ctgcctgcac ctttcggcag aggaaccccc 4620
accagacatc accctttgcc ttagcagggg tgactttgtc tctcctggct gggccatcct 4680
tccgccaatc tggcccttac acactcaggc ctgtgcccac tccctatctc cttcccaccc 4740
ctacacacac actccctgct tgcaggaggc caaactgtcc ctcccttgct gaacacacac 4800
acacacacac acacacaggt ggggactggg cacagctctt cacaccattc attctggtca 4860
tttcccccaa aggcattcca gcctgggggc cagtggggaa ctgagggcaa ggggatatag 4920
tgatggggct cagatggact gggaggaggg ggagggtgat gcattaatta atggcttcgt 4980
taattaatgt catgttgctt gtcgctttct cagtgtgtgt gtgtggtcca tgcccactgc 5040
tggtgccagg gtgggtgtcc atgtgcaccc ggcttgatg ccagctgtgt ccttcggggg 5100
cgtgcgtgta actgtagtgt agtcagggtc tcaatggaga atataaacat atacagaaaa 5160
atatatatat taagtttaaa aaacagaaaa acagacaaaa caatcccat caggtagctg 5220
tctaaccctc agctgggtct aatccttctc attaccacc cgacctggct gccctcacc 5280
ttgggctggg ggactggggg gccatttcct tttctctgcc ctttttttgt tgttctat 5340
tgtacagaca agttggaaaa acaacagcga caaaaaagtc aagaaacttt gtaaaatatc 5400
gtgtgtgtga ttccttgtaa aatattttca aatggtttat tacagaagat cagttattaa 5460
ataatgttca tattttcact tc
5482

```

<210> 2

<211> 1145

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Ala Val Pro Ala Arg Thr Cys Gly Ala Ser Arg Pro Gly Pro Ala
  1              5              10              15

Arg Thr Ala Arg Pro Trp Pro Gly Cys Gly Pro His Pro Gly Pro Gly
          20              25              30

Thr Arg Arg Pro Thr Ser Gly Pro Pro Arg Pro Leu Trp Leu Leu Leu
      35              40              45

Pro Leu Leu Pro Leu Leu Ala Ala Pro Gly Ala Ser Ala Tyr Ser Phe
    50              55              60

```

Pro Gln Gln His Thr Met Gln His Trp Ala Arg Arg Leu Glu Gln Glu
 65 70 75 80
 Val Asp Gly Val Met Arg Ile Phe Gly Gly Val Gln Gln Leu Arg Glu
 85 90 95
 Ile Tyr Lys Asp Asn Arg Asn Leu Phe Glu Val Gln Glu Asn Glu Pro
 100 105 110
 Gln Lys Leu Val Glu Lys Val Ala Gly Asp Ile Glu Ser Leu Leu Asp
 115 120 125
 Arg Lys Val Gln Ala Leu Lys Arg Leu Ala Asp Ala Ala Glu Asn Phe
 130 135 140
 Gln Lys Ala His Arg Trp Gln Asp Asn Ile Lys Glu Glu Asp Ile Val
 145 150 155 160
 Tyr Tyr Asp Ala Lys Ala Asp Ala Glu Leu Asp Asp Pro Glu Ser Glu
 165 170 175
 Asp Val Glu Arg Gly Ser Lys Ala Ser Thr Leu Arg Leu Asp Phe Ile
 180 185 190
 Glu Asp Pro Asn Phe Lys Asn Lys Val Asn Tyr Ser Tyr Ala Ala Val
 195 200 205
 Gln Ile Pro Thr Asp Ile Tyr Lys Gly Ser Thr Val Ile Leu Asn Glu
 210 215 220
 Leu Asn Trp Thr Glu Ala Leu Glu Asn Val Phe Met Glu Asn Arg Arg
 225 230 235 240
 Gln Asp Pro Thr Leu Leu Trp Gln Val Phe Gly Ser Ala Thr Gly Val
 245 250 255
 Thr Arg Tyr Tyr Pro Ala Thr Pro Trp Arg Ala Pro Lys Lys Ile Asp
 260 265 270
 Leu Tyr Asp Val Arg Arg Arg Pro Trp Tyr Ile Gln Gly Ala Ser Ser
 275 280 285
 Pro Lys Asp Met Val Ile Ile Val Asp Val Ser Gly Ser Val Ser Gly
 290 295 300
 Leu Thr Leu Lys Leu Met Lys Thr Ser Val Cys Glu Met Leu Asp Thr
 305 310 315 320

Leu Ser Asp Asp Asp Tyr Val Asn Val Ala Ser Phe Asn Glu Lys Ala
 325 330 335

Gln Pro Val Ser Cys Phe Thr His Leu Val Gln Ala Asn Val Arg Asn
 340 345 350

Lys Lys Val Phe Lys Glu Ala Val Gln Gly Met Val Ala Lys Gly Thr
 355 360 365

Thr Gly Tyr Lys Ala Gly Phe Glu Tyr Ala Phe Asp Gln Leu Gln Asn
 370 375 380

Ser Asn Ile Thr Arg Ala Asn Cys Asn Lys Met Ile Met Met Phe Thr
 385 390 395 400

Asp Gly Gly Glu Asp Arg Val Gln Asp Val Phe Glu Lys Tyr Asn Trp
 405 410 415

Pro Asn Arg Thr Val Arg Val Phe Thr Phe Ser Val Gly Gln His Asn
 420 425 430

Tyr Asp Val Thr Pro Leu Gln Trp Met Ala Cys Ala Asn Lys Gly Tyr
 435 440 445

Tyr Phe Glu Ile Pro Ser Ile Gly Ala Ile Arg Ile Asn Thr Gln Glu
 450 455 460

Tyr Leu Asp Val Leu Gly Arg Pro Met Val Leu Ala Gly Lys Glu Ala
 465 470 475 480

Lys Gln Val Gln Trp Thr Asn Val Tyr Glu Asp Ala Leu Gly Leu Gly
 485 490 495

Leu Val Val Thr Gly Thr Leu Pro Val Phe Asn Leu Thr Gln Asp Gly
 500 505 510

Pro Gly Glu Lys Lys Asn Gln Leu Ile Leu Gly Val Met Gly Ile Asp
 515 520 525

Val Ala Leu Asn Asp Ile Lys Arg Leu Thr Pro Asn Tyr Thr Leu Gly
 530 535 540

Ala Asn Gly Tyr Val Phe Ala Ile Asp Leu Asn Gly Tyr Val Leu Leu
 545 550 555 560

His Pro Asn Leu Lys Pro Gln Thr Thr Asn Phe Arg Glu Pro Val Thr
 565 570 575

Leu Asp Phe Leu Asp Ala Glu Leu Glu Asp Glu Asn Lys Glu Glu Ile
 580 585 590

Arg Arg Ser Met Ile Asp Gly Asn Lys Gly His Lys Gln Ile Arg Thr
 595 600 605

Leu Val Lys Ser Leu Asp Glu Arg Tyr Ile Asp Glu Val Thr Arg Asn
 610 615 620

Tyr Thr Trp Val Pro Ile Arg Ser Thr Asn Tyr Ser Leu Gly Leu Val
 625 630 635 640

Leu Pro Pro Tyr Ser Thr Phe Tyr Leu Gln Ala Asn Leu Ser Asp Gln
 645 650 655

Ile Leu Gln Val Lys Tyr Phe Glu Phe Leu Leu Pro Ser Ser Phe Glu
 660 665 670

Ser Glu Gly His Val Phe Ile Ala Pro Arg Glu Tyr Cys Lys Asp Leu
 675 680 685

Asn Ala Ser Asp Asn Asn Thr Glu Phe Leu Lys Asn Phe Ile Glu Leu
 690 695 700

Met Glu Lys Val Thr Pro Asp Ser Lys Gln Cys Asn Asn Phe Leu Leu
 705 710 715 720

His Asn Leu Ile Leu Asp Thr Gly Ile Thr Gln Gln Leu Val Glu Arg
 725 730 735

Val Trp Arg Asp Gln Asp Leu Asn Thr Tyr Ser Leu Leu Ala Val Phe
 740 745 750

Ala Ala Thr Asp Gly Gly Ile Thr Arg Val Phe Pro Asn Lys Ala Ala
 755 760 765

Glu Asp Trp Thr Glu Asn Pro Glu Pro Phe Asn Ala Ser Phe Tyr Arg
 770 775 780

Arg Ser Leu Asp Asn His Gly Tyr Val Phe Lys Pro Pro His Gln Asp
 785 790 795 800

Ala Leu Leu Arg Pro Leu Glu Leu Glu Asn Asp Thr Val Gly Ile Leu
 805 810 815

Val Ser Thr Ala Val Glu Leu Ser Leu Gly Arg Arg Thr Leu Arg Pro
 820 825 830

Ala Val Val Gly Val Lys Leu Asp Leu Glu Ala Trp Ala Glu Lys Phe
835 840 845

Lys Val Leu Ala Ser Asn Arg Thr His Gln Asp Gln Pro Gln Lys Cys
850 855 860

Gly Pro Asn Ser His Cys Glu Met Asp Cys Glu Val Asn Asn Glu Asp
865 870 875 880

Leu Leu Cys Val Leu Ile Asp Asp Gly Gly Phe Leu Val Leu Ser Asn
885 890 895

Gln Asn His Gln Trp Asp Gln Val Gly Arg Phe Phe Ser Glu Val Asp
900 905 910

Ala Asn Leu Met Leu Ala Leu Tyr Asn Asn Ser Phe Tyr Thr Arg Lys
915 920 925

Glu Ser Tyr Asp Tyr Gln Ala Ala Cys Ala Pro Gln Pro Pro Gly Asn
930 935 940

Leu Gly Ala Ala Pro Arg Gly Val Phe Val Pro Thr Val Ala Asp Phe
945 950 955 960

Leu Asn Leu Ala Trp Trp Thr Ser Ala Ala Ala Trp Ser Leu Phe Gln
965 970 975

Gln Leu Leu Tyr Gly Leu Ile Tyr His Ser Trp Phe Gln Ala Asp Pro
980 985 990

Ala Glu Ala Glu Gly Ser Pro Glu Thr Arg Glu Ser Ser Cys Val Met
995 1000 1005

Lys Gln Thr Gln Tyr Tyr Phe Gly Ser Val Asn Ala Ser Tyr Asn Ala
1010 1015 1020

Ile Ile Asp Cys Gly Asn Cys Ser Arg Leu Phe His Ala Gln Arg Leu
1025 1030 1035 1040

Thr Asn Thr Asn Leu Leu Phe Val Val Ala Glu Lys Pro Leu Cys Ser
1045 1050 1055

Gln Cys Glu Ala Gly Arg Leu Leu Gln Lys Glu Thr His Cys Pro Ala
1060 1065 1070

Asp Gly Pro Glu Gln Cys Glu Leu Val Gln Arg Pro Arg Tyr Arg Arg
1075 1080 1085

Gly Pro His Ile Cys Phe Asp Tyr Asn Ala Thr Glu Asp Thr Ser Asp
 1090 1095 1100

Cys Gly Arg Gly Ala Ser Phe Pro Pro Ser Leu Gly Val Leu Val Ser
 1105 1110 1115 1120

Leu Gln Leu Leu Leu Leu Leu Gly Leu Pro Pro Arg Pro Gln Pro Gln
 1125 1130 1135

Val Leu Val His Ala Ser Arg Arg Leu
 1140 1145

<210> 3

<211> 3770

<212> DNA

<213> Homo sapiens

<400> 3

```
tactataggg cggccgcgaa ttcggcacga ggcggcgcgg agcggagcag gcagccccgc 60
gcgctcgccc accgcccgt cgcgcagct ccccgcgccc gctctcgctc ccgcccgcagc 120
gggcgcgctc gagggagccc agcatggccg ggccgggctc gccgcgccgc gcgtcccggg 180
gggcctcggc gcttctcgct gccgcgcttc tctacgccgc gctgggggac gtggtgcgct 240
cggagcagca gataccgctc tccgtggtga agctctgggc ctcggtttt ggtggggaga 300
taaaatccat tgctgctaag tactccggtt cccagcttct gcaaaagaaa tacaaagagt 360
atgagaaaga cgttgccata gaagaaattg atggcctcca actggtaaag aagctggcaa 420
agaacatgga agagatgttt cacaagaagt ctgaggccgt caggcgtctg gtggaggctg 480
cagaagaagc acacctgaaa catgaatttg atgcagactt acagtatgaa tacttcaatg 540
ctgtgctgat aaatgaaagg gacaaagacg ggaatttttt ggagctggga aaggaattca 600
tcttagcccc aaatgaccat tttaataatt tgcctgtgaa catcagtcta agtgacgtcc 660
aagtaccaac gaacatgtac aacaaagacc ctgcaattgt caatggggtt tattggtctg 720
aatctctaaa caaagttttt gtagataact ttgaccgtga cccatctctc atatggcagt 780
actttggaag tgcaaagggc ttttttaggc agtatccggg gattaaatgg gaaccagatg 840
agaatggagt cattgccttc gactgcagga accgaaaatg gtacatccag gcagcaactt 900
ctccgaaaga cgtggtcatt ttagttgacg tcagtggcag catgaaagga ctccgtctga 960
ctatcgcgaa gcaaacagtc tcatccattt tggatacact tggggatgat gacttcttca 1020
acataattgc ttataatgag gagcttcaat atgtggaacc ttgcctgaat ggaacttttg 1080
tgcaagccga caggacaaac aaagagcact tcaggagca tctggacaaa cttttcgcca 1140
aaggaattgg aatgttgat atagctctga atgaggcctt caacattctg agtgatttca 1200
accacacggg acaaggaagt atctgcagtc aggccatcat gtcataact gatggggcgg 1260
tggaacaccta tgatacaatc tttgcaaaat acaattggcc agatcgaaag gttcgcactt 1320
tcacatacct cattggacga gaggctgcgt ttgcagacaa tctaaagtgg atggcctgtg 1380
ccaacaaagg attttttacc cagatctcca ccttggctga tgtgcaggag aatgtcatgg 1440
aataccttca cgtgcttagc cggcccaaag tcatcgacca ggagcatgat gtggtgtgga 1500
ccgaagctta cattgacagc actctgactg atgatcaggg ccccgctctg atgaccactg 1560
tagccatgcc tgtgtttagt aagcagaacg aaaccagatc gaagggcatt cttctgggag 1620
tggttggcac agatgtccca gtgaaagaac ttctgaagac catcccaaaa tacaagttag 1680
ggattcacgg ttatgccttt gcaatcacia ataatggrta tatcctgacg catccggaac 1740
```

```

tcaggctgct gtacgaagaa ggaaaaaagc gaaggaaacc taactatagt agcgttgacc 1800
tctctgaggt ggagtgggaa gaccgagatg acgtgttgag aaatgctatg gtgaatcgaa 1860
agacggggaa gttttccatg gaggtgaaga agacagtgga caaagggaaa cgggttttgg 1920
tgatgacaaa tgactactat tatacagaca tcaagggtac tcctttcagt ttaggtgtgg 1980
cgctttccag aggtcatggg aaatatttct tccgagggaa tgtaaccatc gaagaaggcc 2040
tgcatgactt agaacatccc gatgtgtcct tggcagatga atggtcctac tgcaacactg 2100
acctacaccc tgagcacccg catctgtctc agttagaagc gattaagctc tacctaaaag 2160
gcaaagaacc tctgctccag tgtgataaag aattgatcca agaagtcctt tttgacgcgg 2220
tggtgagtg cccattgaa gcgtattgga ccagcctggc cctcaacaaa tctgaaaatt 2280
ctgacaaggg cgtggagggt gccttctctg gcactcgac gggcctctcc agaatcaacc 2340
tgtttgcgg ggctgagcag ctcaccaatc aggacttctt gaaagctggc gacaaggaga 2400
acatttttaa cgcagaccat ttccctctct ggtaccgaag agccgctgag cagattccag 2460
ggagcttcgt ctactcgatc ccattcagca ctggaccagt caataaaagc aatgtggtga 2520
cagcaagtac atccatccag ctctggatg aacggaaatc tcctgtggtg gcagctgtag 2580
gcattcagat gaaacttgaa tttttccaaa ggaagtctg gactgccagc agacagtgtg 2640
cttccctgga tggcaaagtc tccatcagct gtgatgatga gactgtgaat tgttacctca 2700
tagacaataa tggatttatt ttggtgtctg aagactacac acagactgga gacttttttg 2760
gtgagatcga gggagctgtg atgaacaaat tgctaacaat gggctccttt aaaagaatta 2820
ccctttatga ctaccaagcc atgtgtagag ccaacaagga aagcagcgat ggcgcccag 2880
gcctcctgga tccttataat gccttctctc ctgcagtaaa atggatcatg acagaacttg 2940
tcttgctcct ggtggaattt aacctctgca gttggtggca ctccgatatg acagctaaag 3000
cccagaaatt gaaacagacc ctggagcctt gtgatactga atatccagca ttcgtctctg 3060
agcgcaccat caaggagact acagggaata ttgcttgta agactgctcc aagtcctttg 3120
tcattccagca aatcccaagc agcaacctgt tcatgggtgt ggtggacagc agctgcctct 3180
gtgaatctgt ggcccccatc accatggcac ccattgaaat caggtataat gaatccctta 3240
agtgtgaacg tctaaaggcc cagaagatca gaaggcgccc agaattctgt catggcttcc 3300
atcctgagga gaatgcaagg gagtgtgggg gtgcgcagag tctccaagcc cagacagtcc 3360
tccttctgct ccctctgctt ttgatgctct tctcaagggt aacttgactg agatgttctc 3420
ttactgactg agatgttctc ttggcatgct aaatcatgga taaactgtga accaaaatat 3480
ggtgcaacat acgagacatg aatatagtcc aaccatcagc atctcatcat gatttttaaac 3540
tgtgcgtgat ataaactctt aaagatatgt tgacaaaaag ttatctatca tctttttact 3600
ttgccagtca tgcaaatgtg agtttgccac atgataatca cccttcatca gaaatgggac 3660
cgcaagtggg aggcagtgtc ccttctgctt gaaacctatt gaaaccaatt taaaactgtg 3720
tactttttta ataaagtata ttaaaatcat aaaaaaaaaa aaaaaaaaaa 3770

```

<210> 4

<211> 5073

<212> DNA

<213> Homo sapiens

<400> 4

```

ccatgcctgc aactcccaac ttctcgcga accccagctc cagcagccgc tggattcccc 60
tccagccaat gcccggtggc tgggcctttg tgcagaagac ctcggccctc ctgtggctgc 120
tgcttctagg cacctccctg tcccctgcgt ggggacaggc caagattcct ctggaaacag 180
tgaagctatg ggctgacacc ttcgggggg acctgtataa cactgtgacc aaatactcag 240
gctctctctt gctgcagaag aagtacaagg atgtggagtc cagtctgaag atcgaggagg 300
tggtatggctt ggagctgggt aggaagttct cagaggacat ggagaacatg ctgcggagga 360

```

```

aagtcgaggc ggtccagaat ctggtggaag ctgccgagga ggccgacctg aaccacgaat 420
tcaatgaatc cctggtgttc gactattaca actcggtcct gatcaacgag agggacgaga 480
agggcaactt cgtggagctg ggcgcgaggt tcctcctgga gtccaatgct cacttcagca 540
acctgccggt gaacacctcc atcagcagcg tgcagctgcc caccaacgtg tacaacaaag 600
acccagatat tttaaattgga gtctacatgt ctgaagcctt gaatgctgtc ttcgtggaga 660
acttccagag agacccaacg ttgacctggc aatatTTTtg cagtgcactt ggattcttca 720
ggatctatcc aggtataaaa tggacacctg atgagaatgg agtcattact tttgactgcc 780
gaaaccgcgg ctggtacatt caagctgcta cttctcccaa ggacatagtg attttgggtg 840
acgtgagcgg cagtatgaag gggctgagga tgactattgc caagcacacc atcaccacca 900
tcttgacac cctgggggag aatgacttcg ttaatatcat agcgtacaat gactacgtcc 960
attacatcga gccttgTTTT aaagggatcc tcgtccaggc ggaccgagac aatcgagagc 1020
atttcaaact gctggtggag gaggttgatg tcaaaggtgt gggggctcgt gaccaagccc 1080
tgagagaagc cttccagatc ctgaagcagt tccaagaggc caagcaagga agcctctgca 1140
accaggccat catgctcatc agcgacggcg ccgtggagga ctacgagccg gtgtttgaga 1200
agtataactg gccagactgt aagggtccgag ttttacttta cctcattggg agagaagtgt 1260
cttttgctga ccgcatgaag tggattgcat gcaacaacaa aggctactac acgcagatct 1320
caacgtgtgg ggacacccag gagaacgtga tggaaatacct gcacgtgtct agccgccccca 1380
tggtcatcaa ccacgaccac gacatcatct ggacagaggc ctacatggac agcaagctcc 1440
tcagctcgca ggctcagagc ctgacactgc tcaccactgt ggccatgcca gtcttcagca 1500
agaagaacga aacgcgatcc catggcattc tcctgggtgt ggtgggtctc gatgtggccc 1560
tgagagagct gatgaagctg gcgccccggt acaagcttgg agtgcacgga tacgccttcc 1620
tgaacaccaa caatggctac atcctctccc atcccgaact ccggccccctg tacagagagg 1680
ggaagaaact aaaacccaaa cctaactaca acagtgtgga tctctccgaa gtggagtggg 1740
aagaccaggc tgaatctctg agaacagcca tgatcaatag ggaaacaggt actctctcga 1800
tggtatgtgaa ggttccgatg gataaaggga agcgagttct tttcctgacc aatgactact 1860
tcttcacgga catcagcgac acccctttca gtttgggggt ggtgctgtcc cggggccacg 1920
gagaatacat ccttctgggg aacacgtctg tggaagaagg cctgcatgac ttgcttcacc 1980
cagacctggc cctggccggt gactggatct actgcatcac agatattgac ccagaccacc 2040
ggaagctcag ccagctagag gccatgatcc gcttcctcac caggaaggac ccagacctgg 2100
agtgtgacga ggagctggtc cgggaggtgc tgtttgacgc ggtggtgaca gcccccatgg 2160
aagcctactg gacagcgctg gccctcaaca tgtccgagga gtctgaacac gtggtggaca 2220
tggccttctt gggcaccggt gctggcctcc tgagaagcag cttgttcgtg ggctccgaga 2280
aggtctccga caggaagttc ctgacacctg aggacgaggc cagcgtgttc accctggacc 2340
gcttcccgtc gtggtaccgc caggcctcag agcatcctgc tggcagcttc gtcttcaacc 2400
tccgctgggc agaaggacca gaaagtgcgg gtgaacccat ggtggtgacg gcaagcacag 2460
ctgtggcggt gaccgtggac aagaggacag ccattgctgc agccgcgggc gtccaaatga 2520
agctggaatt cctccagcgc aaattctggg cggcaacgcg gcagtgcagc actgtggatg 2580
ggccgtgcac acagagctgc gaggacagtg atctggactg cttcgtcatc gacaacaacg 2640
ggttcattct gatctccaag aggtcccag agacgggaag atttctgggg gaggtggatg 2700
gtgctgtcct gaccagctg ctacagatgg ggggtgttcag ccaagtgact atgtatgact 2760
atcaggccat gtgcaaacc ctagtcacc accacagtgc agcccagccc ctggtcagcc 2820
caatttctgc cttcttgacg gcgaccaggt ggctgctgca ggagctggtg ctgttcctgc 2880
tgagtgagg tgtctggggc tcctggtacg acagaggggc cgaggccaaa agtgtcttcc 2940
atcactccca caaacacaag aagcaggacc cgctgcagcc ctgcgacacg gagtacccccg 3000
tgttcgtgta ccagccggcc atccgggagg ccaacgggat cgtggagtgc gggccctgcc 3060
agaaggtatt tgtggtgcag cagattccca acagtaacct cctcctcctg gtgacagacc 3120
ccacctgtga ctgcagcatc ttcccaccag tgctgcagga ggcgacagaa gtcaaataata 3180
atgcctctgt caaatgtgac cggatgcgct ccagaagct ccgccggcga ccagactcct 3240

```

```

gccacgcctt ccatccagag gagaatgccc aggactgceg cggcgccctcg gacacctcag 3300
cctcgccgcc cctactcctg ctgcctgtgt gtgcctgggg gctactgccc caactcctgc 3360
ggtgacacca cccagcctga cctgtgtttt ggcaagggtga tccttccaga gccatcccaa 3420
aaagtacagca ctgacatggg atgcagctaa ctgcagttgg gtcgccccca ggccaacgct 3480
cctctcaatc ctgggctggg ggcccctggc tccggagaat gctggatgga acaggaaacc 3540
aatcacctgg caccactttc aagatgcttc atggtgcccg gtaccatctg ccctaggtct 3600
caacatgagc atacttctga cctaaccctc ctgtctcttc ttcgggaagc cagcgtgagc 3660
tcagcttggg ccaagacaaa ataatttagt tcttctgtga ctccagagtc cagaccacgc 3720
caagaaaggg tcagttgttt ctgacccttt ctgtcggagt ggtctctggt agaaccacaag 3780
gacttctggg tactgagaag cagcagcaga atgaggccaa atgcagagat gaggctaagg 3840
caagaatatg ccccaactaa agcatagatt ccccaaagtg aggctcatgg tgggaggcca 3900
ctcaccttcc tagctgctgc tcgaaaaggt tttgactgtg ttgggggtgg ggttgggtaa 3960
gggaatggtc aagactgaga aaggaatgaa atccattcag gaaatatcga cagggttaca 4020
cgtgatgtcc ccaaactgct gctattgaag aacttcccaa aacttcttta caaagcccta 4080
aaggaaagtt tgcatttatg aaaagccaat aggtgagac atccaattgc tgcattgaaa 4140
ttgatgtaca ttcaggggac ggcaaaaaata gctgtaaaat agtgaaaaag agcagtgggt 4200
gtgctctttt ctggccaatg atttacaaaa gaattctactt gactctgtcc ctggagtga 4260
atccttaggg ttggaacttg tgggaacatt ccaacttgct aagcagggtc cactgggagg 4320
gaagctctat ctgggaactc acccccagcg cacacacatc tccccagggt tccaaggcc 4380
ccgcagcttc ctccccgac caaaccccaa gacctggatc ccaggagaca acagtctcca 4440
catgagagca acattaaggg caaagccatg gagaaatgtg ggagaggccg gcctcaaate 4500
tttccattta acaaacccca gtgatgggtg tggacagcat gcagggtctt tggggcgctt 4560
ccccccgctc ctccatcacc ctacgcctcc acacttcaaa gttcaagttc aaagctgttc 4620
aagtttccta ccagcaataa gccctaactt gcctctagag taggccaaat gccactctg 4680
taaaacacac ttacattatc ggttacagaa tgtcactctt accatcatgt cttgcaacaa 4740
ccctgtgagg gcagtattaa tgccccctta cagcagaaga cactgcagct cgaagacagc 4800
ttaagtggca gaataatgct agaacagcta aggtttacat gtaccaaata acatgtttca 4860
gctcattcca tctcacaac agccccctga aagtgggtac tatcattagt ccatgtttat 4920
agaaactgca gcagagttga aaattgcctc caaattaccg gaagagtgtg tgaagattga 4980
atgtgatgta ttcacgtaac atgcttgaaa ctgcctggca tataactaac gctaaataaa 5040
tacatgctaa ctgcaaaaaa aaaaaaaaaa aaa 5073

```

<210> 5

<211> 1085

<212> PRT

<213> Homo sapiens

<400> 5

```

Met Ala Gly Pro Gly Ser Pro Arg Arg Ala Ser Arg Gly Ala Ser Ala
  1               5               10              15

```

```

Leu Leu Ala Ala Ala Leu Leu Tyr Ala Ala Leu Gly Asp Val Val Arg
          20              25              30

```

```

Ser Glu Gln Gln Ile Pro Leu Ser Val Val Lys Leu Trp Ala Ser Ala
    35              40              45

```

Phe Gly Gly Glu Ile Lys Ser Ile Ala Ala Lys Tyr Ser Gly Ser Gln
 50 55 60
 Leu Leu Gln Lys Lys Tyr Lys Glu Tyr Glu Lys Asp Val Ala Ile Glu
 65 70 75 80
 Glu Ile Asp Gly Leu Gln Leu Val Lys Lys Leu Ala Lys Asn Met Glu
 85 90 95
 Glu Met Phe His Lys Lys Ser Glu Ala Val Arg Arg Leu Val Glu Ala
 100 105 110
 Ala Glu Glu Ala His Leu Lys His Glu Phe Asp Ala Asp Leu Gln Tyr
 115 120 125
 Glu Tyr Phe Asn Ala Val Leu Ile Asn Glu Arg Asp Lys Asp Gly Asn
 130 135 140
 Phe Leu Glu Leu Gly Lys Glu Phe Ile Leu Ala Pro Asn Asp His Phe
 145 150 155 160
 Asn Asn Leu Pro Val Asn Ile Ser Leu Ser Asp Val Gln Val Pro Thr
 165 170 175
 Asn Met Tyr Asn Lys Asp Pro Ala Ile Val Asn Gly Val Tyr Trp Ser
 180 185 190
 Glu Ser Leu Asn Lys Val Phe Val Asp Asn Phe Asp Arg Asp Pro Ser
 195 200 205
 Leu Ile Trp Gln Tyr Phe Gly Ser Ala Lys Gly Phe Phe Arg Gln Tyr
 210 215 220
 Pro Gly Ile Lys Trp Glu Pro Asp Glu Asn Gly Val Ile Ala Phe Asp
 225 230 235 240
 Cys Arg Asn Arg Lys Trp Tyr Ile Gln Ala Ala Thr Ser Pro Lys Asp
 245 250 255
 Val Val Ile Leu Val Asp Val Ser Gly Ser Met Lys Gly Leu Arg Leu
 260 265 270
 Thr Ile Ala Lys Gln Thr Val Ser Ser Ile Leu Asp Thr Leu Gly Asp
 275 280 285
 Asp Asp Phe Phe Asn Ile Ile Ala Tyr Asn Glu Glu Leu His Tyr Val
 290 295 300

Glu Pro Cys Leu Asn Gly Thr Leu Val Gln Ala Asp Arg Thr Asn Lys
 305 310 315 320
 Glu His Phe Arg Glu His Leu Asp Lys Leu Phe Ala Lys Gly Ile Gly
 325 330 335
 Met Leu Asp Ile Ala Leu Asn Glu Ala Phe Asn Ile Leu Ser Asp Phe
 340 345 350
 Asn His Thr Gly Gln Gly Ser Ile Cys Ser Gln Ala Ile Met Leu Ile
 355 360 365
 Thr Asp Gly Ala Val Asp Thr Tyr Asp Thr Ile Phe Ala Lys Tyr Asn
 370 375 380
 Trp Pro Asp Arg Lys Val Arg Ile Phe Thr Tyr Leu Ile Gly Arg Glu
 385 390 395 400
 Ala Ala Phe Ala Asp Asn Leu Lys Trp Met Ala Cys Ala Asn Lys Gly
 405 410 415
 Phe Phe Thr Gln Ile Ser Thr Leu Ala Asp Val Gln Glu Asn Val Met
 420 425 430
 Glu Tyr Leu His Val Leu Ser Arg Pro Lys Val Ile Asp Gln Glu His
 435 440 445
 Asp Val Val Trp Thr Glu Ala Tyr Ile Asp Ser Thr Leu Thr Asp Asp
 450 455 460
 Gln Gly Pro Val Leu Met Thr Thr Val Ala Met Pro Val Phe Ser Lys
 465 470 475 480
 Gln Asn Glu Thr Arg Ser Lys Gly Ile Leu Leu Gly Val Val Gly Thr
 485 490 495
 Asp Val Pro Val Lys Glu Leu Leu Lys Thr Ile Pro Lys Tyr Lys Leu
 500 505 510
 Gly Ile His Gly Tyr Ala Phe Ala Ile Thr Asn Asn Gly Tyr Ile Leu
 515 520 525
 Thr His Pro Glu Leu Arg Leu Leu Tyr Glu Glu Gly Lys Lys Arg Arg
 530 535 540
 Lys Pro Asn Tyr Ser Ser Val Asp Leu Ser Glu Val Glu Trp Glu Asp
 545 550 555 560

Arg Asp Asp Val Leu Arg Asn Ala Met Val Asn Arg Lys Thr Gly Lys
 565 570 575

Phe Ser Met Glu Val Lys Lys Thr Val Asp Lys Gly Lys Arg Val Leu
 580 585 590

Val Met Thr Asn Asp Tyr Tyr Tyr Thr Asp Ile Lys Gly Thr Pro Phe
 595 600 605

Ser Leu Gly Val Ala Leu Ser Arg Gly His Gly Lys Tyr Phe Phe Arg
 610 615 620

Gly Asn Val Thr Ile Glu Glu Gly Leu His Asp Leu Glu His Pro Asp
 625 630 635 640

Val Ser Leu Ala Asp Glu Trp Ser Tyr Cys Asn Thr Asp Leu His Pro
 645 650 655

Glu His Arg His Leu Ser Gln Leu Glu Ala Ile Lys Leu Tyr Leu Lys
 660 665 670

Gly Lys Glu Pro Leu Leu Gln Cys Asp Lys Glu Leu Ile Gln Glu Val
 675 680 685

Leu Phe Asp Ala Val Val Ser Ala Pro Ile Glu Ala Tyr Trp Thr Ser
 690 695 700

Leu Ala Leu Asn Lys Ser Glu Asn Ser Asp Lys Gly Val Glu Val Ala
 705 710 715 720

Phe Leu Gly Thr Arg Thr Gly Leu Ser Arg Ile Asn Leu Phe Val Gly
 725 730 735

Ala Glu Gln Leu Thr Asn Gln Asp Phe Leu Lys Ala Gly Asp Lys Glu
 740 745 750

Asn Ile Phe Asn Ala Asp His Phe Pro Leu Trp Tyr Arg Arg Ala Ala
 755 760 765

Glu Gln Ile Pro Gly Ser Phe Val Tyr Ser Ile Pro Phe Ser Thr Gly
 770 775 780

Pro Val Asn Lys Ser Asn Val Val Thr Ala Ser Thr Ser Ile Gln Leu
 785 790 795 800

Leu Asp Glu Arg Lys Ser Pro Val Val Ala Ala Val Gly Ile Gln Met
 805 810 815

Lys Leu Glu Phe Phe Gln Arg Lys Phe Trp Thr Ala Ser Arg Gln Cys
 820 825 830
 Ala Ser Leu Asp Gly Lys Cys Ser Ile Ser Cys Asp Asp Glu Thr Val
 835 840 845
 Asn Cys Tyr Leu Ile Asp Asn Asn Gly Phe Ile Leu Val Ser Glu Asp
 850 855 860
 Tyr Thr Gln Thr Gly Asp Phe Phe Gly Glu Ile Glu Gly Ala Val Met
 865 870 875 880
 Asn Lys Leu Leu Thr Met Gly Ser Phe Lys Arg Ile Thr Leu Tyr Asp
 885 890 895
 Tyr Gln Ala Met Cys Arg Ala Asn Lys Glu Ser Ser Asp Gly Ala His
 900 905 910
 Gly Leu Leu Asp Pro Tyr Asn Ala Phe Leu Ser Ala Val Lys Trp Ile
 915 920 925
 Met Thr Glu Leu Val Leu Phe Leu Val Glu Phe Asn Leu Cys Ser Trp
 930 935 940
 Trp His Ser Asp Met Thr Ala Lys Ala Gln Lys Leu Lys Gln Thr Leu
 945 950 955 960
 Glu Pro Cys Asp Thr Glu Tyr Pro Ala Phe Val Ser Glu Arg Thr Ile
 965 970 975
 Lys Glu Thr Thr Gly Asn Ile Ala Cys Glu Asp Cys Ser Lys Ser Phe
 980 985 990
 Val Ile Gln Gln Ile Pro Ser Ser Asn Leu Phe Met Val Val Val Asp
 995 1000 1005
 Ser Ser Cys Leu Cys Glu Ser Val Ala Pro Ile Thr Met Ala Pro Ile
 1010 1015 1020
 Glu Ile Arg Tyr Asn Glu Ser Leu Lys Cys Glu Arg Leu Lys Ala Gln
 1025 1030 1035 1040
 Lys Ile Arg Arg Arg Pro Glu Ser Cys His Gly Phe His Pro Glu Glu
 1045 1050 1055
 Asn Ala Arg Glu Cys Gly Gly Ala Pro Ser Leu Gln Ala Gln Thr Val
 1060 1065 1070

Leu Leu Leu Leu Pro Leu Leu Leu Met Leu Phe Ser Arg
 1075 1080 1085

<210> 6

<211> 1120

<212> PRT

<213> Homo sapiens

<400> 6

Met Pro Ala Thr Pro Asn Phe Leu Ala Asn Pro Ser Ser Ser Ser Arg
 1 5 10 15

Trp Ile Pro Leu Gln Pro Met Pro Val Ala Trp Ala Phe Val Gln Lys
 20 25 30

Thr Ser Ala Leu Leu Trp Leu Leu Leu Leu Gly Thr Ser Leu Ser Pro
 35 40 45

Ala Trp Gly Gln Ala Lys Ile Pro Leu Glu Thr Val Lys Leu Trp Ala
 50 55 60

Asp Thr Phe Gly Gly Asp Leu Tyr Asn Thr Val Thr Lys Tyr Ser Gly
 65 70 75 80

Ser Leu Leu Leu Gln Lys Lys Tyr Lys Asp Val Glu Ser Ser Leu Lys
 85 90 95

Ile Glu Glu Val Asp Gly Leu Glu Leu Val Arg Lys Phe Ser Glu Asp
 100 105 110

Met Glu Asn Met Leu Arg Arg Lys Val Glu Ala Val Gln Asn Leu Val
 115 120 125

Glu Ala Ala Glu Glu Ala Asp Leu Asn His Glu Phe Asn Glu Ser Leu
 130 135 140

Val Phe Asp Tyr Tyr Asn Ser Val Leu Ile Asn Glu Arg Asp Glu Lys
 145 150 155 160

Gly Asn Phe Val Glu Leu Gly Ala Glu Phe Leu Leu Glu Ser Asn Ala
 165 170 175

His Phe Ser Asn Leu Pro Val Asn Thr Ser Ile Ser Ser Val Gln Leu
 180 185 190

Pro Thr Asn Val Tyr Asn Lys Asp Pro Asp Ile Leu Asn Gly Val Tyr
 195 200 205

Met Ser Glu Ala Leu Asn Ala Val Phe Val Glu Asn Phe Gln Arg Asp
 210 215 220

Pro Thr Leu Thr Trp Gln Tyr Phe Gly Ser Ala Thr Gly Phe Phe Arg
 225 230 235 240

Ile Tyr Pro Gly Ile Lys Trp Thr Pro Asp Glu Asn Gly Val Ile Thr
 245 250 255

Phe Asp Cys Arg Asn Arg Gly Trp Tyr Ile Gln Ala Ala Thr Ser Pro
 260 265 270

Lys Asp Ile Val Ile Leu Val Asp Val Ser Gly Ser Met Lys Gly Leu
 275 280 285

Arg Met Thr Ile Ala Lys His Thr Ile Thr Thr Ile Leu Asp Thr Leu
 290 295 300

Gly Glu Asn Asp Phe Val Asn Ile Ile Ala Tyr Asn Asp Tyr Val His
 305 310 315 320

Tyr Ile Glu Pro Cys Phe Lys Gly Ile Leu Val Gln Ala Asp Arg Asp
 325 330 335

Asn Arg Glu His Phe Lys Leu Leu Val Glu Glu Leu Met Val Lys Gly
 340 345 350

Val Gly Val Val Asp Gln Ala Leu Arg Glu Ala Phe Gln Ile Leu Lys
 355 360 365

Gln Phe Gln Glu Ala Lys Gln Gly Ser Leu Cys Asn Gln Ala Ile Met
 370 375 380

Leu Ile Ser Asp Gly Ala Val Glu Asp Tyr Glu Pro Val Phe Glu Lys
 385 390 395 400

Tyr Asn Trp Pro Asp Cys Lys Val Arg Val Phe Thr Tyr Leu Ile Gly
 405 410 415

Arg Glu Val Ser Phe Ala Asp Arg Met Lys Trp Ile Ala Cys Asn Asn
 420 425 430

Lys Gly Tyr Tyr Thr Gln Ile Ser Thr Leu Ala Asp Thr Gln Glu Asn
 435 440 445

Val Met Glu Tyr Leu His Val Leu Ser Arg Pro Met Val Ile Asn His
 450 455 460

Asp His Asp Ile Ile Trp Thr Glu Ala Tyr Met Asp Ser Lys Leu Leu
 465 470 475 480

Ser Ser Gln Ala Gln Ser Leu Thr Leu Leu Thr Thr Val Ala Met Pro
 485 490 495

Val Phe Ser Lys Lys Asn Glu Thr Arg Ser His Gly Ile Leu Leu Gly
 500 505 510

Val Val Gly Ser Asp Val Ala Leu Arg Glu Leu Met Lys Leu Ala Pro
 515 520 525

Arg Tyr Lys Leu Gly Val His Gly Tyr Ala Phe Leu Asn Thr Asn Asn
 530 535 540

Gly Tyr Ile Leu Ser His Pro Asp Leu Arg Pro Leu Tyr Arg Glu Gly
 545 550 555 560

Lys Lys Leu Lys Pro Lys Pro Asn Tyr Asn Ser Val Asp Leu Ser Glu
 565 570 575

Val Glu Trp Glu Asp Gln Ala Glu Ser Leu Arg Thr Ala Met Ile Asn
 580 585 590

Arg Glu Thr Gly Thr Leu Ser Met Asp Val Lys Val Pro Met Asp Lys
 595 600 605

Gly Lys Arg Val Leu Phe Leu Thr Asn Asp Tyr Phe Phe Thr Asp Ile
 610 615 620

Ser Asp Thr Pro Phe Ser Leu Gly Val Val Leu Ser Arg Gly His Gly
 625 630 635 640

Glu Tyr Ile Leu Leu Gly Asn Thr Ser Val Glu Glu Gly Leu His Asp
 645 650 655

Leu Leu His Pro Asp Leu Ala Leu Ala Gly Asp Trp Ile Tyr Cys Ile
 660 665 670

Thr Asp Ile Asp Pro Asp His Arg Lys Leu Ser Gln Leu Glu Ala Met
 675 680 685

Ile Arg Phe Leu Thr Arg Lys Asp Pro Asp Leu Glu Cys Asp Glu Glu
 690 695 700

Leu Val Arg Glu Val Leu Phe Asp Ala Val Val Thr Ala Pro Met Glu
 705 710 715 720

Ala Tyr Trp Thr Ala Leu Ala Leu Asn Met Ser Glu Glu Ser Glu His
725 730 735

Val Val Asp Met Ala Phe Leu Gly Thr Arg Ala Gly Leu Leu Arg Ser
740 745 750

Ser Leu Phe Val Gly Ser Glu Lys Val Ser Asp Arg Lys Phe Leu Thr
755 760 765

Pro Glu Asp Glu Ala Ser Val Phe Thr Leu Asp Arg Phe Pro Leu Trp
770 775 780

Tyr Arg Gln Ala Ser Glu His Pro Ala Gly Ser Phe Val Phe Asn Leu
785 790 795 800

Arg Trp Ala Glu Gly Pro Glu Ser Ala Gly Glu Pro Met Val Val Thr
805 810 815

Ala Ser Thr Ala Val Ala Val Thr Val Asp Lys Arg Thr Ala Ile Ala
820 825 830

Ala Ala Ala Gly Val Gln Met Lys Leu Glu Phe Leu Gln Arg Lys Phe
835 840 845

Trp Ala Ala Thr Arg Gln Cys Ser Thr Val Asp Gly Pro Cys Thr Gln
850 855 860

Ser Cys Glu Asp Ser Asp Leu Asp Cys Phe Val Ile Asp Asn Asn Gly
865 870 875 880

Phe Ile Leu Ile Ser Lys Arg Ser Arg Glu Thr Gly Arg Phe Leu Gly
885 890 895

Glu Val Asp Gly Ala Val Leu Thr Gln Leu Leu Ser Met Gly Val Phe
900 905 910

Ser Gln Val Thr Met Tyr Asp Tyr Gln Ala Met Cys Lys Pro Ser Ser
915 920 925

His His His Ser Ala Ala Gln Pro Leu Val Ser Pro Ile Ser Ala Phe
930 935 940

Leu Thr Ala Thr Arg Trp Leu Leu Gln Glu Leu Val Leu Phe Leu Leu
945 950 955 960

Glu Trp Ser Val Trp Gly Ser Trp Tyr Asp Arg Gly Ala Glu Ala Lys
965 970 975

Ser Val Phe His His Ser His Lys His Lys Lys Gln Asp Pro Leu Gln
 980 985 990

Pro Cys Asp Thr Glu Tyr Pro Val Phe Val Tyr Gln Pro Ala Ile Arg
 995 1000 1005

Glu Ala Asn Gly Ile Val Glu Cys Gly Pro Cys Gln Lys Val Phe Val
 1010 1015 1020

Val Gln Gln Ile Pro Asn Ser Asn Leu Leu Leu Leu Val Thr Asp Pro
 1025 1030 1035 1040

Thr Cys Asp Cys Ser Ile Phe Pro Pro Val Leu Gln Glu Ala Thr Glu
 1045 1050 1055

Val Lys Tyr Asn Ala Ser Val Lys Cys Asp Arg Met Arg Ser Gln Lys
 1060 1065 1070

Leu Arg Arg Arg Pro Asp Ser Cys His Ala Phe His Pro Glu Glu Asn
 1075 1080 1085

Ala Gln Asp Cys Gly Gly Ala Ser Asp Thr Ser Ala Ser Pro Pro Leu
 1090 1095 1100

Leu Leu Leu Pro Val Cys Ala Trp Gly Leu Leu Pro Gln Leu Leu Arg
 1105 1110 1115 1120

<210> 7

<211> 24

<212> DNA

<213> Homo sapiens

<400> 7

aggatggccc tggggaaaag aaga

24

<210> 8

<211> 20

<212> DNA

<213> Homo sapiens

<400> 8

atcatcaatg aggacacaga

20

<210> 9
<211> 20
<212> DNA
<213> Homo sapiens

<400> 9
agaacgaaac cagatcgaag 20

<210> 10
<211> 21
<212> DNA
<213> Homo sapiens

<400> 10
cgattcacca tagcatttct c 21

<210> 11
<211> 17
<212> DNA
<213> Homo sapiens

<400> 11
ctaccaagcc atgtgta 17

<210> 12
<211> 20
<212> DNA
<213> Mus musculus

<400> 12
agaacgaaac taggtcaaag 20

<210> 13
<211> 21
<212> DNA
<213> Mus musculus

<400> 13
cgatttacca tggcatttcg t 21

<210> 14

<211> 254

<212> DNA

<213> Rattus rattus

<400> 14

```

gattcttctg ggtgtggttg gcacagatgt cccagtaaaa gagcttctga agaccatccc 60
caaatacaag ttaggaattc atggttatgc ctttgccatc acgaataatg gatacatctt 120
gacacacccg gagctcaggc cctgtatga agaagggaag aagcgaagga agcctaatta 180
cagtagtgtg gatctctcgg aagtcgagtg ggaagatcgg gatgatgtgt tacgaaatgc 240
catggtaaat cgac                                     254

```

<210> 15

<211> 5001

<212> DNA

<213> Homo sapiens

<400> 15

```

ccatgcctgc aactcccaac ttctctgcaa accccagctc cagcagccgc tggattcccc 60
tccagccaat gcccggtggc tgggcctttg tgcagaagac ctcgccctc ctgtggctgc 120
tgcttctagg cacctccctg tcccctgcgt ggggacaggc caagattcct ctggaaacag 180
tgaagctatg ggctgacacc ttccggcggg acctgtataa cactgtgacc aaatactcag 240
gctctctctt gctgcagaag aagtacaagg atgtggagtc cagtctgaag atcgaggagg 300
tggatggctt ggagctggtg aggaagtctt cagaggacat ggagaacatg ctgctggagga 360
aagtcgaggc ggtccagaat ctggtggaag ctgccgagga ggccgacctg aaccacgaat 420
tcaatgaatc cctggtgttc gactattaca actcggctct gatcaacgag agggacgaga 480
agggcaactt cgtggagctg ggccgagagt tcctcctgga gtccaatgct cacttcagca 540
acctgccggt gaacacctcc atcagcagcg tgcagctgcc caccaacgtg tacaacaaag 600
accagatat tttaaatgga gtctacatgt ctgaagcctt gaatgctgtc ttcgtggaga 660
acttccagag agacccaacg ttgacctggc aatatttttg cagtgcact ggattcttca 720
ggatctatcc aggtataaaa tggacacctg atgagaatgg agtcattact tttgactgcc 780
gaaaccgcgg ctggtacatt caagctgcta cttctcccaa ggacatagtg attttggtgg 840
acgtgagcgg cagtatgaag gggctgagga tgactattgc caagcacacc atcaccacca 900
tcttgacac cctgggggag aatgacttcg ttaatatcat agcgtacaat gactacgtcc 960
attacatcga gccttggtt aaagggatcc tcgtccaggc ggaccgagac aatcgagagc 1020
atttcaaact gctggtggag gagttgatgg tcaaagggtg gggggctcgt gaccaagccc 1080
tgagagaagc cttccagatc ctgaagcagt tccaagaggc caagcaagga agcctctgca 1140
accaggccat catgctcatc agcgacggcg ccgtggagga ctacgagccg gtgtttgaga 1200
agtataactg gccagactgt aaggtccgag ttttacttta cctcattggg agagaagtgt 1260
cttttgctga ccgcatgaag tggattgcat gcaacaacaa aggctactac acgcagatct 1320
caacgctggc ggacacccag gagaacgtga tggaaatacct gcacgtgctc agccgcccc 1380
tggatcatcaa ccacgaccac gacatcatct ggacagaggc ctacatggac agcaagctcc 1440
tcagctcgca ggctcagagc ctgacactgc tcaccactgt ggccatgcca gtcttcagca 1500
agaagaacga aacgcgatcc catggcatc tcctgggtgt ggtgggctca gatgtggccc 1560
tgagagagct gatgaagctg gcgccccggg acaagcttgg agtgcacgga tacgcctttc 1620
tgaacaccaa caatggctac atcctctccc atcccgaact ccggcccttg tacagagagg 1680
ggaagaaact aaaacccaaa cctaactaca acagtgtgga tctctccgaa gtggagtggg 1740
aagaccaggc tgaatctaag cgagttcttt tcctgaccaa tgactacttc ttcacggaca 1800

```



```

tcagcgacac ccctttcagt ttgggggtgg tgctgtcccg gggccacgga gaatacatcc 1860
ttctggggaa cacgtctgtg gaagaaggcc tgcattgactt gcttcaccca gacctggccc 1920
tggccggtga ctggatctac tgcattcacag atattgaccc agaccaccgg aagctcagcc 1980
agctagaggc catgatccgc ttcttcacca ggaaggaccc agacctggag tgtgacgagg 2040
agctgggtccg ggaggtgctg tttgacgcgg tggtagacagc ccccatggaa gcctactgga 2100
cagcgctggc cctcaacatg tccgaggagt ctgaacacgt ggtggacatg gccttcctgg 2160
gcacccgggc tggcctcctg agaagcagct tgttcgtggg ctccgagaag gtctccgaca 2220
ggaagtctct gacacctgag gacgaggcca gcgtgttcac cctggaccgc tcccgtctgt 2280
ggtaccgcca ggcctcagag catcctgctg gcagcttcgt cttcaacctc cgctgggcag 2340
aaggaccaga aagtgcgggt gaacccatgg tggtagcggc aagcacagct gtggcgggtga 2400
ccgtggacaa gaggacagcc attgctgcag ccgcgggctt ccaaataaag ctggaattcc 2460
tccagcgcaa attctgggcg gcaacgcggc agtgcagcac tgtggatggg ccgtgcacac 2520
agagctgcga ggacagtgat ctggactgct tcgtcatcga caacaacggg ttcattctga 2580
tctccaagag gtcccgagag acgggaagat ttctggggga ggtggatggt gctgtcctga 2640
cccagctgct cagcatgggg gtgttcagcc aagtgaactat gtatgactat caggccatgt 2700
gcaaaccctc gagtcaccac cacagtgcag cccagccctt ggtcagccca atttctgcct 2760
tcttgacggc gaccaggtgg ctgctgcagg agctgggtgt gttcctgtgt gactggagtg 2820
tctggggctc ctggtacgac agaggggccc agggcaaaaag tgtcttccat cactcccaca 2880
aacacaagaa gcaggacccc ctgcagccct gcgacacgga gtaccccggt ttcgtgtacc 2940
agccggccat ccgggaggcc aacgggatcg tggagtgcgg gccctgccag aaggtatttg 3000
tggtagcaga gattcccaac agtaacctcc tctcctggt gacagacccc acctgtgact 3060
gcagcatctt cccaccagtg ctgcaggagg cgacagaagt caaatataat gcctctgtca 3120
aatgtgaccg gatgcgctcc cagaagctcc gccggcgacc agactcctgc cagccttcc 3180
atccagagga gaatgccag gactgcggcg gcgcctcgga cacctcagcc tcgcccgc 3240
tactcctgct gcctgtgtgt gcctgggggc tactgccccca actcctgcgg tgacaccacc 3300
cagcctgacc tgtgttttgg caaggtgatc ctccagagc catcccaaaa agtcagcact 3360
gacatgggat gcagctaact gcagttgggt cggccccagg ccaacgctcc tctcaatcct 3420
gggctggtgg cccctggctc cggagaatgc tggatggaac aggaaaccaa tcacctggca 3480
ccactttcaa gatgcttcat ggtgcccggg accatctgcc ctaggctctc acatgagcat 3540
acttctgacc taaccttctt gtctcctctt cgggaagcca gcgtgagctc agcttggacc 3600
aagacaaaat aatttagttc ttctgtact ccagagtcca gaccagcca agaaagggtc 3660
agttgtttct gaccctttct gtcggagtgg tctctggtag aaccaagga cttctgggtg 3720
ctgagaagca gcagcagaat gaggccaaat gcagagatga ggctaaggca agaatatgcc 3780
ccaactaaag catagattcc ccaaagtgag gctcatggtg ggaggccact caccttccct 3840
gctgctgctc gaaaagggtt tgactgtgtt ggggtggggg ttgggtaagg gaatggtcaa 3900
gactgagaaa ggaatgaaat ccattcagga aatatcgaca gggctacacg tgatgtcccc 3960
aaactgctgc tattgaagaa cttcccaaaa cttctttaca aagccctaaa ggaaagtgtg 4020
catctatgaa aagccaatag gctgagacat ccaattgctg catggaaatt gatgtacatt 4080
caggggacgg caaaaatagc tgtaaaatag tgaaaaagag cagtggttgt gctcttttct 4140
ggccaatgat ttacaaaaga atctacttga ctctgtccct ggagtgaat ccttaggggt 4200
ggaacttgtg ggaacattcc aacttgctaa gcagggtcca ctgggaggga agctctatct 4260
gggaactcac cccagcgca cacacatctc cccagggtc ccaaggcccc gcagcttctc 4320
ccccgacca aacccaaga cctggatccc aggagacaac agtctccaca tgagagcaac 4380
attaagggca aagccatgga gaaatgtggg agaggccggc ctcaaactct tccatttaac 4440
aaaccccagt gatgggtatg gacagcatgc agggcttttg gggcgcttcc ccccgctcct 4500
ccatcacccct cagcctccac acttcaaagt tcaagttcaa agctgttcaa gtttcttacc 4560
agcaaatagc cctaacttgc ctctagagta ggccaaatgc caactctgta aaacacactt 4620
acattatcgg ttacagaatg tcaactctac catcatgtct tgcaacaacc ctgtgagggc 4680

```

```

agtattaatg ccccttaca gcagaagaca ctgcagctcg aagacagctt aagtggcaga 4740
ataatgctag aacagctaag gtttacatgt accaaataac atgtttcage tcattccatc 4800
ctcacaacag cccctgaaa gtgggtacta tcattagtcg catgttatag aaactgcagc 4860
agagttgaaa attgcctcca aattaccgga agagtgtatg aagattgaat gtgatgtatt 4920
cacgtaacat gcttgaaact gcctggcata tactaaacgc taaataaata catgctaact 4980
gcaaaaaaaaa aaaaaaaaaa a 5001

```

<210> 16

<211> 5712

<212> DNA

<213> Homo sapiens

<400> 16

```

ccatgcctgc aactcccaac ttctctgcaa accccagctc cagcagccgc tggattcccc 60
tccagccaat gcccggtggc tgggcctttg tgcagaagac ctcgccctc ctgtggctgc 120
tgcttctagg caccctccctg tcccttgggt ggggacaggg caagatttct ctggaaacag 180
tgaagctatg ggctgacacc ttccggcggg acctgtataa cactgtgacc aaatactcag 240
gctctctctt gctgcagaag aagtacaagg atgtggagtc cagtctgaag atcgaggagg 300
tggatggctt ggagctggtg aggaagttct cagaggacat ggagaacatg ctgcggaggga 360
aagtcgaggg ggtccagaat ctggtggaag ctgccgagga ggccgacctg aaccacgaat 420
tcaatgaatc cctggtgttc gactattaca actcggctct gatcaacgag agggacgaga 480
agggcaactt cgtggagctg ggcgcggagt tctctctgga gtccaatgct cacttcagca 540
acctgccggt gaacacctcc atcagcagcg tgcagctgcc caccaacgtg tacaacaaag 600
accagatat tttaaatgga gtctacatgt ctgaagcctt gaatgctgtc ttcgtggaga 660
acttccagag agaccaacg ttgacctggc aatattttgg cagtgcactt ggattcttca 720
ggatctatcc aggtataaaa tggacacctg atgagaatgg agtcattact tttgactgcc 780
gaaaccgcgg ctggtacatt caagctgcta cttctcccaa ggacatagtg attttggtgg 840
acgtgagcgg cagtatgaag gggctgagga tgactattgc caagcacacc atcaccacca 900
tcttgacac cctgggggag aatgacttcr ttaatatcat agcgtacaat gactacgtcc 960
attacatcga gccttgttt aaagggatcc tcgtccaggc ggaccgagac aatcgagagc 1020
atttcaaact gctggtggag gagttgatgg tcaaagggtg gggggctcgt gaccaagccc 1080
tgagagaagc cttccagatc ctgaagcagt tccaagaggc caagcaagga agcctctgca 1140
accaggccat catgctcatc agcgacggcg ccgtggagga ctacgagccg gtgtttgaga 1200
agtataactg gccagactgt aaggtccgag ttttcaacta cctcattggg agagaagtgt 1260
cttttgctga ccgcatgaag tggattgcat gcaacaacaa aggctactac acgcagatct 1320
caacgctggc ggacaccag gagaacgtga tggataacct gcacgtgctc agccgcccc 1380
tggatcatcaa ccacgaccac gacatcatct ggacagaggg ctacatggac agcaagctcc 1440
tcagctcgca ggctcagagc ctgacactgc tcaccactgt ggccatgcc 1500
agaagaacga aacgcgatcc catggcatc tcttgggtgt ggtgggctca gatgtggccc 1560
tgagagagct gatgaagctg gcgccccggt acaagcttgg agtgcacgga tacgccttcc 1620
tgaacaccaa caatggctac atcctctccc atcccgacct ccggcccctg tacagagagg 1680
ggaagaaact aaacccaaa cctaactaca acagtgtgga tctctccgaa gtggagtggg 1740
aagaccaggc tgaatctctg agaacagcca tgatcaatag ggaaacaggt actctctcga 1800
tggatgtgaa ggttccgatg gataaaggga agcgagttct tttcctgacc aatgactact 1860
tcttcacgga catcagcgac acccctttca gtttgggggt ggtgctgtcc cggggccacg 1920
gagaatacat ccttctgggg aacacgtctg tggagaaggg cctgcatgac ttgcttcacc 1980
cagacctggc cctggccggt gactggatct actgcatcac agatattgac ccagaccacc 2040

```

```

ggaagctcag ccagctagag gccatgatcc gcttcctcac caggaaggac ccagacctgg 2100
agtgtgacga ggagctgggc cgggaggtgc tgtttgacgc ggtggtgaca gcccccatgg 2160
aagcctactg gacagcgctg gccctcaaca tgtccgagga gtctgaacac gtggtggaca 2220
tggccttcct gggcaccggt gctggcctcc tgagaagcag cttgttcgtg ggctccgaga 2280
aggtctccga caggaagttc ctgacacctg aggacgaggc cagcgtgttc accctggacc 2340
gcttcccgtc gtggtaccgc caggcctcag agcatcctgc tggcagcttc gtcttcaacc 2400
tccgctgggc agaaggacca gaaagtgcgg gtgaacccat ggtggtgacg gcaagcacag 2460
ctgtggcggg gaccgtggac aagaggacag ccattgctgc agccgcgggc gtccaaatga 2520
agctggaatt cctccagcgc aaattctggg cggcaacgcg gcagtgcagc actgtggatg 2580
ggcctgacac acagagctgc gaggacagtg atctggactg cttcgtcatc gacaacaacg 2640
ggttcattct gatctccaag aggtcccagag agacgggaag atttctgggg gaggtggatg 2700
gtgctgtcct gaccagctg ctcagcatgg ggtgttcag ccaagtgact atgtatgact 2760
atcaggccat gtgcaaacc tccagtcacc accacagtgc agccagccc ctggtcagcc 2820
caatttctgc cttcttgacg gcgaccaggt ggctgctgca ggagctggtg cttgtgagtg 2880
ggggtagaca cggggctggt ggaggctgca tgcgagggtg gcttaggagg gtgtccttga 2940
tcaggaggct gcaaggtctc caggacaacc cacttgctac caagaccccg gggaaggagg 3000
gcacaatccc tgggcatgga cggccctctc tccctgcatg cttggccctg ggaaggacct 3060
cattgctcaa ccagagccct caagcaggga agagggtgtc ctggaggaga ggggatgggc 3120
cgggggctgt cagggatact ccagctcctt gggaacccaa gtcgggaggg ctcagaggtc 3180
tccgagattc agtcctgtgt ctgacaggtt cctgctggag tggagtgtct ggggctcctg 3240
gtacgacaga ggggcccagg gtgagtgcac ggagctgcag ggccatgtgc tgaagagcag 3300
tggcattttg gtccactaac gtgagaccat tccctgtggg gtgggtgaca gtggggatag 3360
gtgaccctga agcatcgttg ttcacatctc accctgcgtg gccttctctc atcacatccc 3420
tcactcctgg ctctgtgtgt gacatcatct tgggacaccg ccactccatg tgccatcatc 3480
accaccccat gacatcctgc cctcatgtgc caccatgttt tctgtgccg tgtccacct 3540
gtgctgggct tatgttccgg ccagccaaaa gtgtcttcca tcaactccac aaacacaaga 3600
agcaggaccc gctgcagccc tgcgacacgg agtaccctgt gttcgtgtac cagccggcca 3660
tccgggaggc caacgggatc gtggagtgcg ggccctgcc aaggtattt gtggtgcagc 3720
agattcccaa cagtaacctc ctctcctggt tgacagaccc cacctgtgac tgcagcatct 3780
tcccaccagt gctgcaggag gcgacagaag tcaaatataa tgcctctgtc aaatgtgacc 3840
ggatgcgctc ccagaagctc cggcggcgac cagactcctg ccacgccttc catccagagg 3900
agaatgcccc ggactgcggy ggcgcctcgg acacctcagc ctgcgccccc ctactcctgc 3960
tgctgtgtgt tgcttggggg ctactgcccc aactcctgcg gtgacaccac ccagcctgac 4020
ctgtgttttg gcaaggtgat ccttccagag ccatcccaaa aagtcagcac tgacatggga 4080
tgcagctaac tgcagttggg tcgccccag gccaacgctc ctctcaatcc tgggctggtg 4140
gcccctggct ccggagaatg ctggatggaa caggaaacca atcacctggc accactttca 4200
agatgcttca tgggtgcccg taccatctgc cctaggtctc aacatgagca tacttctgac 4260
ctaacccttc tgtctcctct tcgggaagcc agcgtgagct cagcttggac caagacaaaa 4320
taatttagtt cttcctgtac tccagagtcc agaccagcc aagaaagggt cagttgtttc 4380
tgaccctttc tgtcggagtgt gtctctggta gaaccaagg acttctgggt actgagaagc 4440
agcagcagaa tgaggccaaa tgcagagatg aggctaaggc aagaatatgc cccaactaaa 4500
gcatagattc cccaaagtga ggctcatggt gggaggccac tcaccttctt agctgctgct 4560
cgaaaagggt ttgactgtgt tgggggtggg gtgggtaag ggaatggtca agactgagaa 4620
aggaatgaaa tccattcagg aaatatcgac agggctacac gtgatgtccc caaactgctg 4680
ctattgaaga acttcccaaa acttctttac aaagccctaa aggaaagttt gcatctatga 4740
aaagccaata ggctgagaca tccaattgct gcatggaaat tgatgtacat tcaggggacg 4800
gcaaaaatag ctgtaaaata gtgaaaaaga gcagtgggtt tgctcttttc tggccaatga 4860
tttacaaaag aatctacttg actctgtccc tggagtgaag tccttagggt tggaaactgt 4920

```

```

gggaacattc caacttgcta agcagggtcc actgggaggg aagctctatc tgggaactca 4980
ccccagcgc acacacatct ccccagggt cccaaggccc cgcagcttcc tccccgacc 5040
aaacccaag acctggatcc caggagacaa cagtctccac atgagagcaa cattaagggc 5100
aaagccatgg agaaatgtgg gagaggccgg cctcaaactt ttccatttaa caaacccag 5160
tgatgggtat ggacagcatg cagggtttt ggggcgcttc ccccgcctcc tccatcacc 5220
tcagcctcca cacttcaaag ttcaagtcca aagctgttca agtttcctac cagcaaatag 5280
ccctaacttg cctctagagt aggccaaatg ccaactctgt aaaacacact tacattatcg 5340
gttacagaat gtcactctta ccatcatgtc ttgcaacaac cctgtgaggg cagtattaat 5400
gcccccttac agcagaagac actgcagctc gaagacagct taagtggcag aataatgcta 5460
gaacagctaa ggtttacatg taccaaataa catgtttcag ctcatccat ctcacaaca 5520
gccccctgaa agtgggtact atcattagtc ccatgttata gaaactgcag cagagttgaa 5580
aattgcctcc aaattaccgg aagagtgtat gaagattgaa tgtgatgtat tcacgtaaca 5640
tgcttgaaac tgcctggcat atactaaacg ctaaataaat acatgctaac tgcaaaaaaa 5700
aaaaaaaaaa aa 5712

```

<210> 17

<211> 1096

<212> PRT

<213> Homo sapiens

<400> 17

```

Met Pro Ala Thr Pro Asn Phe Leu Ala Asn Pro Ser Ser Ser Ser Arg
  1              5              10              15

```

```

Trp Ile Pro Leu Gln Pro Met Pro Val Ala Trp Ala Phe Val Gln Lys
          20              25              30

```

```

Thr Ser Ala Leu Leu Trp Leu Leu Leu Leu Gly Thr Ser Leu Ser Pro
      35              40              45

```

```

Ala Trp Gly Gln Ala Lys Ile Pro Leu Glu Thr Val Lys Leu Trp Ala
      50              55              60

```

```

Asp Thr Phe Gly Gly Asp Leu Tyr Asn Thr Val Thr Lys Tyr Ser Gly
      65              70              75              80

```

```

Ser Leu Leu Leu Gln Lys Lys Tyr Lys Asp Val Glu Ser Ser Leu Lys
          85              90              95

```

```

Ile Glu Glu Val Asp Gly Leu Glu Leu Val Arg Lys Phe Ser Glu Asp
      100              105              110

```

```

Met Glu Asn Met Leu Arg Arg Lys Val Glu Ala Val Gln Asn Leu Val
      115              120              125

```

```

Glu Ala Ala Glu Glu Ala Asp Leu Asn His Glu Phe Asn Glu Ser Leu
      130              135              140

```

Val Phe Asp Tyr Tyr Asn Ser Val Leu Ile Asn Glu Arg Asp Glu Lys
 145 150 155 160
 Gly Asn Phe Val Glu Leu Gly Ala Glu Phe Leu Leu Glu Ser Asn Ala
 165 170 175
 His Phe Ser Asn Leu Pro Val Asn Thr Ser Ile Ser Ser Val Gln Leu
 180 185 190
 Pro Thr Asn Val Tyr Asn Lys Asp Pro Asp Ile Leu Asn Gly Val Tyr
 195 200 205
 Met Ser Glu Ala Leu Asn Ala Val Phe Val Glu Asn Phe Gln Arg Asp
 210 215 220
 Pro Thr Leu Thr Trp Gln Tyr Phe Gly Ser Ala Thr Gly Phe Phe Arg
 225 230 235 240
 Ile Tyr Pro Gly Ile Lys Trp Thr Pro Asp Glu Asn Gly Val Ile Thr
 245 250 255
 Phe Asp Cys Arg Asn Arg Gly Trp Tyr Ile Gln Ala Ala Thr Ser Pro
 260 265 270
 Lys Asp Ile Val Ile Leu Val Asp Val Ser Gly Ser Met Lys Gly Leu
 275 280 285
 Arg Met Thr Ile Ala Lys His Thr Ile Thr Thr Ile Leu Asp Thr Leu
 290 295 300
 Gly Glu Asn Asp Phe Val Asn Ile Ile Ala Tyr Asn Asp Tyr Val His
 305 310 315 320
 Tyr Ile Glu Pro Cys Phe Lys Gly Ile Leu Val Gln Ala Asp Arg Asp
 325 330 335
 Asn Arg Glu His Phe Lys Leu Leu Val Glu Glu Leu Met Val Lys Gly
 340 345 350
 Val Gly Val Val Asp Gln Ala Leu Arg Glu Ala Phe Gln Ile Leu Lys
 355 360 365
 Gln Phe Gln Glu Ala Lys Gln Gly Ser Leu Cys Asn Gln Ala Ile Met
 370 375 380
 Leu Ile Ser Asp Gly Ala Val Glu Asp Tyr Glu Pro Val Phe Glu Lys
 385 390 395 400

Tyr Asn Trp Pro Asp Cys Lys Val Arg Val Phe Thr Tyr Leu Ile Gly
 405 410 415
 Arg Glu Val Ser Phe Ala Asp Arg Met Lys Trp Ile Ala Cys Asn Asn
 420 425 430
 Lys Gly Tyr Tyr Thr Gln Ile Ser Thr Leu Ala Asp Thr Gln Glu Asn
 435 440 445
 Val Met Glu Tyr Leu His Val Leu Ser Arg Pro Met Val Ile Asn His
 450 455 460
 Asp His Asp Ile Ile Trp Thr Glu Ala Tyr Met Asp Ser Lys Leu Leu
 465 470 475 480
 Ser Ser Gln Ala Gln Ser Leu Thr Leu Thr Thr Val Ala Met Pro
 485 490 495
 Val Phe Ser Lys Lys Asn Glu Thr Arg Ser His Gly Ile Leu Leu Gly
 500 505 510
 Val Val Gly Ser Asp Val Ala Leu Arg Glu Leu Met Lys Leu Ala Pro
 515 520 525
 Arg Tyr Lys Leu Gly Val His Gly Tyr Ala Phe Leu Asn Thr Asn Asn
 530 535 540
 Gly Tyr Ile Leu Ser His Pro Asp Leu Arg Pro Leu Tyr Arg Glu Gly
 545 550 555 560
 Lys Lys Leu Lys Pro Lys Pro Asn Tyr Asn Ser Val Asp Leu Ser Glu
 565 570 575
 Val Glu Trp Glu Asp Gln Ala Glu Ser Lys Arg Val Leu Phe Leu Thr
 580 585 590
 Asn Asp Tyr Phe Phe Thr Asp Ile Ser Asp Thr Pro Phe Ser Leu Gly
 595 600 605
 Val Val Leu Ser Arg Gly His Gly Glu Tyr Ile Leu Leu Gly Asn Thr
 610 615 620
 Ser Val Glu Glu Gly Leu His Asp Leu Leu His Pro Asp Leu Ala Leu
 625 630 635 640
 Ala Gly Asp Trp Ile Tyr Cys Ile Thr Asp Ile Asp Pro Asp His Arg
 645 650 655

Lys Leu Ser Gln Leu Glu Ala Met Ile Arg Phe Leu Thr Arg Lys Asp
 660 665 670
 Pro Asp Leu Glu Cys Asp Glu Glu Leu Val Arg Glu Val Leu Phe Asp
 675 680 685
 Ala Val Val Thr Ala Pro Met Glu Ala Tyr Trp Thr Ala Leu Ala Leu
 690 695 700
 Asn Met Ser Glu Glu Ser Glu His Val Val Asp Met Ala Phe Leu Gly
 705 710 715 720
 Thr Arg Ala Gly Leu Leu Arg Ser Ser Leu Phe Val Gly Ser Glu Lys
 725 730 735
 Val Ser Asp Arg Lys Phe Leu Thr Pro Glu Asp Glu Ala Ser Val Phe
 740 745 750
 Thr Leu Asp Arg Phe Pro Leu Trp Tyr Arg Gln Ala Ser Glu His Pro
 755 760 765
 Ala Gly Ser Phe Val Phe Asn Leu Arg Trp Ala Glu Gly Pro Glu Ser
 770 775 780
 Ala Gly Glu Pro Met Val Val Thr Ala Ser Thr Ala Val Ala Val Thr
 785 790 795 800
 Val Asp Lys Arg Thr Ala Ile Ala Ala Ala Gly Val Gln Met Lys
 805 810 815
 Leu Glu Phe Leu Gln Arg Lys Phe Trp Ala Ala Thr Arg Gln Cys Ser
 820 825 830
 Thr Val Asp Gly Pro Cys Thr Gln Ser Cys Glu Asp Ser Asp Leu Asp
 835 840 845
 Cys Phe Val Ile Asp Asn Asn Gly Phe Ile Leu Ile Ser Lys Arg Ser
 850 855 860
 Arg Glu Thr Gly Arg Phe Leu Gly Glu Val Asp Gly Ala Val Leu Thr
 865 870 875 880
 Gln Leu Leu Ser Met Gly Val Phe Ser Gln Val Thr Met Tyr Asp Tyr
 885 890 895
 Gln Ala Met Cys Lys Pro Ser Ser His His His Ser Ala Ala Gln Pro
 900 905 910

Leu Val Ser Pro Ile Ser Ala Phe Leu Thr Ala Thr Arg Trp Leu Leu
 915 920 925

Gln Glu Leu Val Leu Phe Leu Leu Glu Trp Ser Val Trp Gly Ser Trp
 930 935 940

Tyr Asp Arg Gly Ala Glu Ala Lys Ser Val Phe His His Ser His Lys
 945 950 955 960

His Lys Lys Gln Asp Pro Leu Gln Pro Cys Asp Thr Glu Tyr Pro Val
 965 970 975

Phe Val Tyr Gln Pro Ala Ile Arg Glu Ala Asn Gly Ile Val Glu Cys
 980 985 990

Gly Pro Cys Gln Lys Val Phe Val Val Gln Gln Ile Pro Asn Ser Asn
 995 1000 1005

Leu Leu Leu Leu Val Thr Asp Pro Thr Cys Asp Cys Ser Ile Phe Pro
 1010 1015 1020

Pro Val Leu Gln Glu Ala Thr Glu Val Lys Tyr Asn Ala Ser Val Lys
 1025 1030 1035 1040

Cys Asp Arg Met Arg Ser Gln Lys Leu Arg Arg Arg Pro Asp Ser Cys
 1045 1050 1055

His Ala Phe His Pro Glu Glu Asn Ala Gln Asp Cys Gly Gly Ala Ser
 1060 1065 1070

Asp Thr Ser Ala Ser Pro Pro Leu Leu Leu Leu Pro Val Cys Ala Trp
 1075 1080 1085

Gly Leu Leu Pro Gln Leu Leu Arg
 1090 1095

<210> 18

<211> 18

<212> DNA

<213> Homo sapiens

<400> 18

gcgaggacag tgatctgg

18

<210> 19

<211> 20
<212> DNA
<213> Homo sapiens

<400> 19
gggtcctcgt tcttggtgtt

20

<210> 20
<211> 20
<212> DNA
<213> Homo sapiens

<400> 20
tcagcctcca cacttcaaag

20

<210> 21
<211> 19
<212> DNA
<213> Homo sapiens

<400> 21
tccgcctgga cgaggatcc

19

<210> 22
<211> 20
<212> DNA
<213> Homo sapiens

<400> 22
gtgtccaaga tgggtggtgat

20

<210> 23
<211> 22
<212> DNA
<213> Homo sapiens

<400> 23
atctactgca tcacagatat tg

22

<210> 24
<211> 19
<212> DNA
<213> Homo sapiens

<400> 24
ggtgaggaag cggatcatg 19

<210> 25
<211> 21
<212> DNA
<213> Mus musculus

<400> 25
ttcaacgaga aggcacagcc t 21

<210> 26
<211> 21
<212> DNA
<213> Mus musculus

<400> 26
gttggcacag gccatccact g 21

<210> 27
<211> 21
<212> DNA
<213> Mus musculus

<400> 27
aggctgtgcc ttctcgttga a 21

<210> 28
<211> 18
<212> DNA
<213> Mus musculus

<400> 28
gagcccccaa gaagatcg 18

<210> 29
<211> 18
<212> DNA
<213> Mus musculus

<400> 29
cgatcttctt gggggctc 18

<210> 30
 <211> 18
 <212> DNA
 <213> Mus musculus

<400> 30
 cacgatgatg accatgtc 18

<210> 31
 <211> 20
 <212> DNA
 <213> Mus musculus

<400> 31
 ggcaagaccc tacactgttg 20

<210> 32
 <211> 19
 <212> DNA
 <213> Mus musculus

<400> 32
 cctggtaata gcgagtgac 19

<210> 33
 <211> 536
 <212> DNA
 <213> Mus musculus

<400> 33
 aagcttctct ctcataacca ggaggaagac atcatgtact acgatgccaa ggctgacgcc 60
 gagctggtaa gtgtcccccac ctttgccgta gaggatgggg agcagccaga gccacacctt 120
 gttcttcttg gccacaacag tctcagctgt aaagtgggtg ttagggatcc atgctcacct 180
 ttctgaactc aaccattctg tgtcgtgctt ggtcagcctc tccttgcca cagctcccta 240
 gagatccttg accctccagg gcgtgtcttc atcaccatta taggctaagc tccccctgca 300
 ccatgtggag caagcagggt ggtagagtgt tggatatcag ggtgggtcca tcccagtatg 360
 aggggctctc tgggctccat gggagtagag aggagaaaga aatggactcc aggacctcct 420
 ggggtaggta catgggagtg agacatggtg acatctaagc cctgcccagg acagtagagg 480
 ctcctttcct tgtgatttg ggaactttgc atcaagctat gtagaagaac ccatgg 536

<210> 34
 <211> 572

<212> DNA

<213> Mus musculus

<400> 34

```

caggtggcct gtggctgggc cccttctctg aacactcaca gtggagacag ggctggccac 60
agnagacccc atccttctct cccttcaggg gctgggggtg gtggtaacag gaacttctcc 120
ctgttttcaa cctgacacag gatggccctg gggaaaagaa ggtgagttgc ccagtgggtt 180
atctggggag gagttggcat gcctggagca ggtctgggga tggaggaggg ttagggcatg 240
ctacagattt ggcaaagcag ctctccgtat cagcagctta gcccttaggc ctgggccagg 300
gggttctact atggagttga ctcatatag cataccttcc cattcctttg tgtccagaac 360
cagttaatcc tgggtgtcat gggcatcgat gtggccttga atgacatcaa aaggctgact 420
cccaactaca cagtaagtgt ccacctgccc ctctgcctg gtttgctgtc catagtgaca 480
caagccagac tcagcagggg agacatgggg actgaaagac cgtcacagaa agacttccca 540
aagggtttgt tctgaagctg tggacagcaa gc 572

```

<210> 35

<211> 1853

<212> DNA

<213> Mus musculus

<400> 35

```

gctttcttgt ggctgcgggc cttggagtgc atgtgagtgc ggtgagctcc ctggggggccg 60
gctgcaggct ccaggcaagc atgctggatg gggggccagc tcacagctcc ctgccaccca 120
ggcggccctt ctccacaggc cacaaaccac atcagccctg cttgctcacc gaggcctgga 180
tgaggggtag gctgagatat ttctttgatg atttagagga gggagagcaa gaaaatctcc 240
ctggaagagc tgggtgtggc ccacatgaga tcctgggaaa tcaaagaaag cctgggcagg 300
cagaaagcag gggaggccat ggagatgggt ttagcagggg gcgaccctga acctcccaac 360
cccagccttc tgccctgccc ctacagctacc gtcacctca atgagcttaa ctggacagag 420
gccctggaga acgtcttcat tgagaacctg aggcaagacc ctacactgtt gtggcaagtc 480
tttggcagtg ccacgggagt cactcgctat taccagga ggcaccactg tctccctggc 540
ccatccagca cccgtcttgc tccatctcca agcctaccca ttctgaggtc catggggtag 600
aatgaaccag gtcaatcccc atcactcccc cctgctccag tcagaccctt ctgccggggc 660
gggccccttc acccctctt tccacagcca caccatggcg agccccaag aagattgacc 720
tgtacgatgt cagaagacga ccctggtgag tgagcaaggg ggggtggaggc gagacacccc 780
ctcaactccc catctctcgt gcccgctccc ctccctccca atatccagac ctccgagcag 840
ggcgcagcca gctctatcca attttcattt cacacatcgc tgccactgga aaatggatcc 900
catgcccag gcaagccgccc cagctgcctc tgccccacg cgtgtcgtcc actaccagc 960
ccccccacac ccactcagaa ctgagagcag accagggaag gtgcttccag gggtagctag 1020
agcctccgtc aggtcagccc gccccaccta ctatttgat ccctggacac cccgaccctc 1080
tgctctgcct ctctcacact actccatgat ctccctccc tcctccatta cacagccaga 1140
ctctctggag tctctctagg acagaggaca caagccacta aagccttctg tccccgtgga 1200
tcacctgccc ctccccctc acctcttggt tacttaatga ggaaccaga tcaactacgt 1260
cacaagaaaa aaaaaactgt ctttttgtat tgagcatggt ctccccagtg cccagaccta 1320
ttccaacccc tgtagtgctg ggtcagtaga aacacaggaa tcaagtgggt ggaagaagga 1380
agaccccgca ggtcccgagg gtgcgctct taactgagtc ttctcactgg caggtatata 1440
cagggggcct catcacccaa ggacatggtc atcattgtgg atgtgtgagt gagccttgta 1500
ggctgggtggg atgggctagg actggactct gcttcctggg caccttatga ggaagggcg 1560

```

```

ggaaaaccct gagagcccac atgcatgcgc ccccttcctg gcctgggttc caggagtggg 1620
agcgtgagcg gcctgactct gaagctgatg aagacgtccg tctgtgagat gctagacacg 1680
ctctctgatg atgactatgt gaacgtggcc tcagtgagtg gcaagggtggc aggcaggctg 1740
ggtaccactc acccccatcc aacctgctcc catgacaacc atcagccctg tacaacagct 1800
gcacactgtg tggccagcct gaagccactc accaccccccc actgtcccca cag          1853

```

<210> 36

<211> 21

<212> DNA

<213> Rattus rattus

<400> 36

```

gacaggacca acaaggagca c          21

```

<210> 37

<211> 21

<212> DNA

<213> Rattus rattus

<400> 37

```

gcccaaccaca cccagaagaa t          21

```

<210> 38

<211> 21

<212> DNA

<213> Rattus rattus

<400> 38

```

aacgcaccat caaggagacc a          21

```

<210> 39

<211> 18

<212> DNA

<213> Rattus rattus

<400> 39

```

aggggcagca gcagcaag          18

```

<210> 40

<211> 516

<212> DNA

<213> Rattus rattus

<400> 40

```

ttcaggggagc atttggacaa acttttttgcc aaagggattg gaatgctcga tattgcgctg 60
aacgaggcct tcaatgtact gagcgatttc aaccacaccg gacaaggaag catttgcagc 120
caggccatta tgctcataac cgatggggca rtggacacct acgayaccat ctttgcaaag 180
tacaattggc cagagcgaaa ggttcgaatc ttcacttacc tcattggacg agaggctgct 240
tttgagaca atctcaagtg gatrgcttgt gctaacaaag gattttttcac ccagatctcc 300
accttggctg atgtgcagga aaatgtcatg gaatacctcc atgtactcag tcgacccaaa 360
gtcatcgacc aggaacatga tgtgggtgtg accgaagcgt acatcgacag cactctccct 420
caggctcaaa agcttgctga tgatcagggc ctgctcttga tgaccacagt ggccatgcct 480
gtgttttagta agcagaacga aactaggtca aagggc 516

```

<210> 41

<211> 274

<212> DNA

<213> Rattus rattus

<400> 41

```

cagggaaacat tgcttgtgaa gaytgctcca agtcctttgt catccagcaa atcccaaagta 60
gcaatctgtt catggyggtg gtggacagta gctgtctctg tgagtctgtg gtccttatca 120
ccatggcacc cattgaaatc aggtataatg aatcccttaa gtgtgaacgg ttaaaggctc 180
agaagatcag acgacgtccg gaatcctgcc acggcttcca tcctgaggag aatgcgagag 240
agtgtggggg tgcatacaagt ctccaggccc aggt 274

```

<210> 42

<211> 1096

<212> PRT

<213> Homo sapiens

<400> 42

```

Met Pro Ala Thr Pro Asn Phe Leu Ala Asn Pro Ser Ser Ser Ser Arg
  1             5             10             15

```

```

Trp Ile Pro Leu Gln Pro Met Pro Val Ala Trp Ala Phe Val Gln Lys
      20             25             30

```

```

Thr Ser Ala Leu Leu Trp Leu Leu Leu Leu Gly Thr Ser Leu Ser Pro
      35             40             45

```

```

Ala Trp Gly Gln Ala Lys Ile Pro Leu Glu Thr Val Lys Leu Trp Ala
      50             55             60

```

```

Asp Thr Phe Gly Gly Asp Leu Tyr Asn Thr Val Thr Lys Tyr Ser Gly
      65             70             75             80

```

```

Ser Leu Leu Leu Gln Lys Lys Tyr Lys Asp Val Glu Ser Ser Leu Lys
      85             90             95

```

Ile Glu Glu Val Asp Gly Leu Glu Leu Val Arg Lys Phe Ser Glu Asp
 100 105 110

Met Glu Asn Met Leu Arg Arg Lys Val Glu Ala Val Gln Asn Leu Val
 115 120 125

Glu Ala Ala Glu Glu Ala Asp Leu Asn His Glu Phe Asn Glu Ser Leu
 130 135 140

Val Phe Asp Tyr Tyr Asn Ser Val Leu Ile Asn Glu Arg Asp Glu Lys
 145 150 155 160

Gly Asn Phe Val Glu Leu Gly Ala Glu Phe Leu Leu Glu Ser Asn Ala
 165 170 175

His Phe Ser Asn Leu Pro Val Asn Thr Ser Ile Ser Ser Val Gln Leu
 180 185 190

Pro Thr Asn Val Tyr Asn Lys Asp Pro Asp Ile Leu Asn Gly Val Tyr
 195 200 205

Met Ser Glu Ala Leu Asn Ala Val Phe Val Glu Asn Phe Gln Arg Asp
 210 215 220

Pro Thr Leu Thr Trp Gln Tyr Phe Gly Ser Ala Thr Gly Phe Phe Arg
 225 230 235 240

Ile Tyr Pro Gly Ile Lys Trp Thr Pro Asp Glu Asn Gly Val Ile Thr
 245 250 255

Phe Asp Cys Arg Asn Arg Gly Trp Tyr Ile Gln Ala Ala Thr Ser Pro
 260 265 270

Lys Asp Ile Val Ile Leu Val Asp Val Ser Gly Ser Met Lys Gly Leu
 275 280 285

Arg Met Thr Ile Ala Lys His Thr Ile Thr Thr Ile Leu Asp Thr Leu
 290 295 300

Gly Glu Asn Asp Phe Xaa Asn Ile Ile Ala Tyr Asn Asp Tyr Val His
 305 310 315 320

Tyr Ile Glu Pro Cys Phe Lys Gly Ile Leu Val Gln Ala Asp Arg Asp
 325 330 335

Asn Arg Glu His Phe Lys Leu Leu Val Glu Glu Leu Met Val Lys Gly
 340 345 350

Val Gly Val Val Asp Gln Ala Leu Arg Glu Ala Phe Gln Ile Leu Lys
 355 360 365
 Gln Phe Gln Glu Ala Lys Gln Gly Ser Leu Cys Asn Gln Ala Ile Met
 370 375 380
 Leu Ile Ser Asp Gly Ala Val Glu Asp Tyr Glu Pro Val Phe Glu Lys
 385 390 395 400
 Tyr Asn Trp Pro Asp Cys Lys Val Arg Val Phe Thr Tyr Leu Ile Gly
 405 410 415
 Arg Glu Val Ser Phe Ala Asp Arg Met Lys Trp Ile Ala Cys Asn Asn
 420 425 430
 Lys Gly Tyr Tyr Thr Gln Ile Ser Thr Leu Ala Asp Thr Gln Glu Asn
 435 440 445
 Val Met Glu Tyr Leu His Val Leu Ser Arg Pro Met Val Ile Asn His
 450 455 460
 Asp His Asp Ile Ile Trp Thr Glu Ala Tyr Met Asp Ser Lys Leu Leu
 465 470 475 480
 Ser Ser Gln Ala Gln Ser Leu Thr Leu Leu Thr Thr Val Ala Met Pro
 485 490 495
 Val Phe Ser Lys Lys Asn Glu Thr Arg Ser His Gly Ile Leu Leu Gly
 500 505 510
 Val Val Gly Ser Asp Val Ala Leu Arg Glu Leu Met Lys Leu Ala Pro
 515 520 525
 Arg Tyr Lys Leu Gly Val His Gly Tyr Ala Phe Leu Asn Thr Asn Asn
 530 535 540
 Gly Tyr Ile Leu Ser His Pro Asp Leu Arg Pro Leu Tyr Arg Glu Gly
 545 550 555 560
 Lys Lys Leu Lys Pro Lys Pro Asn Tyr Asn Ser Val Asp Leu Ser Glu
 565 570 575
 Val Glu Trp Glu Asp Gln Ala Glu Ser Leu Arg Thr Ala Met Ile Asn
 580 585 590
 Arg Glu Thr Gly Thr Leu Ser Met Asp Val Lys Val Pro Met Asp Lys
 595 600 605

Gly Lys Arg Val Leu Phe Leu Thr Asn Asp Tyr Phe Phe Thr Asp Ile
 610 615 620

Ser Asp Thr Pro Phe Ser Leu Gly Val Val Leu Ser Arg Gly His Gly
 625 630 635 640

Glu Tyr Ile Leu Leu Gly Asn Thr Ser Val Glu Glu Gly Leu His Asp
 645 650 655

Leu Leu His Pro Asp Leu Ala Leu Ala Gly Asp Trp Ile Tyr Cys Ile
 660 665 670

Thr Asp Ile Asp Pro Asp His Arg Lys Leu Ser Gln Leu Glu Ala Met
 675 680 685

Ile Arg Phe Leu Thr Arg Lys Asp Pro Asp Leu Glu Cys Asp Glu Glu
 690 695 700

Leu Val Arg Glu Val Leu Phe Asp Ala Val Val Thr Ala Pro Met Glu
 705 710 715 720

Ala Tyr Trp Thr Ala Leu Ala Leu Asn Met Ser Glu Glu Ser Glu His
 725 730 735

Val Val Asp Met Ala Phe Leu Gly Thr Arg Ala Gly Leu Leu Arg Ser
 740 745 750

Ser Leu Phe Val Gly Ser Glu Lys Val Ser Asp Arg Lys Phe Leu Thr
 755 760 765

Pro Glu Asp Glu Ala Ser Val Phe Thr Leu Asp Arg Phe Pro Leu Trp
 770 775 780

Tyr Arg Gln Ala Ser Glu His Pro Ala Gly Ser Phe Val Phe Asn Leu
 785 790 795 800

Arg Trp Ala Glu Gly Pro Glu Ser Ala Gly Glu Pro Met Val Val Thr
 805 810 815

Ala Ser Thr Ala Val Ala Val Thr Val Asp Lys Arg Thr Ala Ile Ala
 820 825 830

Ala Ala Ala Gly Val Gln Met Lys Leu Glu Phe Leu Gln Arg Lys Phe
 835 840 845

Trp Ala Ala Thr Arg Gln Cys Ser Thr Val Asp Gly Pro Cys Thr Gln
 850 855 860

Ser Cys Glu Asp Ser Asp Leu Asp Cys Phe Val Ile Asp Asn Asn Gly
 865 870 875 880
 Phe Ile Leu Ile Ser Lys Arg Ser Arg Glu Thr Gly Arg Phe Leu Gly
 885 890 895
 Glu Val Asp Gly Ala Val Leu Thr Gln Leu Leu Ser Met Gly Val Phe
 900 905 910
 Ser Gln Val Thr Met Tyr Asp Tyr Gln Ala Met Cys Lys Pro Ser Ser
 915 920 925
 His His His Ser Ala Ala Gln Pro Leu Val Ser Pro Ile Ser Ala Phe
 930 935 940
 Leu Thr Ala Thr Arg Trp Leu Leu Gln Glu Leu Val Leu Val Ser Gly
 945 950 955 960
 Gly Arg His Gly Ala Gly Gly Gly Cys Met Arg Gly Trp Leu Arg Arg
 965 970 975
 Val Ser Leu Ile Arg Arg Leu Gln Gly Leu Gln Asp Asn Pro Leu Ala
 980 985 990
 Thr Lys Thr Pro Gly Lys Glu Gly Thr Ile Pro Gly His Gly Arg His
 995 1000 1005
 Leu Phe Pro Ala Cys Leu Pro Leu Gly Gly Thr Ser Leu Leu Asn Gln
 1010 1015 1020
 Ser Pro Gln Ala Gly Lys Arg Val Ser Trp Arg Arg Gly Asp Gly Pro
 1025 1030 1035 1040
 Gly Ala Val Arg Asp Thr Pro Ala Pro Trp Glu Pro Lys Ser Gly Gly
 1045 1050 1055
 Leu Arg Gly Leu Arg Asp Ser Val Leu Cys Leu Thr Gly Ser Cys Trp
 1060 1065 1070
 Ser Gly Val Ser Gly Ala Pro Gly Thr Thr Glu Gly Pro Arg Val Ser
 1075 1080 1085
 Ala Arg Ser Cys Arg Ala Met Cys
 1090 1095

<210> 43

<211> 2008

<212> DNA

<213> Homo sapiens

<400> 43

```

tactataggg cggccgcgaa ttcggcacga ggcggcgcg ggcgggagcag gcagccccgc 60
gcgtcgcgcc accgcccgt cgcgcgagct ccccgcgcc gctctcgtcg ccgcccgcagc 120
gggcgcgctg gagggagccc agcatggcgg ggcggggctc gccgcgccgc gcgtcccggg 180
gggcctcggc gcttctcgtc gccgcgttc tctacgcgc gctgggggac gtggtgcgct 240
cggagcagca gataccgctc tccgtggtga agctctgggc ctcggtttt ggtggggaga 300
taaaatccat tgctgctaag tactccggtt cccagcttct gcaaaagaaa tacaagagt 360
atgagaaaga cgttgccata gaagaaattg atggcctcca actggtaaag aagctggcaa 420
agaacatgga agagatgttt cacaagaagt ctgaggccgt caggcgtctg gtggaggctg 480
cagaagaagc acacctgaaa catgaatttg atgcagactt acagtatgaa tacttcaatg 540
ctgtgctgat aaatgaaagg gacaaagacg ggaattttt ggagctggga aaggaattca 600
tcttagcccc aaatgacctt ttaataatt tgcctgtgaa catcagtcta agtgacgtcc 660
aagtaccaac gaacatgtac aacaaagacc ctgcaattgt caatggggtt tattgggtctg 720
aatctctaaa caaagttttt gtagataact ttgaccgtga cccatctctc atatggcagt 780
actttggaag tgcaaagggc ttttttaggc agtatccggg gattaaatgg gaaccagatg 840
agaatggagt cattgccttc gactgcagga accgaaaatg gtacatccag gcagcaactt 900
ctccgaaaga cgtggtcatt ttagttgacg tcagtggcag catgaaagga ctccgtctga 960
ctatcgcgaa gcaaacagtc tcatccattt tggatacact tggggatgat gacttcttca 1020
acataattgc ttataatgag gagcttcaat atgtggaacc ttgcctgaat ggaactttgg 1080
tgcaagccga caggacaaac aaagagcact tcaggggagca tctggacaaa cttttcgcca 1140
aaggaattgg aatgttgat atagytctga atgaggcctt caacattctg agtgatttca 1200
accacacggg acaaggaagt atctgcagtc aggccatcat gtcataact gatggggcgg 1260
tggacaccta tgatacaatc tttgcaaat acaattggcc agatcgaaag gttcgcatct 1320
tcacatacct cattggacga gaggtcgtt ttgcagacaa tctaaagtgg atggcctgtg 1380
ccaacaaagg attttttacc cagatctcca ccttggtga tgtgcaggag aatgtcatgg 1440
aataccttca cgtgcttagc cggcccaaag tcatcgacca ggagcatgat gtggtgtgga 1500
ccgaagctta cattgacagc actctgactg atgatcaggg ccccgctctg atgaccactg 1560
tagccatgcc tgtgtttagt aagcagaacg aaaccagatc gaagggcatt cttctgggag 1620
tggttggcac agatgtccca gtgaaagaac ttctgaagac catcccaaaa tacaagttag 1680
ggattcacgg ttatgccttt gcaatcacia ataattgata tatcctgacg catccggaac 1740
tcaggctgct gtacgaagaa ggaaaaaagc gaaggaaacc taactatagt agcgttgacc 1800
tctctgaggt ggagtgggaa gaccgagatg acgtgttgag aaatgctatg gtgaatcgaa 1860
agacggggaa gttttccatg gaggtgaaga agacagtgga caaaggggta catttttctc 1920
aaacattttt gctgcttaat ttaaaacaaa ccactgtgaa aaattagctt tgaaagctat 1980
atctggaata aatatctttc gctgaagg
2008

```

<210> 44

<211> 3598

<212> DNA

<213> Homo sapiens

<400> 44

```

tactataggg cggccgcgaa ttcggcacga ggcggcgcg ggcgggagcag gcagccccgc 60

```

```

gcgctcgccc accgcccgct ccgcgcagct ccccgcgggc gctctcgteg ccgcccgcagc 120
gggcgcgctg gagggagccc agcatggccg ggccgggctc gccgcgccgc gcgtcccggg 180
gggcctcggc gcttctcgct gccgcgcttc tctacgccgc gctgggggac gtggtgcgct 240
cggagcagca gataccgctc tccgtggtga agctctgggc ctgggctttt ggtggggaga 300
taaaatccat tgctgctaag tactccggtt cccagcttct gcaaaagaaa tacaagagt 360
atgagaaaga cggtgccata gaagaaattg atggcctcca actggtaaag aagctggcaa 420
agaacatgga agagatgttt cacaagaagt ctgaggccgt caggcgctctg gtggaggctg 480
cagaagaagc acacctgaaa catgaatttg atgcagactt acagtatgaa tacttcaatg 540
ctgtgctgat aaatgaaagg gacaaagacg ggaatttttt ggagctggga aaggaattca 600
tcttagcccc aaatgaccat tttaataatt tgcctgtgaa catcagtcta agtgacgtcc 660
aagtaccaac gaacatgtac aacaaagacc ctgcaattgt caatgggggtt tattggtctg 720
aatctctaaa caaagttttt gtagataact ttgaccgtga cccatctctc atatggcagt 780
actttggaag tgcaaagggc ttttttaggc agtatccggg gattaaatgg gaaccagatg 840
agaatggagt cattgccttc gactgcagga accgaaaatg gtacatccag gcagcaactt 900
ctccgaaaga cgtggtcatt ttagttgacg tcagtggcag catgaaagga ctccgtctga 960
ctatcgcgaa gcaaacagtc tcatccattt tggatacact tggggatgat gacttcttca 1020
acataattgc ttataatgag gagcttcaat atgtggaacc ttgcctgaat ggaacttttg 1080
tgcaagccga caggacaaac aaagagcact tcaggagca tctggacaaa cttttcgcca 1140
aaggaattgg aatgttggat atagctctga atgaggcctt caacattctg agtgatttca 1200
accacacggg acaaggaagt atctgcagtc aggccatcat gtcataact gatggggcgg 1260
tggacacctt tgatacaatc tttgcaaaat acaattggcc agatcgaaag gttcgcattc 1320
tcacatacct cattggacga gaggtgcgt ttgcagacaa tctaaagtgg atggcctgtg 1380
ccaacaaagg attttttacc cagatctcca ccttggtgta tgtgcaggag aatgtcatgg 1440
aataccttca cgtgcttagc cggcccaaag tcatcgacca ggagcatgat gtggtgtgga 1500
ccgaagctta cattgacagc actctgactg atgatcaggg ccccgctctg atgaccactg 1560
tagccatgcc tgtgtttagt aagcagaacg aaaccagatc gaagggcatt cttctgggag 1620
tggttggcac agatgtccca gtgaaagaac ttctgaagac catcccaaaa tacaagttag 1680
ggattcacgg ttatgccttt gcaatcacia ataattggrta tatcctgacg catccggaac 1740
tcaggctgct gtacgaagaa ggaaaaaagc gaaggaaaacc taactatagt agcgttgacc 1800
tctctgaggt ggagtgggaa gaccgagatg acgtgttgag aaatgctatg gtgaatcgaa 1860
agacggggaa gttttccatg gaggtgaaga agacagtgga caaagggaaa cgggtttttg 1920
tgatgacaaa tgactactat tatacagaca tcaagggtac tcctttcagt ttaggtgtgg 1980
cgctttccag aggtcatggg aaatatctct tccgagggaa tgtaaccatc gaagaaggcc 2040
tgcatgactt agaacatccc gatgtgtcct tggcagatga atggctctac tgcaacactg 2100
acctacaccc tgagcacgcg catctgtctc agttagaagc gattaagctc tacctaaaag 2160
gcaaagaacc tctgctccag tgtgataaag aattgatcca agaagtcctt tttgacgcgg 2220
tggtgagtgc ccccatgaa gcgtattgga ccagcctggc cctcaacaaa tctgaaaatt 2280
ctgacaaggg cgtggagggt gccttcctcg gcactcgac gggcctctcc agaatacaac 2340
tgtttgtcgg ggctgagcag ctaccaatc aggacttcct gaaagctggc gacaaggaga 2400
acatttttaa cgcagaccat tccctctctt ggtaccgaag agccgctgag cagattccag 2460
ggagcttcgt ctactcgatc ccattcagca ctggaccagt caataaaagc aatgtggtga 2520
cagcaagtac atccatccag ctctggatg aacggaaatc tcctgtgagt gcagctgtag 2580
gcattcagat gaaacttgaa tttttccaaa ggaagtctct gactgccagc agacagtgtg 2640
cttccctgga tggcaaatgc tccatcagct gtgatgatga gactggagac ttttttggtg 2700
agatcgaggg agctgtgatg aacaaattgc taacaatggg ctcttttaaa agaattaccc 2760
tttatgacta ccaagccatg tgtagagcca acaaggaaag cagcgatggc gcccatggcc 2820
tcctggatcc cagaaattga aacagaccct ggagccttgt gatactgaat atccagcatt 2880
cgtctctgag cgcaccatca aggagactac agggaatatt gcttgtgaag actgctccaa 2940

```

```

gtcctttgtc atccagcaaa tcccaagcag caacctgttc atggtggtgg tggacagcaa 3000
ctgcctctgt gaatctgtgg ccccatcac catggcacc attgaaatca ggtataatga 3060
atcccttaag tgtgaacgtc taaaggccca gaagatcaga aggcgcccag aatcttgtca 3120
tggttccat cctgaggaga atgcaagga gtgtgggggt gcgccgagtc tccaagccca 3180
gacagtcctc cttctgtctc ctctgtttt gatgctctt tcaagggtgac actgactgag 3240
atgttctctt actgactgag atgttctctt ggcatgctaa atcatggata aactgtgaac 3300
caaaatatgg tgcaacatac gagacatgaa tatagtccaa ccatcagcat ctcatcatga 3360
ttttaaaactg tgcgtgatat aaactcttaa agatatgttg acaaaaagtt atctatcatc 3420
tttttacttt gccagtcatg caaatgtgag ttgcccacat gataatcacc ctcatcaga 3480
aatgggaccg caagtggtag gcagtgtccc ttctgttga aacctattga aaccaattta 3540
aaactgtgta ctttttaaat aaagtatat aaatcataa aaaaaaaaaa aaaaaaaa 3598

```

<210> 45

<211> 27

<212> DNA

<213> Homo sapiens

<400> 45

ccatcctaatac gactcact atagggc

27

<210> 46

<211> 23

<212> DNA

<213> Homo sapiens

<400> 46

actcactata gggctcgagc ggc

23

<210> 47

<211> 1036

<212> DNA

<213> Homo sapiens

<400> 47

```

ctgtgagtg agctgtaggc attcagatga aacttgaatt tttccaaagg aagttctgga 60
ctgccagcag acagtgtgct tccctggatg gcaaatgctc catcagctgt gatgatgaga 120
ctggagactt ttttggtgag atcgaggag ctgtgatgaa caaattgcta acaatgggct 180
cctttaaag aattaccctt tatgactacc aagccatgtg tagagccaac aaggaaagca 240
gcgatggcgc ccatggcctc ctggatccca gaaattgaaa cagaccctgg agccttgtga 300
tactgaatat ccagcatteg tctctgagcg caccatcaag gagactacag ggaatattgc 360
ttgtgaagac tgetccaagt cctttgtcat ccagcaaata ccaagcagca acctgttcat 420
ggtggtggtg gacagcaact gcctctgtga atctgtggcc cccatcacca tggcacccat 480
tgaaatcagg tataatgaat cccttaagtg tgaacgtcta aaggccaga agatcagaag 540
gcgccagaa tcttgtcatg gcttccatcc tgaggagaat gcaaggaggt gtgggggtgc 600
gccgagtctc caagccaga cagtcctcct tctgtcctc ctgcttttga tgetcttctc 660

```

aagggtgacac tgactgagat gttctcttac tgactgagat gttctcttgg catgctaaat 720
catggataaa ctgtgaacca aaatatgggtg caacatacga gacatgaata tagtccaacc 780
atcagcatct catcatgatt ttaaactgtg cgtgatataa actcttaaag atatgttgac 840
aaaaagttat ctatcatctt ttacttttgc cagtcatgca aatgtgagtt tgccacatga 900
taatcaccct tcatcagaaa tgggaccgca agtggtaggc agtgtcctt ctgcttgaaa 960
cctattgaaa ccaattttaa actgtgtact ttttaaataa agtatattaa aatcataaaa 1020
aaaaaaaaa aaaaaa 1036

<210> 48

<211> 26

<212> DNA

<213> Homo sapiens

<400> 48

ctagaggcca tgatccgctt cctcac 26

<210> 49

<211> 20

<212> DNA

<213> Homo sapiens

<400> 49

gcccacgaac aagctgcttc 20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23519

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C07K14/47 C07K16/18 C07K16/28
C12Q1/68 A61K38/17 G01N33/68 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, STRAND, MEDLINE, BIOSIS, SCISEARCH, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC AA190607, 21 January 1997 (1997-01-21) HILLIER, L. ET AL.: "zq44e03.r1 Stratagene hNT neuron, Homosapiens cDNA clone IMAGE: 632572 5' similar to TR:G179762 G179762 Calcium Channel Alpha-2B subunit; mRNA sequence" XP002136760 see the whole document: 97,6% identity in 413bp overlap with SEQ ID No. 3; 96,8% identity in 340bp overlap with SEQ ID No. 43; 97,6% identity in 413bp overlap with SEQ ID No. 44</p> <p style="text-align: center;">--- -/-</p>	1,2,22, 23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 July 2000

Date of mailing of the international search report

24.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alt, G

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC Z44942, 6 November 1994 (1994-11-06) AUFFRAY, C. ET AL.: "Homo sapiens partial cDNA sequence; clone c-2dd03" XP002136761 see the whole document: 99,7% identity in 340 bp overlap with SEQ ID No. 3; 100% identity in 17bp overlap with SEQ ID No. 11</p> <p>---</p>	1,2,22, 23
X	<p>DATABASE EMBL 'Online! AC R20288, 23 April 1995 (1995-04-23) HILLIER, L. ET AL.: "yg20f03.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:32708 5', mRNA sequence" XP002136762 see the whole document: 97,6% identity in 340 bp overlap with SEQ ID No. 3</p> <p>---</p>	1,2
X	<p>DATABASE EMBL 'Online! AC AA459684, 13 June 1997 (1997-06-13) HILLIER, L. ET AL.: "zx49d08.s1 Soares testis NHT Homo sapiens cDNA clone 759567 3' EST" XP002136763 see whole document: 100% identity in 304bp overlap with SEQ ID No. 3</p> <p>---</p>	1,2
X	<p>WO 95 04822 A (SALK INST BIOTECH IND) 16 February 1995 (1995-02-16) see SEQ ID No. 31: 34,4% identity in 540 aa overlap with SEQ ID No. 5; 29,1% identity in 1122aa overlap with SEQ ID No. 6;</p> <p>---</p>	8
X	<p>DATABASE EMBL 'Online! ACAC005343, 4 August 1998 (1998-08-04) MUZNY, D. ET AL.: "Homo sapiens chromosome 12p13.3 BAC RPCI 11-21K20 (Roswell Park Cnacer Institute Human BAC Library) complete sequence" XP002143146 see the whole document: 98,5% identity in 1847 bp overlap with SEQ ID No. 4, 15, 16;</p> <p>---</p>	1,2,22, 23
X	<p>DATABASE EMBL 'Online! AC AA719773, 7 January 1998 (1998-01-07) HILLIER, L. ET AL.: "zh38g01.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone 414384 3'" XP002143147 see the whole document: 98,4% identity in 436 bp overlap with SEQ ID NO. 4</p> <p>---</p>	1,2,22, 23
	<p>---</p> <p>-/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC AA001473, 20 July 1996 (1996-07-20) HILLIER, L. ET AL.: "ze45d04.r1 Soares retina N2b4Hr Homo sapiens cDNA clone 361927 5'" XP002143148 see the whole document: 97,8% identity in 489bp overlap with SEQ ID NO. 4, 15, 16</p>	1,2,22, 23
X	<p>WO 98 11131 A (CHEN AI RU SUN ;FRANCO RODRIGO (US); AMERICAN HOME PROD (US); SHUE) 19 March 1998 (1998-03-19) see SEQ ID NO.4: 29,0% identity in 1129aa overlap with SEQ ID No. 6</p>	8
X	<p>DATABASE EMBL 'Online! AC Z75742, 9 July 1996 (1996-07-09) WILKINSON; J.: "Human DNA sequence from cosmid LUCA10 on chromosome 3p21.3 contains ESTs" XP002143149 see the whole document: 82,8% identity in 87bp overlap with SEQ ID No. 33</p>	23
A	<p>DATABASE EMBL 'Online! AC AB011130, 10 April 1998 (1998-04-10) OHARA, O. ET AL.: "Homo sapiens mRNA for KIAA0558 protein, partial cds." XP002143150 see the whole document; 100% identity in 1145aa overlap with SEQ ID No. 2</p>	22-26,34
Y	<p>GEE N S ET AL: "THE NOVEL ANTICONVULSANT DRUG, GABAPENTIN (NEURONTIN), BINDS TO THEALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5768-5776, XP002022221 ISSN: 0021-9258 cited in the application see the whole document</p>	34

-/-

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>BROWN J P ET AL: "CLONING AND DELETION MUTAGENESIS OF THE ALPHA 2 DELTA CALCIUM CHANNEL SUBUNIT FROM PORCINE CEREBRAL CORTEX" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 39, 1998, pages 25458-25465, XP000887190 ISSN: 0021-9258 see the paragraph bridging pages 25461-25462</p>	34
P, X	<p>KLUGBAUER, N. ET AL.: "Molecular diversity of the calcium channel alpha 2 delta subunit" NEUROSCIENCE, vol. 19, no. 2, 15 January 1999 (1999-01-15), pages 684-691, XP000886459 see Figure 1; 89,4% identity in 1902bp overlap with SEQ ID 3; 94,0% identity in 251bp overlap with SEQ ID No. 14; 94,8% identity in 561 bp overlap with SEQ ID NO. 40; 96,0% identity in 273bp overl overlap with SEQ ID No. 41; 88,0% identity in 1494bp of SEQ ID NO. 43; 88,1% identity in 1494bp overlap with SEQ ID NO. 44; 57,1% identity in 2962bp overlap with SEQ ID No. 4; 65,6% identity in 1454bp overlap with SEQ ID NO. 15; 65,6% identity in 1454bp overlap with SEQ ID No. 16;</p>	1,2,4, 6-10,22, 23
E	<p>WO 00 12711 A (INCYTE PHARMA INC ;AZIMZAI YALDA (US); CORLEY NEIL C (US); REDDY R) 9 March 2000 (2000-03-09) see SEQ ID No. 28: 98.1% identity in SEQ ID No. 28: 1276bp overlap with SEQ ID 3; 89,5% identity in 516bp overlap with SEQ ID No. 40; 98,0% identity in 1276bp overlap with SEQ ID No. 43; 98,1% identity in 1276bp overlap with SEQ ID No. 44; 67,0% identity in 1268bp overlap SEQ ID NO. 4 and SEQ ID No. 28; 67,0% identity in 1268bp overlap with SEQ ID No. 15; 67,0% identity in 1268bp overlap with SEQ ID No. 16;</p>	1,2,8, 22,23

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WILLIAMS, M.E. ET AL.: "Structure and functional expression of alpha 1, alpha2, and beta subunits of a novel human neuronal calcium channel subtype" NEURON, vol. 8, January 1992 (1992-01), pages 71-84, XP000886416 see Figure 3; last paragraph, second column, page 84</p> <p style="text-align: center;">---</p>	1
A	<p>WALKER, D. AND DE WAARD, M.: "Subunit interaction sites in voltage-dependent Ca²⁺ channels: role in channel function" TRENDS IN NEUROSCIENCES, vol. 21, no. 4, 1998, XP000887176 cited in the application see the whole document</p> <p style="text-align: center;">-----</p>	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/23519

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 19, 20, 31-33
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-26, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta C protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 3; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 5; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta C"; claims 22-26 as far as they relate to SEQ ID Nos. 11, 14, 40, 41, 43, 44, 47-49; claims 34 as far as it is related to accession nos. from AU022914.1 to AI051759.1 and SEQ ID Nos. 3, 5, 9-14, 36-41, 43, 44, 47

2. Claims: 1-26 (all partially), 27-30, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta D protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 4; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 6; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta D"; claims 22-26 as far as they relate to SEQ ID Nos. 15, 16, 21-24; claim 34 as far as it is related to accession nos. from T70594.1 to AA001473.1 and SEQ ID Nos. 4, 6, 15, 16, 18-24, 42, 45, 46, 48, 49.

3. Claims: 22-26, 34

subject-matter related to calcium channel alpha 2 delta B protein: claims 22-26 as far as they relate to SEQ ID Nos. 31-35; claim 34 as far as it relates to accession no. AF040709.1 and accession nos. from T80372.1 to Z84492.1 as well as SEQ ID Nos. 1, 2, 7, 8, 25-35.

4. Claim : 34 (partially)

method of using polynucleotides sequences to identify the binding potential of polynucleotide sequences to gabapentin: claim 34 as far as it is related to accession nos. not mentioned before

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 33 directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Although claims 19, 20, 31, 32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 19, 20, 31-33

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/23519

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504822 A	16-02-1995	US 5874236 A	23-02-1999
		AU 3390499 A	19-08-1999
		AU 707793 B	22-07-1999
		AU 7632294 A	28-02-1995
		EP 0716695 A	19-06-1996
		GB 2284814 A, B	21-06-1995
		JP 9509041 T	16-09-1997
WO 9811131 A	19-03-1998	US 6040436 A	21-03-2000
		AU 4343097 A	02-04-1998
WO 0012711 A	09-03-2000	AU 6137699 A	21-03-2000